<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004388.pub6" GROUP_ID="ANAESTH" ID="038903011113025117" MERGED_FROM="" MODIFIED="2017-02-06 18:49:52 +0000" MODIFIED_BY="Jane Cracknell" REVIEW_NO="114" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2017-02-06 18:49:51 +0000" MODIFIED_BY="Jane Cracknell">
<TITLE MODIFIED="2012-07-23 16:02:29 +0100" MODIFIED_BY="Jane Cracknell">Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients</TITLE>
<CONTACT MODIFIED="2017-02-06 18:49:51 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc, PhD</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><COUNTRY CODE="VE">Venezuela</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-02-06 18:49:51 +0000" MODIFIED_BY="Jane Cracknell"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc, PhD</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><COUNTRY CODE="VE">Venezuela</COUNTRY></ADDRESS></PERSON><PERSON ID="12177" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Ivan</FIRST_NAME><LAST_NAME>Solà</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>isola@santpau.cat</EMAIL_1><EMAIL_2>ensayos@cochrane.es</EMAIL_2><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP) - Universitat Autònoma de Barcelona</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1><ADDRESS_2>Pavilion 18</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 935 537 814</PHONE_1><FAX_1>+34 935 537 809</FAX_1></ADDRESS></PERSON><PERSON ID="6439" ROLE="AUTHOR"><FIRST_NAME>Christian</FIRST_NAME><LAST_NAME>Gluud</LAST_NAME><SUFFIX>M.D, Dr. Med. Sci.</SUFFIX><POSITION>Head of Department</POSITION><EMAIL_1>cgluud@ctu.dk</EMAIL_1><ADDRESS><DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT><ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION><ADDRESS_1>Blegdamsvej 9</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+ 45 3545 7175</PHONE_1><FAX_1>+ 45 3545 7101</FAX_1></ADDRESS></PERSON><PERSON ID="21562E5782E26AA200DA2AF3AD698E2D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dimitrios</FIRST_NAME><LAST_NAME>Lathyris</LAST_NAME><POSITION>Anaesthesiologist-Intensivist</POSITION><EMAIL_1>lathyrisd@hotmail.com</EMAIL_1><ADDRESS><ORGANISATION>"George Gennimatas" General Hospital</ORGANISATION><CITY>Thessaloniki</CITY><COUNTRY CODE="GR">Greece</COUNTRY><PHONE_1>+30 2313 307658</PHONE_1></ADDRESS></PERSON><PERSON ID="12198212384027664543110518112951" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vidhu</FIRST_NAME><LAST_NAME>Anand</LAST_NAME><POSITION>Resident Physician</POSITION><EMAIL_1>vidhuanand2003@gmail.com</EMAIL_1><EMAIL_2>vanand@umn.edu</EMAIL_2><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Minnesota</ORGANISATION><ADDRESS_1>420 Delaware Street SE</ADDRESS_1><ADDRESS_2>Mayo Mail Code 195</ADDRESS_2><CITY>Minneapolis</CITY><ZIP>55455</ZIP><REGION>MN</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>651-315-9798</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-04-03 17:09:54 +0100" MODIFIED_BY="Arturo Martí-Carvajal">
<UP_TO_DATE>
<DATE DAY="26" MONTH="6" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="6" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="11" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2017-02-06 18:48:41 +0000" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-02-06 18:48:41 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="6" MONTH="2" YEAR="2017"/>
<DESCRIPTION>
<P>No update planned due to intervention no longer being available on the market</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-02-06 18:45:31 +0000" MODIFIED_BY="Jane Cracknell">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-02-06 18:45:28 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="12" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>One new author (Christian Gluud) has joined the review team</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-02-06 18:45:31 +0000" MODIFIED_BY="Jane Cracknell">
<DATE DAY="11" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<OL>
<LI>This systematic review has been updated with results of the one new randomized clinical trial (<LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>). </LI>
<LI>We reran the searches until June 2012 </LI>
<LI>We included trial sequential analysis</LI>
<LI>Adverse events was considered as primary outcome.</LI>
</OL>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-08 18:04:51 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="17" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-10-08 18:09:59 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="15" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>Important note (warning) added to the systematic review's abstract, plain language summary, main text conclusion and <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK> in response to the withdrawal of the drug Xigris</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-08 18:10:49 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="15" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>This systematic review will be updated when results of the PROWESS-SHOCK or other trials are published.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-10-08 18:19:15 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="14" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<OL>
<LI>This review is an update of the previous Cochrane systematic review (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2008" TYPE="REFERENCE">Martí-Carvajal 2008</LINK>) that included four RCTs, excluded 19 studies and had two ongoing studies.</LI>
<LI>In the previous version (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2008" TYPE="REFERENCE">Martí-Carvajal 2008</LINK>) we searched the databases until 2005. In this updated version we reran the searches until June 16th 2010.</LI>
<LI>This new updated version now includes five RCTs in total. The previous ongoing study NCT00190788 2005 has now been completed. We have assessed it and it meets our inclusion criteria (<LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>). This study strengthens but does not change the updated review's conclusions.</LI>
<LI>Change in authors: Georgia Salanti (co-author in <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2008" TYPE="REFERENCE">Martí-Carvajal 2008</LINK>) has left the review team. Two new authors (Mr Ivan Solà and Dr Dimitrios Lathyris) have joined the review team of this updated version.</LI>
</OL>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-10-08 18:19:15 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="14" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<OL>
<LI>We found 19 new excluded studies (<LINK REF="STD-Bearden-2002" TYPE="STUDY">Bearden 2002</LINK>; <LINK REF="STD-Bertolini-2007" TYPE="STUDY">Bertolini 2007</LINK>; <LINK REF="STD-Costa-2007" TYPE="STUDY">Costa 2007</LINK>; <LINK REF="STD-Decruyenaere-2009" TYPE="STUDY">Decruyenaere 2009</LINK>; <LINK REF="STD-Ferrer-2009" TYPE="STUDY">Ferrer 2009</LINK>; <LINK REF="STD-Goldstein-2006" TYPE="STUDY">Goldstein 2006</LINK>; Gullo 2005; Higgins 2005; Hodder 2009; <LINK REF="STD-Houston-2009" TYPE="STUDY">Houston 2009</LINK>; Kubler 2006; <LINK REF="REF-Levi-2008" TYPE="REFERENCE">Levi 2008</LINK>; <LINK REF="STD-Lucioni-2002" TYPE="STUDY">Lucioni 2002</LINK>; Mackenzie 2006; <LINK REF="STD-Marraro-2009" TYPE="STUDY">Marraro 2009</LINK>; Riou 2006; <LINK REF="STD-van-Doorn-2008" TYPE="STUDY">van Doorn 2008</LINK>; <LINK REF="STD-Wheeler-2008" TYPE="STUDY">Wheeler 2008</LINK>; <LINK REF="STD-Wiedermann-2005" TYPE="STUDY">Wiedermann 2005</LINK>.</LI>
<LI>We included three new ongoing studies NCT00625209; NCT00604214; NCT00067730.</LI>
<LI>We amended the plain language summary.</LI>
<LI>We included new subheadings in the background, methods and discussion sections.</LI>
<LI>We incorporated risk of bias (ROB) and summary of findings tables (SOF).</LI>
</OL>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-08 18:08:16 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="31" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-10-08 18:07:22 +0100" MODIFIED_BY="Jane Cracknell">
<DATE DAY="12" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment. The conclusion of the updated review (in the abstract and the text) was amended in response to Dr Peter C. Gotzsche's comments. The updated review found no evidence suggesting that APC should be used for treating patients with severe sepsis or septic shock</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-07-11 10:28:40 +0100" MODIFIED_BY="Jane Cracknell">
<INTERNAL_SOURCES MODIFIED="2012-07-11 10:28:40 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<SOURCE MODIFIED="2012-07-11 10:28:40 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<NAME>Cochrane Hepato Biliary Group</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION>
<P>Academic.</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-07-11 10:28:40 +0100" MODIFIED_BY="Jane Cracknell">
<SOURCE MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell">
<NAME>Iberoamerican Cochrane Centre</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Academic support</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell">
<NAME>Cochrane Anaesthesia Review Group</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION>
<P>Academic support</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-10-06 20:11:50 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-10-28 05:01:56 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-07-23 15:53:14 +0100" MODIFIED_BY="Jane Cracknell">Human recombinant activated protein C for severe sepsis and septic shock in adult and paediatric patients</TITLE>
<SUMMARY_BODY MODIFIED="2012-10-28 05:01:56 +0000" MODIFIED_BY="[Empty name]">
<P>Sepsis and septic shock are major causes of death. Sepsis is a complex syndrome resulting from a presumed or known infection, and its pathogenesis involves interactions between inflammation and blood clotting pathways. This serious medical condition is characterized by an inflammatory response to an infection which can affect the whole body. Patients with sepsis may have developed the inflammatory response because of microbes in their blood, urine, lungs, skin, or other tissues. Severe sepsis can lead to multiple organ failure due to blood clotting in the finer blood vessels. This reduces the amount of blood reaching the organs and septic shock ensues. Protein C reduces the clotting process and a lack of protein C can lead to an exaggeration of blood clotting. Sepsis and septic shock decrease protein C levels in the body. It has been suggested that human recombinant activated protein C (APC) will increase the levels of protein C and ameliorate or prevent multiple organ failure. In this updated Cochrane review we searched the databases until June 2012. We included six randomized clinical trials which involved 6781 people (6307 adult and 474 paediatric participants) with either a high or low risk of death. All trials had high risk of bias and were sponsored by the pharmaceutical industry (Eli Lilly). We found no evidence suggesting that APC reduced the risk of death in adults or children with severe sepsis or septic shock. On the contrary, APC increased the risk of serious bleeding.<BR/>
<BR/>On 25th October 2011, the European Medicines Agency issued a press release on the worldwide withdrawal of Xigris® (human recombinant activated protein C) from the market by Eli Lilly due to lack of beneficial effect on 28-day mortality in the PROWESS-SHOCK trial. Furthermore, Eli Lily has announced the discontinuation of all ongoing clinical trials. APC should not be used for sepsis or septic shock outside randomized clinical trials.</P>
<P>Current evidence does not support the use of human recombinant activated protein C in adults or children with severe sepsis or septic shock; moreover, there is an increased risk of bleeding associated with its use.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-10-06 19:44:11 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-10-28 04:53:48 +0000" MODIFIED_BY="[Empty name]">
<P>Sepsis is a common and frequently fatal condition. Human recombinant activated protein C (APC) has been introduced to reduce the high risk of death associated with severe sepsis or septic shock. This systematic review is an update of a Cochrane review originally published in 2007.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-06-25 19:41:29 +0100" MODIFIED_BY="Jane Cracknell">
<P>We assessed the benefits and harms of APC for patients with severe sepsis or septic shock.<B>
<BR/>
</B>
</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-05-29 17:54:28 +0100" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (<I>The Cochrane Library</I> 2013, Issue 5); MEDLINE (June 2012 to May 2013); EMBASE (June 2012 to May 2013); BIOSIS (June 2012 to May 2013); CINAHL (June 2012 to May 2013) and LILACS (June 2012 to May 2013). There was no language restriction.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-10-28 04:54:56 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomized clinical trials assessing the effects of APC for severe sepsis or septic shock in adults and children. We excluded studies on neonates. We considered all-cause mortality at day 28 and at the end of study follow up, and hospital mortality as the primary outcomes.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-07-10 12:27:53 +0100" MODIFIED_BY="[Empty name]">
<P>We independently performed trial selection, risk of bias assessment, and data extraction in duplicate. We estimated relative risks (RR) for dichotomous outcomes. We measured statistical heterogeneity using the I<SUP>2</SUP> statistic. We used a random-effects model. 
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-10-06 19:44:11 +0100" MODIFIED_BY="[Empty name]">
<P>We identified one new randomized clinical trial in this update which includes six randomized clinical trials involving 6781 participants in total, five randomized clinical trials in adult (N = 6307) and one randomized clinical trial in paediatric (N = 474) participants. All trials had high risk of bias and were sponsored by the pharmaceutical industry. APC compared with placebo did not significantly affect all-cause mortality at day 28 compared with placebo (856/3643 (23.49%) versus 837/3549 (23.58%); RR 1.00, 95% confidence interval (CI) 0.88 to 1.14; I<SUP>2</SUP> = 49%). APC did not significantly affect in-hospital mortality (393/1767 (22.2%) versus 379/1710 (22.1%); RR 1.01, 95% CI 0.87 to 1.16; I<SUP>2</SUP> = 20%). APC was associated with an increased risk of serious bleeding (113/3424 (3.3%) versus 74/3343 (2.2%); RR 1.45, 95% CI 1.08 to 1.94; I<SUP>2</SUP> = 0%). APC did not significantly affect serious adverse events (463/3334 (13.9%) versus 439/3302 (13.2%); RR 1.04, 95% CI 0.92 to 1.18; I<SUP>2</SUP> = 0%). Trial sequential analyses showed that more trials do not seem to be needed for reliable conclusions regarding these outcomes.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-10-28 04:57:55 +0000" MODIFIED_BY="[Empty name]">
<P>This updated review found no evidence suggesting that APC should be used for treating patients with severe sepsis or septic shock. APC seems to be associated with a higher risk of bleeding. The drug company behind APC, Eli Lilly, has announced the discontinuation of all ongoing clinical trials using this drug for treating patients with severe sepsis or septic shock. APC should not be used for sepsis or septic shock outside randomized clinical trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-10-06 20:11:50 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-11-01 17:52:08 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-11-01 17:52:08 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Definition of sepsis and its nature</HEADING>
<P>Sepsis is a Greek word that means 'decomposition of animal or vegetable organic matter in the presence of bacteria' (<LINK REF="REF-Geroulanos-2006" TYPE="REFERENCE">Geroulanos 2006</LINK>). It is defined as clinical evidence of infection plus a systemic inflammatory response to infection that is associated with more than one disturbance of systems and control mechanisms that maintain relatively constant body conditions (homeostasis). These disturbances manifest as abnormal body temperature, elevated heart rate, excessive rapidity of breathing (tachypnoea) or hyperventilation, and altered white blood cell count (<LINK REF="REF-ACCP_x002d_SCCM-1992" TYPE="REFERENCE">ACCP-SCCM 1992</LINK>; <LINK REF="REF-Bone-1992" TYPE="REFERENCE">Bone 1992</LINK>). Sepsis is severe when it is accompanied by acute organ dysfunction, decreased blood flow in an organ (hypoperfusion), or abnormally low blood pressure (hypotension). Septic shock occurs when severe sepsis persists despite adequate fluid resuscitation (<LINK REF="REF-ACCP_x002d_SCCM-1992" TYPE="REFERENCE">ACCP-SCCM 1992</LINK>; <LINK REF="REF-Annane-2005" TYPE="REFERENCE">Annane 2005</LINK>; <LINK REF="REF-Bone-1992" TYPE="REFERENCE">Bone 1992</LINK>). Septic shock is the most common form of shock among patients in the intensive care unit (<LINK REF="REF-Vincent-2013" TYPE="REFERENCE">Vincent 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Epidemiology and burden of sepsis</HEADING>
<P>Severe sepsis is a common and frequently fatal condition with high associated costs (<LINK REF="REF-Guidet-2005" TYPE="REFERENCE">Guidet 2005</LINK>). The US Centers of Disease Control and Prevention estimated an increase in incidence from 73.6 per 100,000 people in 1979 to 175.9 per 100,000 people in 1989 (<LINK REF="REF-Angus-2001a" TYPE="REFERENCE">Angus 2001a</LINK>). The incidence and mortality from sepsis varies according to the season, country, ethnic group, anatomical sites, number of organ dysfunctions, the population studied, hospital site and period. The mortality rates vary from 20% to 80% (<LINK REF="REF-Angus-2001b" TYPE="REFERENCE">Angus 2001b</LINK>; <LINK REF="REF-Barnato-2008" TYPE="REFERENCE">Barnato 2008</LINK>; <LINK REF="REF-Brun_x002d_Buisson-1995" TYPE="REFERENCE">Brun-Buisson 1995</LINK>; <LINK REF="REF-Brun_x002d_Buisson-2006" TYPE="REFERENCE">Brun-Buisson 2006</LINK>; <LINK REF="REF-Danai-2007" TYPE="REFERENCE">Danai 2007</LINK>; <LINK REF="REF-Das-2000" TYPE="REFERENCE">Das 2000</LINK>; <LINK REF="REF-Khwannimit-2009" TYPE="REFERENCE">Khwannimit 2009</LINK>; <LINK REF="REF-Rangel_x002d_Frausto-1995" TYPE="REFERENCE">Rangel-Frausto 1995</LINK>).</P>
<P>Average costs per patient with sepsis in the USA are USD 22,100, with annual total national costs of USD 16.7 billion (<LINK REF="REF-Angus-2001b" TYPE="REFERENCE">Angus 2001b</LINK>). Annual overall costs have been estimated in Spain to be EUR 70 million (<LINK REF="REF-I_x00f1_igo-2006" TYPE="REFERENCE">Iñigo 2006</LINK>). In China, the mean hospital cost was estimated at USD 11,390 per patient and USD 502 per patient per day (<LINK REF="REF-Cheng-2007" TYPE="REFERENCE">Cheng 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Approaches for treating sepsis</HEADING>
<P>Sepsis involves a high heterogeneity of patients and types of infections (<LINK REF="REF-Carlet-2008" TYPE="REFERENCE">Carlet 2008</LINK>; <LINK REF="REF-Holmes-2003" TYPE="REFERENCE">Holmes 2003</LINK>; <LINK REF="REF-Marshall-2008" TYPE="REFERENCE">Marshall 2008</LINK>; <LINK REF="REF-Matsuda-2007" TYPE="REFERENCE">Matsuda 2007</LINK>; <LINK REF="REF-Remick-2007" TYPE="REFERENCE">Remick 2007</LINK>; <LINK REF="REF-Sipahi-2006" TYPE="REFERENCE">Sipahi 2006</LINK>; <LINK REF="REF-Treacher-2009" TYPE="REFERENCE">Treacher 2009</LINK>). Current treatment of severe sepsis involves treatment of the infection with appropriate early antibiotic therapy against the identified or presumed organisms, surgical drainage where necessary, and supportive treatment according to the patient's symptoms and signs (<LINK REF="REF-Bochud-2001" TYPE="REFERENCE">Bochud 2001</LINK>; <LINK REF="REF-Bochud-2004" TYPE="REFERENCE">Bochud 2004</LINK>; <LINK REF="REF-Cohen-2004" TYPE="REFERENCE">Cohen 2004</LINK>; <LINK REF="REF-Cunneen-2004" TYPE="REFERENCE">Cunneen 2004</LINK>; <LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>; <LINK REF="REF-Garnacho-2003" TYPE="REFERENCE">Garnacho 2003</LINK>; <LINK REF="REF-Garnacho-2006" TYPE="REFERENCE">Garnacho 2006</LINK>; <LINK REF="REF-Girbes-2008" TYPE="REFERENCE">Girbes 2008</LINK>; <LINK REF="REF-Marshall-2004" TYPE="REFERENCE">Marshall 2004</LINK>; <LINK REF="REF-Schuerholz-2008" TYPE="REFERENCE">Schuerholz 2008</LINK>).</P>
<P>However, antibiotic, surgical and supportive care are not always enough, and there is an urgent need for new therapies to reduce the mortality associated with severe sepsis (<LINK REF="REF-Paul-2009" TYPE="REFERENCE">Paul 2009</LINK>; <LINK REF="REF-Vincent-2002" TYPE="REFERENCE">Vincent 2002</LINK>). Clinical practice guidelines (<LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>; <LINK REF="REF-Vincent-2004" TYPE="REFERENCE">Vincent 2004</LINK>) include recommendations about adjunctive therapies that have been developed in an effort to reduce mortality from severe sepsis, such as supportive care (early goal-directed therapy, vasopressor, haemofiltration); target bacterial virulence factors (antiendotoxin antibodies); target host response factors (activated protein C, moderate doses of steroids, and blockage of cytokines); and immunotherapy (<LINK REF="REF-Azevedo-2008" TYPE="REFERENCE">Azevedo 2008</LINK>; <LINK REF="REF-Boussekey-2008" TYPE="REFERENCE">Boussekey 2008</LINK>; <LINK REF="REF-Cohen--2009" TYPE="REFERENCE">Cohen 2009</LINK>; <LINK REF="REF-Cunnington-2008" TYPE="REFERENCE">Cunnington 2008</LINK>; <LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>; <LINK REF="REF-Hotchkiss-2010" TYPE="REFERENCE">Hotchkiss 2010</LINK>; <LINK REF="REF-Iannaro-2009" TYPE="REFERENCE">Iannaro 2009</LINK>; <LINK REF="REF-Kumar-2004" TYPE="REFERENCE">Kumar 2004</LINK>; <LINK REF="REF-Leon-2008" TYPE="REFERENCE">Leon 2008</LINK>; <LINK REF="REF-Leone-2010" TYPE="REFERENCE">Leone 2010</LINK>; <LINK REF="REF-Moine-2007" TYPE="REFERENCE">Moine 2007</LINK>; <LINK REF="REF-Parrish-2008" TYPE="REFERENCE">Parrish 2008</LINK>; <LINK REF="REF-Rhodes-2004" TYPE="REFERENCE">Rhodes 2004</LINK>; <LINK REF="REF-Rigato-2006" TYPE="REFERENCE">Rigato 2006</LINK>; <LINK REF="REF-Sandrock-2010" TYPE="REFERENCE">Sandrock 2010</LINK>; <LINK REF="REF-Sibila-2008" TYPE="REFERENCE">Sibila 2008</LINK>; <LINK REF="REF-Vincent-2002" TYPE="REFERENCE">Vincent 2002</LINK>; <LINK REF="REF-Wang-2009a" TYPE="REFERENCE">Wang 2009a</LINK>; <LINK REF="REF-Wang-2009b" TYPE="REFERENCE">Wang 2009b</LINK>; <LINK REF="REF-Wesche_x002d_Soldato-2007" TYPE="REFERENCE">Wesche-Soldato 2007</LINK>; <LINK REF="REF-Wittebole-2008" TYPE="REFERENCE">Wittebole 2008</LINK>). A number of these recommendations have been insufficiently studied (<LINK REF="REF-Perner-2012" TYPE="REFERENCE">Perner 2012</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2013-11-01 15:13:47 +0000" MODIFIED_BY="[Empty name]">
<P>Sepsis is associated with alterations in blood coagulation, the fibrinolytic systems, and inflammatory pathways (<LINK REF="REF-Cinel-2009" TYPE="REFERENCE">Cinel 2009</LINK>; <LINK REF="REF-King-2013" TYPE="REFERENCE">King 2013</LINK>; <LINK REF="REF-Levi-2008" TYPE="REFERENCE">Levi 2008</LINK>; <LINK REF="REF-Rittirsch-2008" TYPE="REFERENCE">Rittirsch 2008</LINK>; <LINK REF="REF-Sriskandan-2008" TYPE="REFERENCE">Sriskandan 2008</LINK>). This leads to disorders of tissue perfusion that generate multiple organ system failure with depletion of platelets and coagulation factors, and activation of natural inhibitors of coagulation (<LINK REF="REF-King-2013" TYPE="REFERENCE">King 2013</LINK>).</P>
<P>One of the natural inhibitors of coagulation is protein C (<LINK REF="REF-Esmon-2006" TYPE="REFERENCE">Esmon 2006</LINK>). In patients with sepsis, protein C is depleted and the production of activated protein C (APC) is impaired, shifting the balance towards more intravascular coagulation and organ failure. The administration of APC, therefore, has theoretical advantages (<LINK REF="REF-Healy-2002" TYPE="REFERENCE">Healy 2002</LINK>; <LINK REF="REF-Hinds-2001" TYPE="REFERENCE">Hinds 2001</LINK>; <LINK REF="REF-Mann-2002" TYPE="REFERENCE">Mann 2002</LINK>). However, APC has a short biological half life and in severe sepsis the pool of circulating protein C is rapidly depleted (<LINK REF="REF-Mann-2002" TYPE="REFERENCE">Mann 2002</LINK>; <LINK REF="REF-Mann-2009" TYPE="REFERENCE">Mann 2009</LINK>; <LINK REF="REF-Yan-2001" TYPE="REFERENCE">Yan 2001</LINK>), which means that protein C levels may serve as a useful prognostic indicator of outcome in sepsis and related diseases (<LINK REF="REF-Fisher-2000" TYPE="REFERENCE">Fisher 2000</LINK>; <LINK REF="REF-Shorr-2006" TYPE="REFERENCE">Shorr 2006</LINK>). In addition, protein C levels have been considered as a possible tool for monitoring treatment with APC (<LINK REF="REF-Shorr-2008" TYPE="REFERENCE">Shorr 2008</LINK>).</P>
<P>In November 2001, the US Food and Drug Administration (FDA) approved recombinant human activated protein C (drotrecogin alfa activated, marketed as Xigris®) for use in people with severe sepsis based on their APACHE II score (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). Eli Lilly and Company's license depended on the results of only one randomized clinical trial (PROWESS, recombinant human activated protein C worldwide evaluation in severe sepsis) (<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>). In August 2002, the European Agency for Evaluation of Medicinal Products approved the addition of the drug to best standard care based on the sepsis-related multiple organ failure (SOFA) score (<LINK REF="REF-EMEA-2005" TYPE="REFERENCE">EMEA 2005</LINK>) as a measure of disease activity (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-11-01 14:58:47 +0000" MODIFIED_BY="[Empty name]">
<P>APC exerts antithrombotic, anticoagulant, anti-inflammatory, and pro-fibrinolytic effects by complex molecular pathways which have recently been reviewed (<LINK REF="REF-Christiaans-2013" TYPE="REFERENCE">Christiaans 2013</LINK>). It is therefore thought that APC may ameliorate or prevent coagulation processes during infection thereby leading to less organ failure and fewer deaths.</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-10-28 05:17:34 +0000" MODIFIED_BY="[Empty name]">
<P>This is the third update of this Cochrane review, which had been performed for the following reasons.</P>
<OL>
<LI>The search strategy has been updated (June 2012) leading to the identification of a new randomized clinical trial on APC in patients with septic shock (<LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>).</LI>
<LI>The trials have undergone updated assessment of risk of bias.</LI>
<LI>The trials have been subjected to trial sequential analyses in order to assess the risk of random errors and the potential need for further trials.</LI>
</OL>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-10-28 05:18:02 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the benefits and harms of activated protein C (APC) for the treatment of patients with severe sepsis or septic shock.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-05-29 17:53:38 +0100" MODIFIED_BY="Jane Cracknell">
<SELECTION_CRITERIA MODIFIED="2012-10-28 05:30:16 +0000" MODIFIED_BY="Jane Cracknell">
<CRIT_STUDIES MODIFIED="2012-07-23 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomized clinical trials with parallel or cross-over designs, irrespective of publication status or language. For cross-over trials, we planned to include only data from the first intervention period.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-10-28 05:19:27 +0000" MODIFIED_BY="Jane Cracknell">
<P>We included patients with severe sepsis or septic shock, irrespective of the aetiology or their ages. We excluded neonates (&lt; 28 days old, at any gestational age or birth weight) because another Cochrane review addresses this question (<LINK REF="STD-Kylat-2012" TYPE="STUDY">Kylat 2012</LINK>).</P>
<P>We sought trials that defined severe sepsis according to standardised international criteria, such as the American College of Chest Physicians and the Society of Critical Care Medicine Consensus Conference international guidelines (<LINK REF="REF-ACCP_x002d_SCCM-1992" TYPE="REFERENCE">ACCP-SCCM 1992</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-10-28 05:20:37 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Intervention</HEADING>
<P>Recombinant human APC delivered intravenously plus conventional care</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Control</HEADING>
<P>Placebo plus conventional care or no intervention plus conventional care</P>
<P>We accepted the definitions of conventional care provided by the trialists, defining it as an integrative approach to sepsis care including sepsis identification and control, antibiotic therapy, fluid therapy, blood product administration, and mechanical ventilation with sepsis-induced acute lung injury (<LINK REF="REF-Dellinger-2008" TYPE="REFERENCE">Dellinger 2008</LINK>).</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-10-28 05:30:16 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-10-28 05:29:47 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>All-cause mortality at day 28, and at the end of study follow up</LI>
<LI>Hospital mortality</LI>
<LI>Adverse events: number and type of adverse events defined as patients with any untoward medical occurrence not necessarily having a causal relationship with the treatment. We reported on adverse events that led to treatment discontinuation and those that did not lead to treatment discontinuation separately</LI>
</OL>
<P>We have defined serious adverse events according to the International Conference on Harmonisation (ICH) Guidelines (<LINK REF="REF-ICH_x002d_GCP1997" TYPE="REFERENCE">ICH-GCP1997</LINK>) as any event that at any dose results in death, is life-threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability, or is a congenital anomaly or birth defect, and any important medical event which may have jeopardised the patient or required intervention to prevent it. All other adverse events were considered non-serious.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-10-28 05:30:16 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Bleeding</LI>
<LI>Thrombotic event</LI>
<LI>Quality of life measures (based on any item from a validated scale)</LI>
<LI>Time to discharge from intensive care unit</LI>
<LI>Development of organ failure</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-05-29 17:53:38 +0100" MODIFIED_BY="Jane Cracknell">
<ELECTRONIC_SEARCHES MODIFIED="2013-05-29 17:53:38 +0100" MODIFIED_BY="Jane Cracknell">
<P>We updated the search of our previous review (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2011" TYPE="REFERENCE">Martí-Carvajal 2011</LINK>) by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>  2013, Issue 5), see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; Ovid MEDLINE (June 2012 to May 2013), see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; Ovid EMBASE (June 2012 to May 2013), see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; LILACS (June 2012 to May 2013), see <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>; BIOSIS via Ovid (June 2012 to May 2013), see <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>; and CINAHL via EBSCOhost (June 2012 to May 2013), see <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>. We used the specific search terms listed below in combination with the Cochrane highly sensitive search strategy for identifying trials (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>Our search terms were:</P>
<OL>
<LI>anticoagulants;</LI>
<LI>protein C;</LI>
<LI>recombinant protein*;</LI>
<LI>blood coagulation factor inhibitor*;</LI>
<LI>disseminated intravascular coagulation;</LI>
<LI>APC alfa;</LI>
<LI>APC;</LI>
<LI>rh APC;</LI>
<LI>recombinant human activated protein C;</LI>
<LI>sepsis;</LI>
<LI>septic shock;</LI>
<LI>shock;</LI>
<LI>septic;</LI>
<LI>sepsis syndrome;</LI>
<LI>septicemia;</LI>
<LI>septicaemia.</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-10-28 05:32:18 +0000" MODIFIED_BY="[Empty name]">
<P>We also searched in:</P>
<OL>
<LI>the references of review articles;</LI>
<LI>books related to sepsis treatment and critical care.</LI>
</OL>
<P>We did not search databases of ongoing trial registers due to the fact that on 25 October 2011 Eli Lilly announced the discontinuation of all ongoing clinical trials. We included all relevant identified studies, regardless of language or publication status (published, unpublished, in press and in progress). We checked the citations in the reports of the trials that were identified by the above methods.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-10-28 05:47:32 +0000" MODIFIED_BY="Jane Cracknell">
<STUDY_SELECTION MODIFIED="2012-10-28 05:33:00 +0000" MODIFIED_BY="[Empty name]">
<P>Arturo Martí-Carvajal (AMC) and Andrés Felipe Cardona (AFC) independently screened the results of the search strategy for potentially relevant trials, and independently assessed them for inclusion based on the inclusion criteria. We resolved disagreements through discussion with Dimitrios Lathyris (DL) until a consensus was reached.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-10-28 05:38:49 +0000" MODIFIED_BY="Jane Cracknell">
<P>Two authors carried out data extraction (AMC and AFC) using a pre-designed data extraction form that contained publication details, patient population, randomization, allocation concealment, details of blinding measures, description of interventions, and results (<LINK REF="REF-Zavala-2006" TYPE="REFERENCE">Zavala 2006</LINK>). We resolved discrepancies through discussion. We involved a third author (Ivan Solà (IS)) to check for accuracy the data entered into the Review Manager software (<LINK REF="REF-RevMan-5.1" TYPE="REFERENCE">RevMan 5.1</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-10-28 05:40:49 +0000" MODIFIED_BY="Jane Cracknell">
<P>All authors independently assessed the risk of bias of the trials according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We assessed the following domains, using the following definitions.</P>
<SUBSECTION>
<HEADING LEVEL="5">Generation of the allocation sequence</HEADING>
<UL>
<LI>Low risk of bias, if the allocation sequence was generated by a computer or random number table, drawing of lots, tossing of a coin, shuffling of cards, or throwing dice.</LI>
<LI>Unclear, if the trial was described as randomized but the method used for the allocation sequence generation was not described.</LI>
<LI>High risk of bias, if a system involving dates, names, or admittance numbers was used for the allocation of patients. These studies are known as quasi-randomized and were excluded from the present review when assessing beneficial effects.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias, if the allocation of patients involved a central independent unit, on-site locked computer, identical-appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.</LI>
<LI>Unclear, if the trial was described as randomized but the method used to conceal the allocation was not described.</LI>
<LI>High risk of bias, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomized. The latter was excluded from the present review when assessing beneficial effects.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blinding (or masking)</HEADING>
<P>We assessed each trial (as 'Low', 'Unclear', or 'High risk') with regard to the following levels of blinding:</P>
<UL>
<LI>blinding of clinician (person delivering treatment) to treatment allocation;</LI>
<LI>blinding of participant to treatment allocation;</LI>
<LI>blinding of outcome assessor to treatment allocation.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or it was specified that there were no dropouts or withdrawals.</LI>
<LI>Unclear, if the report gave the impression that there had been no dropouts or withdrawals but this was not specifically stated.</LI>
<LI>High risk of bias, if the number or reasons for dropouts and withdrawals were not described.</LI>
</UL>
<P>We further examined the percentage of dropouts overall in each trial and per randomization arm and we evaluated whether intention-to-treat analysis was performed or could be performed from the published information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk of bias, if pre-defined or clinically relevant and reasonably expected outcomes were reported on.</LI>
<LI>Unclear, if not all pre-defined or clinically relevant and reasonably expected outcomes were reported on or were not reported on fully, or it was unclear whether data on these outcomes were recorded or not.</LI>
<LI>High risk of bias, if one or more clinically relevant and reasonably expected outcomes were not reported on; and data on these outcomes were likely to have been recorded.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other bias</HEADING>
<UL>
<LI>Low risk of bias, the trial appeared to be free of other components that could put it at risk of bias.</LI>
<LI>Unclear, the trial may or may not be free of other components that could put it at risk of bias.</LI>
<LI>High risk of bias, there were other factors in the trial that could put it at risk of bias.</LI>
</UL>
<P>We considered low risk of bias trials to be those that adequately generated their allocation sequence; had adequate allocation concealment, adequate blinding, adequate handling of incomplete outcome data; were free of selective outcome reporting; and were free of other bias.</P>
<P>We considered trials in which we could assess one of the domains as high risk of bias or unclear risk of bias as trials with high risk of bias.</P>
<P>AMC and IS assessed the included studies and registered the information in tables; see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. AFC and DL checked the entered data.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-06-29 11:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>We pooled the relative risk (RR) with 95% confidence interval (CI) for the following binary outcomes: all-cause mortality at day 28, and at the end of study follow up; hospital mortality; bleeding; a thrombotic event; development of organ failure; and adverse events.</P>
<P>For continuous outcomes (quality of life and time to discharge from the intensive care unit) the standardised mean difference with 95% CI was calculated, as recommended by <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2012-10-28 05:42:40 +0000" MODIFIED_BY="[Empty name]">
<P>For all included trials, we registered the levels of attrition. We contacted the main author of <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> and researchers of <LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK> for missing data. We used data gathered from the FDA website (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>) to manage unpublished data from <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-10-28 05:43:15 +0000" MODIFIED_BY="[Empty name]">
<P>We quantified the statistical heterogeneity using the I<SUP>2</SUP>statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). When heterogeneity was detected (I<SUP>2 </SUP>&gt; 50%) we attempted to identify the possible causes of the heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-10-28 05:43:25 +0000" MODIFIED_BY="[Empty name]">
<P>We did not assess publication bias by a funnel plot because we included only six randomized clinical trials.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-07-20 15:54:20 +0100" MODIFIED_BY="Jane Cracknell">
<P>We pooled the results from the trials using the Review Manager software (<LINK REF="REF-RevMan-5.1" TYPE="REFERENCE">RevMan 5.1</LINK>). We summarised the findings using a random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-10-28 05:47:08 +0000" MODIFIED_BY="[Empty name]">
<P>We devoted further efforts to identifying possible causes of heterogeneity. We explored the impact of the included trials' risk of bias and the condition of the individuals by subgroup analyses. We anticipated clinical heterogeneity for the following participant and intervention characteristics.</P>
<OL>
<LI>Participants' severity of disease (APACHE score, dichotomized at 25).</LI>
<LI>Participants' age.</LI>
<LI>Level of protein C content in the blood.</LI>
<LI>Site of infection.</LI>
<LI>Number of organs showing dysfunction.</LI>
<LI>Positive blood culture.</LI>
</OL>
<P>These different variables justified subgroup analyses. We performed subgroup analysis only for the primary outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial sequential analysis</HEADING>
<P>Meta-analysis of cumulative data may run the risk of random errors (&#8216;play of chance&#8217;) due to sparse data and repetitive analyses of the same data (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; 
<LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>; 
<LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; 
<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). In order to assess the risks of random errors in our cumulative meta-analyses, we conducted diversity-adjusted trial sequential analyses based upon the proportion with the outcome in the control group; an a priori set relative risk reduction of 20%; an alpha of 5%, a beta of 20%; and the diversity in the meta-analysis (<LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). We conducted sensitivity analysis of the trial sequential analysis to estimate the potential need for further trials.<BR/>
</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-10-28 05:47:32 +0000" MODIFIED_BY="Jane Cracknell">
<P>Our search strategy found two FDA reports (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>) which made it clear that the <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> contained two substudies: one with 720 participants where the trial was carried out following the initial protocol; and another trial with 970 participants where the original protocol had been amended. We used this information to perform a sensitivity analysis. See <LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings tables</HEADING>
<P>We used the GRADE proposals (<LINK REF="REF-Guyatt-2011" TYPE="REFERENCE">Guyatt 2011</LINK>) to assess the quality of the body of evidence associated with the following outcomes: 28-day all-cause mortality in adult and paediatric patients, in-hospital mortality, and serious bleeding events (days 0 to 28). We constructed a '<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> (SoF) using the GRADEPro software (<A HREF="http://ims.cochrane.org/revman/other-resources/gradepro">http://ims.cochrane.org/revman/other-resources/gradepro</A>). GRADE classifies the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the outcome being assessed (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>; <LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>; <LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>; <LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>; <LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>; <LINK REF="REF-Guyatt-2011f" TYPE="REFERENCE">Guyatt 2011f</LINK>; <LINK REF="REF-Guyatt-2011g" TYPE="REFERENCE">Guyatt 2011g</LINK>).<BR/>
</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-10-06 20:11:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-10-28 10:49:16 +0000" MODIFIED_BY="Jane Cracknell">
<SEARCH_RESULTS MODIFIED="2012-10-28 05:49:39 +0000" MODIFIED_BY="Jane Cracknell">
<P>In this updated version we detected 519 references of potential interest after duplicates were removed (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We identified and retrieved 10 potentially relevant articles (see table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'). From these 529 references we excluded 491 as they did not meet our inclusion criteria. We included 38 references, including the FDA's reports developed during APC approval (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>), to six randomized clinical trials.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-10-28 10:49:16 +0000" MODIFIED_BY="[Empty name]">
<P>All the trials included in this review were funded by Eli Lilly and Company and involved authors that were stockholders, had served as consultants, or were employed by the company.</P>
<P>This update adds a new randomized clinical trial (<LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>) to the five included in our previous version of the review. These randomized clinical trials included 6781 participants, 6307 adults (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>) and 474 paediatric patients (<LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>). All included studies compared APC with placebo. The first trial on the topic was a randomized phase II dose-ranging trial (<LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>), whereas the rest were phase III clinical trials to assess the efficacy and safety of APC (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>). Five randomized clinical trials were conducted using a dose of 24 µg/kg/hr intravenously for a total duration of 96 hours (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>). The <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK> trial was carried out but with the same dose of drug but with a total duration of 168 hours.</P>
<P>With the exception of the <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK> that took place in the United States and Canada, the rest were international trials in: 164 centres in 11 countries (<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>); 516 centres from 34 countries (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>); 64 centres in nine countries (<LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>); 104 centres in 18 countries (<LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>); and 208 centres in Europe, North and South America, Australia, New Zealand, and India (<LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>). Five trials enrolled adult participants (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>) and the remaining trial enrolled children (N = 79 &gt; 1 month to &lt; 18 years old) and neonates (N = 3 &lt; 1 month old) (<LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>). We could not discriminate the outcomes in the two subgroups of paediatric patients so we included all. Data from the <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK> and <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> trials were used in the regulatory process by the FDA.</P>
<P>We provide an outline of the characteristics of the included trials as follows. These are described in full in the 'Characteristics of included studies' table.</P>
<P>The <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK> assessed the safety and effect on coagulopathy of a range of doses of APC (in 90 patients with a mean APACHE II score of 16.8 (SD 5.2)) compared with a saline placebo (in 41 patients with a mean APACHE II score of 18.4 (SD 6.9)). Up to 70% of patients were in septic shock and needed mechanical support on the day prior to infusion; with an underlying medical cause of sepsis in most of them. One third of patients had multiple organ failure and the rest had single organ failure, it was the cardiovascular and respiratory systems that most frequently failed. Decisions regarding the use of antimicrobial agents, intravenous fluids, cardiovascular and respiratory support, and surgical intervention were left to the treating physician and were not pre-specified in the protocol. The intervention could be provided for between 48 and 96 hours but the study did not report the administration time.</P>
<P>The PROWESS study was the first phase III trial. It set out to assess the reduction in rate of death from all causes at 28 days with APC (drotrecogin alfa activated) compared with a placebo consisting of 0.9% saline and the addition of 0.1% human serum albumin (<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>). The trial established the standard dose of 24 µg/kg/hr intravenously for a total duration of 96 hrs, assessed in the rest of the included trials. Despite the information reported in the main publication of the PROWESS study, the data from two FDA reports (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>) made it clear that the trial contained two different protocols, one with 720 participants following the initial protocol and a subsequent phase with 970 participants where the registered protocol had been changed. The study defined sepsis as an infection with at least three signs of systemic inflammatory response syndrome and one sepsis-induced organ dysfunction. A sample size calculation was detailed only in the FDA reports, which included up to 27 subgroups analyses. The FDA report stated that the study planned to enrol 2280 patients with two interim analyses, after 760 and 1520 patients had been enrolled. The journal publication reported the results for 1690 randomized patients (850 receiving APC and 840 receiving placebo) because recruitment was recommended to be suspended after the second interim analysis due to a statistically significant reduction in 28-day mortality.</P>
<P>Data gathered from the FDA reports showed that the trial was split into two different protocols (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>), an issue that was not reported in the main PROWESS publication. After the enrolment of 720 participants under the first protocol (from July 1998 to July 1999), a second protocol was approved (on 5 March 1999) seven months before the first interim analysis, after which an additional 970 participants were enrolled (from June 1999 to June 2000). The amendment was approved &#8216;prior to the first unblinding of the external statistical services organization statistician, who prepared analyses for the prospectively defined first interim analysis' (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>). Some baseline characteristics, by the first and second protocols, are shown in <LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK> (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>).</P>
<P>The main changes from the first protocol were the addition of new exclusion criteria and the addition of 0.1% human serum albumin to the initial 0.9% sodium chloride placebo. Furthermore, in August 1999 the sponsor introduced a change in the manufacturing of the drug (<LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>). The original manufactured drug was referred to as 'Bulk Drug Substance' (BDS) BDS2 and the newly manufactured drug as BDS2+. A number of extensive analyses were conducted. No differences were detected between the two manufactured products. Given the complexity of the molecule, however, one cannot exclude the possibility of undetected differences (<LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>). Detailed changes to the PROWESS protocol are shown in <LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK> and <LINK REF="APP-11" TYPE="APPENDIX">Appendix 11</LINK>. The exclusion criteria of PROWESS are shown in <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>.</P>
<P>After the FDA approval of APC, the <LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK> study was designed to assess the effects of drotrecogin alfa activated in adults with severe sepsis and a low risk of death. Although the sample size was calculated for 11,444 patients, the data monitoring committee recommended the early termination of enrolment for futility after an interim analysis when the recruitment reached 1500 patients. At the time of trial termination, 2640 had enrolled in the study but data were analysed for 2613: 1316 receiving drotrecogin alfa activated and 1297 receiving 0.9% sodium chloride. Despite its objective, the trial included 12% of patients at high risk of death.</P>
<P>The RESOLVE study was the only included trial that recruited paediatric patients (between 38 weeks and 17 years of age) with severe sepsis and organ dysfunction (<LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>). The trial compared results of 240 children receiving drotrecogin alfa activated with 237 children receiving 0.9% saline. The sample size was calculated to show differences regarding a composite time to complete organ failure resolution (CTCOFR) score of three organ systems, cardiovascular, respiratory, and renal, based on The International Paediatric Sepsis Conference (<LINK REF="REF-Goldstein-2005" TYPE="REFERENCE">Goldstein 2005</LINK>). After two years, enrolment was suspended when the second planned interim analysis suggested that there was little chance of reaching the efficacy endpoint by completion of the trial (<LINK REF="REF-FDA-2005" TYPE="REFERENCE">FDA 2005</LINK>). <LINK REF="APP-13" TYPE="APPENDIX">Appendix 13</LINK> shows the RESOLVE trial resolution organ dysfunction definitions.</P>
<P>
<LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK> assessed an extended dose of drotrecogin alfa activated (during 72 additional hours after 96 hours of APC) in 94 patients with vasopressor requirements and persistent septic shock compared with 99 patients that received the sodium chloride placebo. APACHE scores were not part of the inclusion criteria but at baseline participants had a mean score of 28.1 (SD 8.1) and a mean of 2.9 (SD 1.0) organ failures. Baseline data also showed an imbalance in protein C levels. The study based its sample size calculation on the PROWESS trial, planning the recruitment of 270 patients. This had to be reduced to 200 patients.</P>
<P>
<LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK> was designed as "Whilst mindful of the results of the PROWESS, ADDRESS and RESOLVE studies, and Lilly&#8217;s obligations to drug registration agencies, the primary goal of the trial is to provide clinicians with robust evidence regarding the efficacy and safety of DAA in a clearly defined and clinically important patient population" (<LINK REF="REF-Finfer-2008" TYPE="REFERENCE">Finfer 2008</LINK>). This trial was conducted to assess the effects of APC in adults patients with septic shock. This randomized clinical trials involved 1680 patients and found that human recombinant activated protein C (rhAPC) failed to reduce 28-day all-cause mortality when compared with placebo (<LINK REF="REF-Mitka-2011" TYPE="REFERENCE">Mitka 2011</LINK>). On 25 October 2011, the European Medicines Agency issued a press release on the worldwide withdrawal of Xigris® (rhAPC) from the market by Eli Lilly due to its lack of beneficial effect on 28-day mortality in the PROWESS-SHOCK study (<LINK REF="REF-EMEA-2011" TYPE="REFERENCE">EMEA 2011</LINK>).<BR/>
</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-10-28 10:46:32 +0000" MODIFIED_BY="[Empty name]">
<P>This updated review excluded a total of 35 studies which did not meet the inclusion criteria (<LINK REF="STD-Barton-2004" TYPE="STUDY">Barton 2004</LINK>; <LINK REF="STD-Bearden-2002" TYPE="STUDY">Bearden 2002</LINK>; <LINK REF="STD-Bernard-2004" TYPE="STUDY">Bernard 2004</LINK>; <LINK REF="STD-Bertolini-2007" TYPE="STUDY">Bertolini 2007</LINK>; <LINK REF="STD-Casey-2002" TYPE="STUDY">Casey 2002</LINK>; <LINK REF="STD-Costa-2007" TYPE="STUDY">Costa 2007</LINK>; <LINK REF="STD-Decruyenaere-2009" TYPE="STUDY">Decruyenaere 2009</LINK>; <LINK REF="STD-Ferrer-2009" TYPE="STUDY">Ferrer 2009</LINK>; <LINK REF="STD-Freeman-2003" TYPE="STUDY">Freeman 2003</LINK>; <LINK REF="STD-Goldstein-2006" TYPE="STUDY">Goldstein 2006</LINK>; <LINK REF="STD-Green-2005" TYPE="STUDY">Green 2005</LINK>; <LINK REF="STD-Heslet-2004" TYPE="STUDY">Heslet 2004</LINK>; <LINK REF="STD-Houston-2009" TYPE="STUDY">Houston 2009</LINK>; <LINK REF="STD-Kanji-2007" TYPE="STUDY">Kanji 2007</LINK>; <LINK REF="REF-Levi-2008" TYPE="REFERENCE">Levi 2008</LINK>; <LINK REF="STD-Lucioni-2002" TYPE="STUDY">Lucioni 2002</LINK>; <LINK REF="STD-Marraro-2009" TYPE="STUDY">Marraro 2009</LINK>; <LINK REF="STD-McCoy-2003" TYPE="STUDY">McCoy 2003</LINK>; <LINK REF="STD-McCoy-2004" TYPE="STUDY">McCoy 2004</LINK>; <LINK REF="STD-Neilson-2003" TYPE="STUDY">Neilson 2003</LINK>; <LINK REF="STD-van-Doorn-2008" TYPE="STUDY">van Doorn 2008</LINK>; <LINK REF="STD-Vincent-2005" TYPE="STUDY">Vincent 2005</LINK>; <LINK REF="STD-Wheeler-2008" TYPE="STUDY">Wheeler 2008</LINK>; <LINK REF="STD-Wiedermann-2005" TYPE="STUDY">Wiedermann 2005</LINK>). See the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
<SUBSECTION>
<HEADING LEVEL="5">Ongoing studies</HEADING>
<P>Eli Lilly has announced the discontinuation of all ongoing clinical trials (<LINK REF="REF-EMEA-2011" TYPE="REFERENCE">EMEA 2011</LINK>).</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-10-28 10:53:30 +0000" MODIFIED_BY="Jane Cracknell">
<P>The risk of bias was evaluated in each of the included randomized clinical trials. Full details are shown in <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.<BR/>
</P>
<ALLOCATION MODIFIED="2012-10-28 10:47:30 +0000" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Risk of bias arising from the method of generation of the allocation sequence was low in two trials ( <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>). It was unclear in the remainder of trials (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>).</P>
<P>Risk of bias arising from the method of allocation concealment was rated as low in one trial (<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>). Allocation concealment was not reported in the remaining trials (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-10-28 10:51:54 +0000" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Risk of bias due to blinding of participants and personnel was rated as low in two trials because the drug preparations were covered to make them indistinguishable (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>). The risk of bias was unclear in the remainder of trials (<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Blinding of outcome assessors (detection bias)</HEADING>
<P>Risk of bias arising from lack of blinding of outcome assessment was rated as unclear in all included trials (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>). From <LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK> we obtained the information that all deaths and serious adverse events in <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> were reviewed by the sponsor (Eli Lilly) in a blinded manner.</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-06-28 09:37:02 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Risk of attrition bias was rated as low in five trials (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>). Risk of attrition bias was rated as high in <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>. </P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-06-28 09:39:25 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Risk of reporting bias was rated as low in all trials (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-10-28 10:53:30 +0000" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>All the trials included in this review were funded by Eli Lilly and Company and involved authors that were stockholders, had served as consultants, or were employed by the company (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>).</P>
<P>There is some concern regarding the completion of the included trials as they were designed based on their original protocols. <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> modified its inclusion criteria and amended the original protocol after the inclusion of 700 patients, and prematurely stopped the recruitment for benefit. Both <LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK> and <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK> terminated the enrolment early for futility.</P>
<P>
<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK> showed a discrepancy in the report with the total number of participants who completed the study and those who were analysed.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-10-06 20:11:50 +0100" MODIFIED_BY="[Empty name]">
<P>Results were based on 6781 participants (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>All-cause mortality at day 28, and at the end of study follow up</I>
</HEADING>
<P>Pooled estimates of the five trials including adult patients (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>) and one trial including paediatric patients (<LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>) did not show differences in 28-day mortality between APC and placebo (1547 events in 6781 patients; RR 1.00, 95% CI 0.86 to 1.16; I<SUP>2</SUP> = 56%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Trial sequential analysis for 28-day all-cause mortality suggested that no more trials may be needed for disproving an intervention effect of 20% relative risk reduction. Smaller risk reductions might still require further trials (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>We found a high statistical heterogeneity (I<SUP>2</SUP> = 56%). Therefore, we performed a subgroup analysis by age (adult patients compared to paediatric patients) and by treatment duration (96 hours compared to &gt; 96 hours) (<LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis by age (adult patients compared to paediatric patients)</HEADING>
<P>Meta-analysis of five trials with adult patients (N = 6307 participants, 1465 events) did not show a difference in 28-day mortality between APC and placebo (pooled RR 1.00, 95% CI 0.84 to 1.19; I<SUP>2</SUP> = 65%) (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>). The paediatric trial did not show a difference in 28-day mortality between APC and placebo (RR 0.98, 95% CI 0.66 to 1.46; P = 0.93) (<LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>). The test for subgroups did not show differences between the groups (I<SUP>2</SUP> = 0%, P = 0.94). See <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.</P>
<P>
<B>Subgroup analysis by treatment duration comparing 96 hours to more than 96 hours</B>
</P>
<P>Meta-analysis of five trials conducted over the conventional treatment duration (96 hours) and including adult and paediatric patients (N = 6588 participants, 1479 events) did not show a difference in 28-day mortality between APC and placebo (pooled RR 0.97, 95% CI 0.83 to 1.14; I<SUP>2</SUP> = 59%) (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>). The extended treatment duration (&gt; 96 hours) trial did not show a difference in 28-day mortality between APC and placebo (RR 1.26, 95% CI 0.86 to 1.85; P = 0.24) (<LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>). The test for subgroups did not show differences between the groups (I<SUP>2</SUP> = 32.7%, P = 0.22). See <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.</P>
<P>
<B>Sensitivity analysis by </B>
<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> <B>first protocol compared to second protocol</B>
</P>
<P>According to the FDA data for the <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> trial (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>), APC did not show a reduction in mortality when the trial maintained the original protocol (RR 0.94, 95% CI 0.75 to 1.1) and only had a beneficial effect in the second half of the study (RR 0.71, 95% CI 0.57 to 0.87) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). The test for subgroups showed significant differences between the groups (I<SUP>2</SUP> = 68.4%, P = 0.08).</P>
<P>We therefore performed a sensitivity analysis including data from all trials (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>) compared with data from <LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK> and the <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> modified protocol. Meta-analysis of six trials did not show differences in 28-day mortality between APC and placebo (RR 1.00, 95% CI 0.86 to 1.16; I<SUP>2</SUP> = 56%). Meta-analysis of six trials but excluding the data of the <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> first protocol did not show a differences in 28-day mortality between APC and placebo and found a higher statistical heterogeneity (RR 0.93, 95% CI 0.70 to 1.24; I<SUP>2</SUP> = 87%). The test for subgroups did not show differences between the groups (I<SUP>2</SUP> = 0%, P = 0.66) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>
<B>Subgroup analysis by severity of disease (APACHE II scores lower compared to higher than 25)</B>
</P>
<P>Three included trials (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>) allowed a subgroup analysis by severity of disease (APACHE II score lower compared to higher than 25). APC did not show a reduction in the patients with a APACHE II score below 25 (low risk of death) (RR 1.05, 95% CI 0.92 to 1.2; I<SUP>2</SUP> = 0%), nor for patients with a high risk of death (RR 0.96, 95% CI 0.68 to 1.35; I<SUP>2 </SUP>= 86%). The test for subgroups did not show differences between the groups (I<SUP>2</SUP> = 0%, P = 0.62) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
<P>
<B>Subgroup analysis of patients according to protein C deficiency class</B>
</P>
<P>Two trials reported the effects of APC according to the protein C content in the blood of the patients (<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>). The effect of APC versus placebo on mortality was not significant in patients having a protein C deficiency (less than 80% of normal value) (700 events in 2613 patients; RR 0.91, 95% CI 0.70 to 1.17; I<SUP>2</SUP> = 75%). Data from <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> and <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK> did not show a difference in the patients not having a protein C deficiency (more than 80% of normal value) on 28-day mortality (62 events in 290 patients; RR 0.65, 95% CI 0.41 to 1.04; I<SUP>2</SUP> = 0%). Data from <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> did not show a difference between APC and placebo in patients with an unknown protein C concentration on 28-day mortality (30 events in 116 patients; RR 1.12, 95% CI 0.60 to 2.07; P = 0.73). The test for subgroups did not show differences between the groups (I<SUP>2</SUP> = 8.6%, P = 0.33) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>
<B>Subgroup analysis of patients according to the baseline organ dysfunction category (single organ dysfunction (&lt; 2) compared to multiple organ dysfunction (&#8805; 2)</B>
</P>
<P>Two trials reported the effects of APC according to single organ dysfunction (&lt; 2) in patients with low and high risk of bias (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>). The effect of APC versus placebo on mortality was not significant in these patients (575 events in 1778 patients; RR 1.17, 95% CI 0.95 to 1.45; I<SUP>2</SUP> = 0%). Two trials reported the effects of APC according to multiple organ dysfunction (in patients with an unknown protein C concentration &#8805; 2) in patients with low and high risk of bias (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>). The effect of APC versus placebo on mortality was not significant in these patients (602 events in 2503 patients; RR 1.04, 95% CI 0.91 to 1.20; I<SUP>2</SUP> = 0%). The test for subgroups did not show differences between the groups (I<SUP>2</SUP> = 0%, P = 0.38) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
<P>
<B>Subgroup analysis of patients according to the baseline organ dysfunction category (baseline organ dysfunction category (&lt; 3) compared to multiple organ dysfunction (&#8805; 3)</B>
</P>
<P>Two trials reported the effects of APC according to the baseline organ dysfunction category (&lt; 3) (<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>). The effect of APC versus placebo on mortality was not significant in these patients (255 events in 1224 patients; RR 1.05, 95% CI 0.60 to 1.86; I<SUP>2</SUP> = 73%). Two trials reported the effects of APC according to multiple organ dysfunction (&#8805; 3) (<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>). The effect of APC versus placebo on mortality was not significant in these patients (637 events in 2145 patients; RR 0.90, 95% CI 0.67 to 1.22; I<SUP>2</SUP> = 81%). The test for subgroups did not show differences between the groups (I<SUP>2</SUP> = 0%, P = 0.64) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Hospital mortality</I>
</HEADING>
<P>Estimates of five trials (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>) did not show differences in hospital mortality between APC and placebo (1187 events in 4307 patients; RR 1.04, 95% CI 0.94 to 1.15; I<SUP>2</SUP> = 11%) with marginal heterogeneity (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
<P>Trial sequential analysis for in-hospital mortality suggested that no more trials may be needed for disproving an intervention effect of 14% relative risk reduction. Smaller risk reductions might still require further trials (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Adverse events</I>
</HEADING>
<P>Adverse events (including bleeding and non-bleeding events such as skin rash, hypertension, abnormal healing, hallucinations) were reported in five studies (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-APROCCHSS-2013" TYPE="STUDY">APROCCHSS 2013</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>). The RR for serious adverse events did not show a difference when APC and placebo were compared (575/3542 (16.23%) versus 550/3505 (15.69%); RR 1.02, 95% CI 0.93 to 1.13; I<SUP>2</SUP> = 0%) (see <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
<P>
Trial sequential analysis for adverse events suggested that no more trials may be needed for disproving an intervention effect of 13% relative risk reduction (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Bleeding</HEADING>
<P>APC showed no an increased risk of serious bleeding when compared with placebo (139/3632 (3.82%) versus 103/3546 (2.90%); RR 1.26, 95% CI 0.94 to 1.67; I<SUP>2</SUP> = 16%) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
<P>
Trial sequential analysis for serious bleeding suggested that no more trials may be needed for disproving an intervention effect of 41% relative risk reduction (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</P>
<P>The RR for serious bleeding during infusion did not show a difference when APC and placebo were compared (RR 1.80, 95% CI 0.96 to 3.40; I<SUP>2</SUP> = 16%). See <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>. The RR for central nervous system bleeding, including paediatric and adult patients, did not show a differences between the APC and placebo groups (RR 1.72, 95% CI 0.72 to 4.12; I<SUP>2</SUP> = 16%) (<LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>). See <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>This outcome was not evaluated in the included trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Development of organ failure</HEADING>
<P>This outcome was not evaluated in the included trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Time to discharge from an intensive care unit</HEADING>
<P>
<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> evaluated the number of days from the start of APC infusion to intensive care unit discharge. APC and placebo-treated patients showed the same median number of days until discharge for hospital survivor patients (nine days, P = 0.7) and for hospital non-survivor patients (eight days, P = 0.58). The interquartile ranges were not reported for any group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Thrombotic events</HEADING>
<P>One trial (<LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK>) reported a similar proportion of thrombotic events in both intervention groups: 2% in APC the group versus 3% in the placebo group.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-11-02 16:04:46 +0000" MODIFIED_BY="Jane Cracknell">
<SUMMARY_OF_RESULTS MODIFIED="2012-10-28 11:24:34 +0000" MODIFIED_BY="[Empty name]">
<P>Meta-analysis of six trials showed that activated protein C (APC) did not have a statistically significant effect on 28-day mortality when compared with placebo in patients with severe sepsis or septic shock. In addition, our results showed an increased risk of bleeding events, which does not support the use of this drug (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-07-13 09:43:53 +0100" MODIFIED_BY="[Empty name]">
<P>The results in this review are based on data from trials that included a broad range of patients with different co-morbidities who received different treatment approaches. Although these aspects could be considered as a threat to applicability, the consistency in the results derived from our analyses shows that the included trials may represent a broad picture of patients with severe sepsis or septic shock. </P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-11-02 16:04:46 +0000" MODIFIED_BY="[Empty name]">
<P>The main source of bias in the included trials was the lack of detail in describing the generation of the randomization sequence or the allocation concealment (<LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK>; <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>; <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK>; <LINK REF="STD-rhAPC-Sepsis-Study-2001" TYPE="STUDY">rhAPC Sepsis Study 2001</LINK>). Apart from that the trials were apparently adequately blinded and were free of outcome reporting biases. However, if the trials had problems with randomization this may also affect blinding to the intervention.</P>
<P>There are two issues that are not negligible and could have an effect on the confidence in the overall estimates shown in this review. All the included trials were sponsored by Eli Lilly and included authors that were stockholders or were employed by this company. A large number of studies show that drug-industry sponsorship is more likely to be associated with statistically significant findings (<LINK REF="REF-Bekelman-2003" TYPE="REFERENCE">Bekelman 2003</LINK>; <LINK REF="REF-Bhandari-2004" TYPE="REFERENCE">Bhandari 2004</LINK>; <LINK REF="REF-J_x00f8_rgensen-2006" TYPE="REFERENCE">Jørgensen 2006</LINK>; <LINK REF="REF-Khan-2008" TYPE="REFERENCE">Khan 2008</LINK>; <LINK REF="REF-Lexchin-2003" TYPE="REFERENCE">Lexchin 2003</LINK>; <LINK REF="REF-Lexchin-2005" TYPE="REFERENCE">Lexchin 2005</LINK>; <LINK REF="REF-Melander-2003" TYPE="REFERENCE">Melander 2003</LINK>; <LINK REF="REF-Sismondo-2008a" TYPE="REFERENCE">Sismondo 2008a</LINK>, <LINK REF="REF-Sismondo-2008b" TYPE="REFERENCE">Sismondo 2008b</LINK>). The pharmaceutical industry has invested in developing new treatments for common clinical conditions, such as severe sepsis with mortality that exceeds 30%, but it should be mandatory that the parties with a special interest conduct randomized clinical trials according to the highest standards and subject to public scrutiny by independent parties.</P>
<P>Most of the included trials had limitations related to the completion of the originally designed protocols. Both <LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK> and <LINK REF="STD-RESOLVE-2007" TYPE="STUDY">RESOLVE 2007</LINK> terminated their recruitment for futility. <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK> had to modify its recruitment rules due to difficulties in enrolling patients, and reduced the planned trial by 25%. The modification of the planned sample size and high attrition could lead to a false negative conclusion in this trial. The <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> turned out to be composed of two different trials after we got access to data from FDA. The first protocol with 720 participants had a focus on protein C deficient patients, which was removed in the second protocol. The second protocol also introduced changes to the manufacturing of the drug. We found no differences between the two manufactured products in our test of interaction analysis. Given the complexity of the molecule, however, one cannot exclude the possibility of undetected differences (<LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>). Furthemore, the sponsor objective excluded patients with non-sepsis related diseases (<LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>). See <LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>; <LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>; <LINK REF="APP-11" TYPE="APPENDIX">Appendix 11</LINK>; <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK> for details of changes between the <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> first and second protocol.</P>
<P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> for details.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-10-28 11:33:32 +0000" MODIFIED_BY="[Empty name]">
<P>In the process for performing a systematic review, there is a group of biases called 'significance-chasing biases' (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). This group includes publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials. However, this Cochrane review has a low risk of publication bias due to the thorough trial search process. Selective outcome reporting bias operates through suppression of information on specific outcomes and has similarities to study publication bias in that &#8216;negative&#8217; results remain unpublished (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). All included randomized clinical trials in this Cochrane review had a low risk of selective outcome reporting bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-11-02 16:03:13 +0000" MODIFIED_BY="Jane Cracknell">
<P>Our review provides evidence derived from six trials conducted in different populations and using different drug dosages and durations of treatment. Our results for the main outcome, 28-day mortality, are similar to the findings from other systematic reviews (<LINK REF="STD-Costa-2007" TYPE="STUDY">Costa 2007</LINK>; <LINK REF="STD-Wiedermann-2005" TYPE="STUDY">Wiedermann 2005</LINK>) and similarly for remarks made that the risks could exceed the benefits.</P>
<P>A recent meta-analysis showed a significant reduction in hospital mortality and increased rates of bleeding in patients with severe sepsis (<LINK REF="REF-Kalil-2012" TYPE="REFERENCE">Kalil 2012</LINK>). This meta-analysis included both randomized clinical trials and analytical, controlled, and single-group studies (prospective matched controlled cohort studies and prospective and retrospective single group studies). This meta-analysis did not report the assessment of risk of bias. Therefore, it contains a high risk of bias (systematic errors). This is a likely explanation why their meta-analysis and our systematic review reach contradicting conclusions (<LINK REF="REF-Deeks-2003" TYPE="REFERENCE">Deeks 2003</LINK>).</P>
<P>One Cochrane review assessing the benefits and harms of APC for neonates with sepsis found insufficient data to support or reject APC (<LINK REF="STD-Kylat-2012" TYPE="STUDY">Kylat 2012</LINK>). Furthermore, due to our present results in adults with sepsis, neonates with sepsis should not be exposed to APC. Further trials in adults that show positive findings should be conducted before use in neonates are considered (<LINK REF="STD-Kylat-2012" TYPE="STUDY">Kylat 2012</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-10-28 11:39:23 +0000" MODIFIED_BY="Jane Cracknell">
<IMPLICATIONS_PRACTICE MODIFIED="2012-10-28 11:38:42 +0000" MODIFIED_BY="Jane Cracknell">
<P>This updated Cochrane review provides evidence to show that APC seems to lack clinical benefits and is associated with an increased risk of bleeding in patients suffering from severe sepsis or septic shock. Therefore, APC should not be used for patients with sepsis outside randomized clinical trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-10-28 11:39:23 +0000" MODIFIED_BY="[Empty name]">
<P>The European Medicines Agency issued a press release on the worldwide withdrawal of Xigris (activated protein C (APC) or drotrecogin alfa) from the market by Eli Lilly due to lack of beneficial effect on 28-day mortality in the PROWESS-SHOCK study. Furthermore, Eli Lily has announced the discontinuation of all other ongoing clinical trials (<LINK REF="REF-EMEA-2011" TYPE="REFERENCE">EMEA 2011</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-10-28 11:39:59 +0000" MODIFIED_BY="Jane Cracknell">
<P>We wish to express our gratitude to the <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK> Steering Committee for supplying unpublished data.</P>
<P>We would like to thank the following.</P>
<P>Dr Peter C Gotzsche for his comments on our original published review (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2007" TYPE="REFERENCE">Martí-Carvajal 2007</LINK>).</P>
<P>Dr Djillali Annane for sending us information about the ongoing trial NCT00625209 (Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHS)).</P>
<P>Dr Georgia Salanti for her participation in the original published reviews (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2007" TYPE="REFERENCE">Martí-Carvajal 2007</LINK>; <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2008" TYPE="REFERENCE">Martí-Carvajal 2008</LINK>).</P>
<P>Dr Nicola Petrucci, Prof Nathan Pace, Dr John Fraser, Prof Leonard Leibovici, Mark Edward and Kathie Godfrey for their help and editorial advice during the preparation of the original review (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2007" TYPE="REFERENCE">Martí-Carvajal 2007</LINK>).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-10-28 11:42:36 +0000" MODIFIED_BY="[Empty name]">
<P>In 2004, Arturo Martí-Carvajal was employed by Eli Lilly to run a four-hour workshop on 'How to critically appraise clinical trials on osteoporosis and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review.</P>
<P>In 2007, Arturo Martí-Carvajal was employed by Merck to run a four-hour workshop on 'How to critically appraise clinical trials and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review.</P>
<P>Ivan Solà: none known.</P>
<P>Christian Gluud: none known.</P>
<P>Dimitrios Lathyris: none known.</P>
<P>Andrés Felipe: none known</P>
<P>Cardona: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-10-28 11:41:38 +0000" MODIFIED_BY="[Empty name]">
<P>Conceiving the review: Arturo Martí-Carvajal (AMC)<BR/>Co-ordinating the review: AMC, Andrés Felipe Cardona (AFC), Dimitrios Lathyris (DL)<BR/>Undertaking manual searches: AMC, AFC<BR/>Screening search results: AMC, AFC<BR/>Organizing retrieval of papers: AMC<BR/>Screening retrieved papers against inclusion criteria: AMC, AFC<BR/>Appraising quality of papers: AMC, Ivan Solà (IS), DL, AFC<BR/>Abstracting data from papers: AMC, AFC, IS<BR/>Writing to authors of papers for additional information: AMC<BR/>Providing additional data about papers: AMC<BR/>Obtaining and screening data on unpublished studies: AMC<BR/>Data management for the review: AMC, AFC, IS<BR/>Entering data into Review Manager (<LINK REF="REF-RevMan-5.1" TYPE="REFERENCE">RevMan 5.1</LINK>): AMC<BR/>RevMan statistical data: AMC, DL, Christian Gluud (CG)<BR/>Other statistical analysis not using RevMan: AMC, CG<BR/>Double entry of data: data entered by person one, AFC; data entered by person two, AMC<BR/>Interpretation of data: AMC, IS, CG, AFC, DL<BR/>Statistical inferences: ACM, CG, DL<BR/>Writing the review: ACM, IS, AFC, DL, CG</P>
<P>Amended the review during the editorial process: ACM, IS<BR/>Securing funding for the review: AMC<BR/>Guarantor for the review (one author): AMC<BR/>Person responsible for reading and checking the review before submission: AMC, IS, DL, AFC, CG</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-10-28 11:43:49 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>We have inserted a statement at the end of the 'Sensitivity analysis' section of the 'Summary of findings' tables.</LI>
<LI>We have performed a trial sequential analyses using Trial Sequential Analysis software (<LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>).</LI>
<LI>For this update we included 'Adverse events' as a primary outcome according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>.</LI>
</OL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-10-28 11:44:10 +0000" MODIFIED_BY="Jane Cracknell">
<P>February 2012</P>
<P>Warning: On October 25th 2011, the European Medicines Agency issued a press release on the worldwide withdrawal of Xigris (activated protein C/drotrecogin alfa) from the market by Eli Lilly due to lack of beneficial effect on 28-day mortality in the PROWESS-SHOCK study. Furthermore, Eli Lily has announced the discontinuation of all other ongoing clinical trials. The final results of the PROWESS-SHOCK study are expected to be published in 2012. This systematic review will be updated when results of the PROWESS-SHOCK or other trials are published.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-02-06 18:49:52 +0000" MODIFIED_BY="Jane Cracknell">
<STUDIES MODIFIED="2013-04-03 23:33:33 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-04-03 23:33:33 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ADDRESS-2005" MODIFIED="2009-08-18 23:52:19 +0100" MODIFIED_BY="[Empty name]" NAME="ADDRESS 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-18 23:51:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, et al</AU>
<TI>Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>13</NO>
<PG>1332-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118424"/><IDENTIFIER TYPE="MEDLINE" VALUE="16192478"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-18 23:52:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laterre PF, Abraham E, Janes JM, Trzaskoma BL, Correl NL, Booth F</AU>
<TI>ADDRESS (ADministration of DRotrecogin alfa[activated] in Early stage Severe sepsis) long-term follow-up: one year safety and efficacy evaluation</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>6</NO>
<PG>1457-63</PG>
<IDENTIFIERS MODIFIED="2008-06-22 18:43:02 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118425"/><IDENTIFIER MODIFIED="2008-06-22 18:41:35 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17452935"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-06-22 18:18:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118423"/><IDENTIFIER MODIFIED="2008-06-22 18:18:09 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-APROCCHSS-2013" MODIFIED="2013-04-03 23:33:33 +0100" MODIFIED_BY="[Empty name]" NAME="APROCCHSS 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-04-03 23:33:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Annane D, Timsit JF, Megarbane B, Martin C, Misset B, Mourvillier B et al</AU>
<TI>Recombinant human activated protein C for adults with septic shock: a randomized controlled trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2013</YR>
<VL>Mar 22</VL>
<NO>Epub ahead of print</NO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118427"/><IDENTIFIER TYPE="PUBMED" VALUE="23525934"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118426"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dhainaut-2009" MODIFIED="2012-06-27 10:13:31 +0100" MODIFIED_BY="Jane Cracknell" NAME="Dhainaut 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-27 10:13:31 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dhainaut JF, Antonelli M, Wright P, Desachy A, Reignier J, Lavoue S et al</AU>
<TI>Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock</TI>
<SO>Intensive Care Medicine </SO>
<YR>2009</YR>
<VL>35</VL>
<NO>7</NO>
<PG>1187-95</PG>
<IDENTIFIERS MODIFIED="2012-06-27 10:13:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118429"/><IDENTIFIER MODIFIED="2012-06-27 10:13:31 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19263034 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118428"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PROWESS-2001" MODIFIED="2012-10-28 12:19:24 +0000" MODIFIED_BY="[Empty name]" NAME="PROWESS 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angus DC, Laterre OF, Helterbrand J, Ely EW, Ball DE, Garg R, et al</AU>
<TI>The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>11</NO>
<PG>2199-206</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118431"/><IDENTIFIER TYPE="MEDLINE" VALUE="15640631"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, et al</AU>
<TI>Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>1</NO>
<PG>1-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118432"/><IDENTIFIER TYPE="MEDLINE" VALUE="12544986"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barie PS, Williams MD, McCollam JS, Bates BM, Qualy RL, Lowry SF, et al</AU>
<TI>Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis</TI>
<SO>American Journal of Surgery</SO>
<YR>2004</YR>
<VL>188</VL>
<NO>3</NO>
<PG>212-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118433"/><IDENTIFIER TYPE="MEDLINE" VALUE="15450822"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL</AU>
<TI>Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis</TI>
<SO>Critical Care</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>2</NO>
<PG>155-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118434"/><IDENTIFIER TYPE="MEDLINE" VALUE="12720562"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, et al</AU>
<TI>Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>125</VL>
<NO>6</NO>
<PG>2206-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118435"/><IDENTIFIER TYPE="MEDLINE" VALUE="15189943"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al</AU>
<TI>Efficacy and safety of recombinant human activated protein C for severe sepsis</TI>
<SO>New England Journal Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>10</NO>
<PG>699-709</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118436"/><IDENTIFIER TYPE="MEDLINE" VALUE="11236773"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, et al</AU>
<TI>Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial</TI>
<SO>Intensive Care Medicine</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>6</NO>
<PG>894-903</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118437"/><IDENTIFIER TYPE="MEDLINE" VALUE="12712239"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, et al</AU>
<TI>The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>9</NO>
<PG>2291-301</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118438"/><IDENTIFIER TYPE="MEDLINE" VALUE="14501959"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, et al</AU>
<TI>Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>11</VL>
<PG>1924-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118439"/><IDENTIFIER TYPE="MEDLINE" VALUE="15550023"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, et al</AU>
<TI>Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2003</YR>
<VL>90</VL>
<NO>4</NO>
<PG>642-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118440"/><IDENTIFIER TYPE="MEDLINE" VALUE="14515185"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ely EW, Angus DC, Williams MD, Bates B, Qualy R, Bernard GR</AU>
<TI>Drotrecogin alfa (activated) treatment of older patients with severe sepsis</TI>
<SO>Clinical Infectious Disease</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>2</NO>
<PG>187-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118441"/><IDENTIFIER TYPE="MEDLINE" VALUE="12856210"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-12 10:31:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, et al</AU>
<TI>Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>1</NO>
<PG>12-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118442"/><IDENTIFIER TYPE="MEDLINE" VALUE="1254498"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-12 10:32:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>FDA 2001a</AU>
<TI>Food and Drug Administration. FDA Anti-Infective Drugs Advisory Committee12 September 2001: Briefing Document for XIGRIS for the Treatment of Severe Sepsis. Eli Lilly and Company. 06 August 2001</TI>
<SO>Available for public disclosure without redaction. Accessed online June 10, 2009. http://www.fda.gov/ohrms/dockets/AC/01/briefing/3797b1_01_Sponsor.pdf</SO>
<YR>2001</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118443"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-12 10:32:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>FDA 2001b</AU>
<TI>FDA Briefing document: Anti-infective Advisory Committee. Drotrecogin alfa (activated). [Recombinant human activated protein (rhAPC)]. XIGRIS&#8482; BLA # 125029/0. September 12</TI>
<SO>http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.pdf</SO>
<YR>2001</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118444"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>FDA 2005</AU>
<TI>2005 Safety Alert: Xigris [drotrecogin alfa (activated)]</TI>
<SO>http://www.fda.gov/medwatch/safety/2005/xigris_DHCP.htm. Accessed online May 28, 2006</SO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118445"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-12 10:33:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fry DE, Beilman G, Johnson S, Williams MD, Rodman G, Booth FV, et al</AU>
<TI>Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis</TI>
<SO>Surgical Infections</SO>
<YR>2004</YR>
<VL>5</VL>
<PG>253-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118446"/><IDENTIFIER TYPE="MEDLINE" VALUE="15684796"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, et al</AU>
<TI>Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study</TI>
<SO>Critical Care Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<PG>952-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118447"/><IDENTIFIER TYPE="MEDLINE" VALUE="15891319"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, et al</AU>
<TI>Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>11</VL>
<PG>2207-18</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118448"/><IDENTIFIER TYPE="MEDLINE" VALUE="15640632"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-14 18:14:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laterre PF, Nelson DR, Macias W, Abraham E, Sashegyi A, Williams MD</AU>
<TI>International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety</TI>
<SO>Journal of Critical Care</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>2</NO>
<PG>142-52</PG>
<IDENTIFIERS MODIFIED="2009-08-14 18:14:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118449"/><IDENTIFIER MODIFIED="2009-08-14 18:14:44 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISSN: 0883-9441"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, Johnson G3rd, et al</AU>
<TI>Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>72</VL>
<NO>4</NO>
<PG>391-402</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118450"/><IDENTIFIER TYPE="MEDLINE" VALUE="2386641"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-28 12:18:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macias WL, Nelson DR</AU>
<TI>Severe protein C deficiency predicts early death in severe sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>5 Suppl</NO>
<PG>223-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118451"/><IDENTIFIER TYPE="MEDLINE" VALUE="15118522"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-28 12:18:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morris P, Kalil A, Schein R</AU>
<TI>Drotrecogin alfa (activated) improved survival in patients with severe sepsis on mechanical ventilation: results from the PROWESS trial [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>8 Suppl</NO>
<PG>A470</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118452"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, et al</AU>
<TI>Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)</TI>
<SO>Clinical Infectious Disease</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>1</NO>
<PG>50-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118453"/><IDENTIFIER TYPE="MEDLINE" VALUE="12830408"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-25 20:08:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M et al</AU>
<TI>International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohort</TI>
<SO>Surgery</SO>
<YR>2006</YR>
<VL>140</VL>
<NO>5</NO>
<PG>726-39</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118454"/><IDENTIFIER TYPE="MEDLINE" VALUE="17084715"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-28 12:19:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schein R, Kalil A, Sollet JP</AU>
<TI>Drotrecogin alfa (activated) reduces mortality in chronic obstructive pulmonary disease patients with severe sepsis. Results from the PROWESS trial [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<PG>23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118455"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-26 16:24:10 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaw AD, Vail GM, Haney DJ, Xie J, Williams MD</AU>
<TI>Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis</TI>
<SO>Journal of Critical Care</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>6</NO>
<PG>539-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118456"/><IDENTIFIER TYPE="PUBMED" VALUE="21737232"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-12 10:35:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, et al</AU>
<TI>Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome</TI>
<SO>Critical Care</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>3</NO>
<PG>R92</PG>
<IDENTIFIERS MODIFIED="2009-08-21 22:07:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118457"/><IDENTIFIER MODIFIED="2009-08-21 22:07:59 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16780598"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-12 10:35:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, et al</AU>
<TI>Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)</TI>
<SO>Critical Care (London, England)</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>2</NO>
<PG>R45</PG>
<IDENTIFIERS MODIFIED="2009-08-19 00:13:41 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118458"/><IDENTIFIER MODIFIED="2009-08-19 00:13:41 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18394162"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-01 18:38:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vail GM</AU>
<TI>Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without streptococcus pneumoniae</TI>
<SO>Infection</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>4</NO>
<PG>358-64</PG>
<IDENTIFIERS MODIFIED="2010-02-01 18:38:08 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118459"/><IDENTIFIER MODIFIED="2010-02-01 18:38:08 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PREV200900533209"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, et al</AU>
<TI>Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>3</NO>
<PG>834-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118460"/><IDENTIFIER TYPE="MEDLINE" VALUE="12626993"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-21 22:03:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vincent JL</AU>
<TI>Drotrecogin alfa (activated) in the treatment of severe sepsis</TI>
<SO>Current Drug Safety</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>3</NO>
<PG>227-31</PG>
<IDENTIFIERS MODIFIED="2009-08-21 22:03:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118461"/><IDENTIFIER MODIFIED="2009-08-21 22:03:19 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18690972"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118430"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PROWESS_x002d_SHOCK-2012" MODIFIED="2012-10-28 12:21:01 +0000" MODIFIED_BY="[Empty name]" NAME="PROWESS-SHOCK 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-10-28 12:20:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al</AU>
<TI>Drotrecogin alfa (activated) in adults with septic shock</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>366</VL>
<NO>22</NO>
<PG>2055-64</PG>
<IDENTIFIERS MODIFIED="2012-06-27 11:00:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118463"/><IDENTIFIER MODIFIED="2012-06-27 11:00:30 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22616830"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-28 12:20:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ranieri VM, Thompson BT, Finfer S, Barie PS, Dhainaut JF, Douglas IS, et al</AU>
<TI>Unblinding plan of PROWESS-SHOCK trial</TI>
<SO>Intensive Care Medicine</SO>
<YR>2011</YR>
<VL>37</VL>
<NO>8</NO>
<PG>1384-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118464"/><IDENTIFIER TYPE="PUBMED" VALUE="21691888"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-28 12:21:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Thompson BT, Ranieri VM, Finfer S, Barie PS, Dhainaut JF, Douglas IS, et al</AU>
<TI>Statistical analysis plan of PROWESS SHOCK study</TI>
<SO>Intensive Care Medicine</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>11</NO>
<PG>1972-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118465"/><IDENTIFIER TYPE="PUBMED" VALUE="20689934"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118462"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RESOLVE-2007" MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="RESOLVE 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, et al</AU>
<TI>Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<NO>9564</NO>
<PG>836-43</PG>
<IDENTIFIERS MODIFIED="2009-08-18 23:50:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118467"/><IDENTIFIER MODIFIED="2009-08-18 23:50:35 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17350452"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118466"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-rhAPC-Sepsis-Study-2001" MODIFIED="2012-06-27 13:34:30 +0100" MODIFIED_BY="[Empty name]" NAME="rhAPC Sepsis Study 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-06-27 13:34:30 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, et al</AU>
<TI>Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2001</YR>
<VL>29</VL>
<NO>11</NO>
<PG>2051-9</PG>
<IDENTIFIERS MODIFIED="2012-06-27 13:34:30 +0100" MODIFIED_BY="Arturo J Marti-Carvajal"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118469"/><IDENTIFIER MODIFIED="2012-06-27 13:34:30 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" TYPE="MEDLINE" VALUE="11700394"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118468"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-10-28 12:26:58 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alaniz-2010" MODIFIED="2012-10-28 12:21:27 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Alaniz 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-28 12:21:27 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="OTHER">
<AU>Alaniz C</AU>
<TI>An update on activated protein C (Xigris) in the management of sepsis</TI>
<SO>P &amp; T</SO>
<YR>2010</YR>
<VL>35</VL>
<NO>9</NO>
<PG>504-29</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118471"/><IDENTIFIER TYPE="PUBMED" VALUE="20975809"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118470"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barie-2011a" MODIFIED="2012-06-26 15:45:18 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Barie 2011a" YEAR="2011">
<REFERENCE MODIFIED="2012-06-26 15:45:18 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="OTHER">
<AU>Barie PS, Hydo LJ, Shou J, Eachempati SR</AU>
<TI>Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome</TI>
<SO>Surgical Infections</SO>
<YR>2011</YR>
<VL>12</VL>
<NO>6</NO>
<PG>443-9</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2012-06-26 15:45:18 +0100" MODIFIED_BY="Arturo J Marti-Carvajal"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118473"/><IDENTIFIER MODIFIED="2012-06-26 15:45:18 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" TYPE="PUBMED" VALUE="22185191"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118472"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barton-2004" MODIFIED="2009-08-18 23:58:12 +0100" MODIFIED_BY="[Empty name]" NAME="Barton 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-18 23:58:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen Cawley R, et al</AU>
<TI>Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>113</VL>
<NO>1 Pt 1</NO>
<PG>7-17</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118475"/><IDENTIFIER TYPE="MEDLINE" VALUE="14702440"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118474"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bearden-2002" MODIFIED="2010-06-26 12:04:10 +0100" MODIFIED_BY="[Empty name]" NAME="Bearden 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-26 12:04:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bearden DT, Garvin CG</AU>
<TI>Recombinant human activated protein C for use in severe sepsis</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>2</NO>
<PG>1424-9</PG>
<IDENTIFIERS MODIFIED="2010-06-11 17:47:11 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118477"/><IDENTIFIER MODIFIED="2010-06-11 17:47:11 +0100" MODIFIED_BY="Jane Cracknell" TYPE="OTHER" VALUE="ISSN: 1060-0280"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118476"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernard-2004" MODIFIED="2009-08-18 23:58:52 +0100" MODIFIED_BY="[Empty name]" NAME="Bernard 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-18 23:58:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, et al</AU>
<TI>Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>125</VL>
<NO>6</NO>
<PG>2206-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118479"/><IDENTIFIER TYPE="MEDLINE" VALUE="15189943"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118478"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bertolini-2007" MODIFIED="2011-03-12 10:36:47 +0000" MODIFIED_BY="[Empty name]" NAME="Bertolini 2007" YEAR="426">
<REFERENCE MODIFIED="2011-03-12 10:36:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D</AU>
<TI>Use of drotrecogin alfa (activated) in Italian intensive care units: The results of a nationwide survey</TI>
<SO>Intensive Care Medicine</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>3</NO>
<PG>426-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118481"/><IDENTIFIER TYPE="MEDLINE" VALUE="17325836 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118480"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyle-2012" MODIFIED="2012-06-26 15:51:38 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Boyle 2012" YEAR="2010">
<REFERENCE MODIFIED="2012-06-26 15:51:38 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="OTHER">
<AU>Boyle A, McKenzie C, Yassin S, McLuckie A, Wyncoll D</AU>
<TI>Adverse events and clinical outcome associated with drotrecogin alfa-activated: A single-center experience of 498 patients over 8 years</TI>
<SO>Journal of Critical Care</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>3</NO>
<PG>320.e7-320.e12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118483"/><IDENTIFIER TYPE="PUBMED" VALUE="22172792"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118482"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-2002" NAME="Casey 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casey M</AU>
<TI>Recombinant activated protein C (drotecogin alfa) in severe sepsis</TI>
<TO>Drotrecogin Alfa Activado (Proteína C activada recombinante) identificación de paciente e indicaciones para el tratamiento de la sepsis severa con alto riesgo de muerte</TO>
<SO>Hematología (Buenos Aires)</SO>
<YR>2002</YR>
<VL>6</VL>
<PG>42-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118485"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118484"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costa-2007" MODIFIED="2008-08-25 20:24:09 +0100" MODIFIED_BY="[Empty name]" NAME="Costa 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-08-25 20:24:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costa V, Brophy JM</AU>
<TI>Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis</TI>
<SO>BMC Anesthesiology</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>5</NO>
<PG>1-11</PG>
<IDENTIFIERS MODIFIED="2008-08-25 20:24:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118487"/><IDENTIFIER MODIFIED="2008-08-25 20:24:09 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17592639"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118486"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Decruyenaere-2009" MODIFIED="2011-03-12 10:37:16 +0000" MODIFIED_BY="[Empty name]" NAME="Decruyenaere 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-03-12 10:37:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Decruyenaere J, De Backer D, Spapen H, Laterre PF, Raemaekers J, Rogiers P, et al</AU>
<TI>90-day follow-up of patients treated with drotrecogin alfa (activated) for severe sepsis: a Belgian open label study</TI>
<SO>Acta Clinica Belgica </SO>
<YR>2009</YR>
<VL>64</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS MODIFIED="2009-08-14 23:50:03 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118489"/><IDENTIFIER MODIFIED="2009-08-14 23:50:03 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19317237"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118488"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrer-2009" MODIFIED="2011-03-12 10:40:23 +0000" MODIFIED_BY="[Empty name]" NAME="Ferrer 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-03-12 10:40:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, et al</AU>
<TI>Effectiveness of treatments for severe sepsis: A prospective multicenter observational study</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2009</YR>
<VL>180</VL>
<NO>9</NO>
<PG>861-6</PG>
<IDENTIFIERS MODIFIED="2010-06-11 17:49:31 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118491"/><IDENTIFIER MODIFIED="2010-06-11 17:49:31 +0100" MODIFIED_BY="Jane Cracknell" TYPE="MEDLINE" VALUE="19696442"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118490"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freeman-2003" NAME="Freeman 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freeman BD, Zehnbauer BA, Buchman TG</AU>
<TI>A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis</TI>
<SO>Shock</SO>
<YR>2003</YR>
<VL>20</VL>
<NO>1</NO>
<PG>5-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118493"/><IDENTIFIER TYPE="MEDLINE" VALUE="12813361"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118492"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldstein-2006" MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="Goldstein 2006" YEAR="200">
<REFERENCE MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein B, Nadel S, Peters M, Barton R, Machado F, Levy H, et al</AU>
<TI>Enhance: Results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis</TI>
<SO>Pediatric Critical Care Medicine</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>3</NO>
<PG>200-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118495"/><IDENTIFIER TYPE="MEDLINE" VALUE="16575354 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118494"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-2005" NAME="Green 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, et al</AU>
<TI>Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris(R)) for the treatment of severe sepsis in adults: a systematic review and economic evaluation</TI>
<SO>Health Technology Assessment</SO>
<YR>2005</YR>
<VL>140</VL>
<PG>1-126</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118497"/><IDENTIFIER TYPE="MEDLINE" VALUE="15774234"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118496"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heslet-2004" MODIFIED="2009-08-19 00:00:47 +0100" MODIFIED_BY="[Empty name]" NAME="Heslet 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-19 00:00:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heslet L, Nielsen JD, Schierbeck J, Andersen JS</AU>
<TI>Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>2004</YR>
<VL>166</VL>
<NO>11</NO>
<PG>997-1002</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118499"/><IDENTIFIER TYPE="MEDLINE" VALUE="15049234"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118498"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Houston-2009" MODIFIED="2012-10-28 12:23:03 +0000" MODIFIED_BY="[Empty name]" NAME="Houston 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-28 12:23:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houston G, Cuthbertson BH</AU>
<TI>Activated protein C for the treatment of severe sepsis</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2009</YR>
<VL>5</VL>
<NO>4</NO>
<PG>319-24</PG>
<IDENTIFIERS MODIFIED="2012-06-29 05:41:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118501"/><IDENTIFIER MODIFIED="2012-06-29 05:41:44 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19416303"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118500"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalil-2010a" MODIFIED="2012-10-28 12:23:19 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Kalil 2010a" YEAR="2010">
<REFERENCE MODIFIED="2012-10-28 12:23:19 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalil A, La Rosa S</AU>
<TI>Real-life experience with drotrecogin alfa activated for severe sepsis: An effectiveness and safety meta-analysis</TI>
<SO>Critical Care Medicine</SO>
<YR>2010</YR>
<VL>38</VL>
<PG>A117</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118503"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118502"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanji-2007" MODIFIED="2009-08-19 00:01:56 +0100" MODIFIED_BY="[Empty name]" NAME="Kanji 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-19 00:01:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanji S, Perreault MM, Chant C, Williamson D, Burry L</AU>
<TI>Evaluating the use of drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study</TI>
<SO>Intensive Care Medicine</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>3</NO>
<PG>517-33</PG>
<IDENTIFIERS MODIFIED="2008-08-25 20:15:54 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118505"/><IDENTIFIER MODIFIED="2008-08-25 20:15:54 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17325837"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118504"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khan-2010" MODIFIED="2012-06-26 15:58:24 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Khan 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-06-26 15:58:24 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan A, Agarwal R, Aggarwal AN, Gupta D</AU>
<TI>Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: A systematic review and meta-analysis</TI>
<SO>Respiratory Care</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>7</NO>
<PG>901-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118507"/><IDENTIFIER TYPE="PUBMED" VALUE="20587103"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118506"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kylat-2012" MODIFIED="2012-06-26 16:01:55 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Kylat 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-06-26 16:01:55 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="OTHER">
<AU>Kylat Ranjit I, Ohlsson A</AU>
<TI>Recombinant human activated protein C for severe sepsis in neonates</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118509"/><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD005385.pub3"/><IDENTIFIER TYPE="OTHER" VALUE="CD005385"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118508"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levi-2007" MODIFIED="2011-03-12 10:42:17 +0000" MODIFIED_BY="[Empty name]" NAME="Levi 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-03-12 10:42:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, et al; Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group</AU>
<TI>Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2007</YR>
<VL>176</VL>
<NO>5</NO>
<PG>483-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118511"/><IDENTIFIER TYPE="MEDLINE" VALUE="17556722"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118510"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez-2010" MODIFIED="2012-10-28 12:24:00 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Lopez 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-28 12:24:00 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez Sanchez F, Mas-Serrano P, Caturla Such J, Mignini M, Navarro J</AU>
<TI>Drotrecogin alfa (activated) in real-life clinical practice for management of severe sepsis in surgical patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>2010</YR>
<VL>36</VL>
<PG>S193</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118513"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118512"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucioni-2002" MODIFIED="2008-08-25 20:52:33 +0100" MODIFIED_BY="[Empty name]" NAME="Lucioni 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-25 20:52:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucioni C, Mazzi S, Christopher C</AU>
<TI>The treatment of patients with severe sepsis using drotrecogin alfa: an economic evaluation for Italy</TI>
<TO>Il trattamento di pazienti con sepsi grave mediante drotrecogin alfa: una valutazione economica con riferimento allItalia</TO>
<SO>Farmeconomia e Percorsi Terapeutici</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>3</NO>
<PG>171-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118515"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118514"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marraro-2009" MODIFIED="2012-06-29 05:42:57 +0100" MODIFIED_BY="[Empty name]" NAME="Marraro 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-06-29 05:42:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marraro GA</AU>
<TI>Treatment of septic shock and use of drotrecogin alfa (activated) in children</TI>
<SO>Expert Review of Anti-Infective Therapy</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>7</NO>
<PG>769-72</PG>
<IDENTIFIERS MODIFIED="2012-06-29 05:42:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118517"/><IDENTIFIER MODIFIED="2012-06-29 05:42:57 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2009575232"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118516"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCoy-2003" MODIFIED="2012-06-29 05:43:47 +0100" MODIFIED_BY="[Empty name]" NAME="McCoy 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-06-29 05:43:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCoy C, Matthews SJ</AU>
<TI>Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis</TI>
<SO>Clinical Therapeutics</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>2</NO>
<PG>396-421</PG>
<IDENTIFIERS MODIFIED="2012-06-29 05:43:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118519"/><IDENTIFIER MODIFIED="2012-06-29 05:43:47 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12749504"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118518"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCoy-2004" MODIFIED="2012-06-29 05:44:26 +0100" MODIFIED_BY="[Empty name]" NAME="McCoy 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-06-29 05:44:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCoy C</AU>
<TI>Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis</TI>
<SO>Expert Opinion on Drug Safety</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>6</NO>
<PG>625-37</PG>
<IDENTIFIERS MODIFIED="2012-06-29 05:44:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118521"/><IDENTIFIER MODIFIED="2012-06-29 05:44:26 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15500421"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118520"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neilson-2003" MODIFIED="2009-08-19 00:04:26 +0100" MODIFIED_BY="[Empty name]" NAME="Neilson 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-19 00:04:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D</AU>
<TI>Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany</TI>
<SO>Journal of Critical Care</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>4</NO>
<PG>217-27</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118523"/><IDENTIFIER TYPE="MEDLINE" VALUE="14691895"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118522"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sadique-2011" MODIFIED="2012-10-28 12:24:56 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Sadique 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-28 12:24:56 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadique MZ, Grieve R, Harrison DA, Cuthbertson BH, Rowan KM</AU>
<TI>Is drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?</TI>
<SO>Critical Care</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>5</NO>
<PG>R228</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118525"/><IDENTIFIER TYPE="PUBMED" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118524"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-2010" MODIFIED="2012-07-23 15:53:15 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Sanchez 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-07-23 15:53:15 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez B, Piacentini E, Pradella V, Mignini M, Nava J</AU>
<TI>Hemodynamic effects of recombinant human activated protein C in patients with septic shock</TI>
<SO>Journal of Critical Care</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>2</NO>
<PG>343-7</PG>
<IDENTIFIERS MODIFIED="2012-06-26 16:17:59 +0100" MODIFIED_BY="Arturo J Marti-Carvajal"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118527"/><IDENTIFIER MODIFIED="2012-06-26 16:17:59 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" TYPE="PUBMED" VALUE="19781904"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118526"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez_x002d_Garcia-2011" MODIFIED="2012-10-28 12:25:35 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Sanchez-Garcia 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-28 12:25:35 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Garcia E, Navarro-Martinez JA, Idrissi A, Paya E, Nicolas N, Mas-Serrano P</AU>
<TI>Use of drotrecogin alpha in a surgical cohort of intra-abdominal infections patients</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>2011</YR>
<VL>28</VL>
<PG>182</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118529"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118528"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shorr-2010" MODIFIED="2012-10-28 12:25:50 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Shorr 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-28 12:25:50 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" PRIMARY="NO" TYPE="OTHER">
<AU>Shorr AF, Janes JM, Artigas A, Tenhunen J, Wyncoll DL, Mercier E, et al</AU>
<TI>Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)</TI>
<SO>Critical Care</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>6</NO>
<PG>R229</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="CN-00802129"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118531"/><IDENTIFIER TYPE="PUBMED" VALUE="21176144"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118530"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Doorn-2008" MODIFIED="2010-07-05 09:06:45 +0100" MODIFIED_BY="[Empty name]" NAME="van Doorn 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-07-05 09:06:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Doorn KJ, Spapen H, Geers C, Diltoer M, Shabana W</AU>
<TI>Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>2008</YR>
<VL>52</VL>
<NO>9</NO>
<PG>1259-64</PG>
<IDENTIFIERS MODIFIED="2010-07-05 09:06:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118533"/><IDENTIFIER MODIFIED="2010-07-05 09:06:45 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18823466"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118532"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vincent-2005" MODIFIED="2009-08-19 00:05:28 +0100" MODIFIED_BY="[Empty name]" NAME="Vincent 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-19 00:05:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, et al</AU>
<TI>Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment</TI>
<SO>Critical Care Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>10</NO>
<PG>2266-77</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118535"/><IDENTIFIER TYPE="MEDLINE" VALUE="16215381"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118534"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wheeler-2008" MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="Wheeler 2008" YEAR="Jan; 36(1): 14-23">
<REFERENCE MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde Zwirble W, et al</AU>
<TI>A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial</TI>
<SO>Critical Care Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>1</NO>
<PG>14-23</PG>
<IDENTIFIERS MODIFIED="2009-08-19 00:06:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118537"/><IDENTIFIER MODIFIED="2009-08-19 00:06:36 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18158435"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118536"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiedermann-2005" MODIFIED="2012-10-28 12:26:58 +0000" MODIFIED_BY="[Empty name]" NAME="Wiedermann 2005" YEAR="Oct 14; 5: 7">
<REFERENCE MODIFIED="2012-10-28 12:26:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiedermann CJ, Kaneider NC</AU>
<TI>A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis</TI>
<SO>BMC Emergency Medicine</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>1-4</PG>
<IDENTIFIERS MODIFIED="2009-08-19 00:07:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3118539"/><IDENTIFIER MODIFIED="2009-08-19 00:07:48 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16225672"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3118538"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-06-27 12:10:15 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2012-06-21 11:13:50 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-02-06 18:49:23 +0000" MODIFIED_BY="Jane Cracknell">
<ADDITIONAL_REFERENCES MODIFIED="2013-11-01 17:51:46 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACCP_x002d_SCCM-1992" MODIFIED="2009-08-19 01:03:33 +0100" MODIFIED_BY="[Empty name]" NAME="ACCP-SCCM 1992" TYPE="JOURNAL_ARTICLE">
<AU>No authors listed</AU>
<TI>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>6</NO>
<PG>864-74</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1597042"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Angus-2001a" MODIFIED="2011-03-12 10:43:50 +0000" MODIFIED_BY="[Empty name]" NAME="Angus 2001a" TYPE="JOURNAL_ARTICLE">
<AU>Angus DC, Wax RS</AU>
<TI>Epidemiology of sepsis: An update</TI>
<SO>Critical Care Medicine</SO>
<YR>2001</YR>
<VL>29 Suppl 7</VL>
<PG>109-16</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11445744"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Angus-2001b" MODIFIED="2009-08-19 01:05:39 +0100" MODIFIED_BY="[Empty name]" NAME="Angus 2001b" TYPE="JOURNAL_ARTICLE">
<AU>Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR</AU>
<TI>Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated cost of care</TI>
<SO>Critical Care Medicine</SO>
<YR>2001</YR>
<VL>29</VL>
<NO>7</NO>
<PG>1303-10</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11445675"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Annane-2005" MODIFIED="2009-08-19 01:07:13 +0100" MODIFIED_BY="[Empty name]" NAME="Annane 2005" TYPE="JOURNAL_ARTICLE">
<AU>Annane D, Bellissant E, Cavaillon JM</AU>
<TI>Septic shock</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9453</NO>
<PG>63-78</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15639681"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Azevedo-2008" MODIFIED="2011-03-12 10:44:16 +0000" MODIFIED_BY="[Empty name]" NAME="Azevedo 2008" TYPE="JOURNAL_ARTICLE">
<AU>Azevedo LC, Park M, Schettino GP</AU>
<TI>Novel potential therapies for septic shock</TI>
<SO>Shock</SO>
<YR>2008</YR>
<VL>30 Suppl 1</VL>
<PG>60-6</PG>
<IDENTIFIERS MODIFIED="2009-08-15 20:22:34 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-15 20:22:34 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18704007"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2012-10-28 12:27:42 +0000" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS MODIFIED="2012-02-09 20:24:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21208779"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barnato-2008" MODIFIED="2009-06-01 23:21:28 +0100" MODIFIED_BY="[Empty name]" NAME="Barnato 2008" TYPE="JOURNAL_ARTICLE">
<AU>Barnato AE, Alexander SL, Linde-Zwirble WT, Angus DC</AU>
<TI>Racial variation in the incidence, care, and outcomes of severe sepsis: analysis of population, patient, and hospital characteristics</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2008</YR>
<VL>177</VL>
<NO>3</NO>
<PG>279-84</PG>
<IDENTIFIERS MODIFIED="2009-06-01 23:10:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-01 23:10:43 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17975201"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bekelman-2003" MODIFIED="2009-08-19 01:08:48 +0100" MODIFIED_BY="[Empty name]" NAME="Bekelman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bekelman JE, Li Y, Gross CP</AU>
<TI>Scope and impact of financial conflicts of interest in biomedical research: a systematic review</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>4</NO>
<PG>454-65</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12533125"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bernard-2001" MODIFIED="2012-10-08 18:27:16 +0100" MODIFIED_BY="Jane Cracknell" NAME="Bernard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al</AU>
<TI>Efficacy and safety of recombinant human activated protein C for severe sepsis</TI>
<SO>New England Journal Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>10</NO>
<PG>699-709</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11236773"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bhandari-2004" NAME="Bhandari 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al</AU>
<TI>Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2004</YR>
<VL>170</VL>
<NO>4</NO>
<PG>477-80</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="14970094"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bochud-2001" MODIFIED="2011-03-12 10:45:14 +0000" MODIFIED_BY="[Empty name]" NAME="Bochud 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bochud PY, Glauser MP, Calandra T; International Sepsis Forum</AU>
<TI>Antibiotics in sepsis</TI>
<SO>Intensive Care Medicine</SO>
<YR>2001</YR>
<VL>27 Suppl 1</VL>
<PG>33-48</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11307369"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bochud-2004" MODIFIED="2012-10-28 12:28:49 +0000" MODIFIED_BY="[Empty name]" NAME="Bochud 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bochud PY, Bonten M, Marchetti O, Calandra T</AU>
<TI>Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>11 Suppl</NO>
<PG>495-512</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15542958"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bone-1992" MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="Bone 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al</AU>
<TI>Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine</TI>
<SO>Chest</SO>
<YR>1992</YR>
<VL>101</VL>
<NO>6</NO>
<PG>1644-55</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1303622"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boussekey-2008" MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="Boussekey 2008" TYPE="JOURNAL_ARTICLE">
<AU>Boussekey N, Chiche A, Faure K, Devos P, Guery B, D'Escrivan T, et al</AU>
<TI>A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock</TI>
<SO>Intensive Care Medicine</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>9</NO>
<PG>1646-53</PG>
<IDENTIFIERS MODIFIED="2009-08-15 20:41:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-15 20:41:55 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18542921"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2012-06-29 13:14:55 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>8</NO>
<PG>763-9</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="18411040"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2012-06-29 13:15:15 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="18824466"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brun_x002d_Buisson-1995" MODIFIED="2009-08-19 01:10:27 +0100" MODIFIED_BY="[Empty name]" NAME="Brun-Buisson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, et al</AU>
<TI>Incidence, risk factors and outcomes of severe sepsis and septic shock in adults: A multicenter prospective study in intensive care units</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<NO>12</NO>
<PG>968-74</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="7674528"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brun_x002d_Buisson-2006" MODIFIED="2009-06-03 23:17:21 +0100" MODIFIED_BY="[Empty name]" NAME="Brun-Buisson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Brun-Buisson C</AU>
<TI>Epidemiology of severe sepsis</TI>
<TO>Épidémiologie des états septiques graves</TO>
<SO>Presse Médicale</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>3 Pt 2</NO>
<PG>513-20</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="16550152"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carlet-2008" MODIFIED="2009-08-14 17:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="Carlet 2008" TYPE="JOURNAL_ARTICLE">
<AU>Carlet J, Cohen J, Calandra T, Opal SM, Masur H</AU>
<TI>Sepsis: time to reconsider the concept</TI>
<SO>Critical Care Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>3</NO>
<PG>964-6</PG>
<IDENTIFIERS MODIFIED="2009-08-14 17:17:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-14 17:17:53 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18431286"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cheng-2007" MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="Cheng 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cheng B, Xie G, Yao S, Wu X, Guo Q, Gu M, et al</AU>
<TI>Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>11</NO>
<PG>2538-46</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="17828034"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Christiaans-2013" MODIFIED="2013-11-01 14:59:27 +0000" MODIFIED_BY="[Empty name]" NAME="Christiaans 2013" TYPE="JOURNAL_ARTICLE">
<AU>Christiaans SC, Wagener BM, Esmon CT, Pittet JF</AU>
<TI>Protein C and acute inflammation: a clinical and biological perspective</TI>
<SO>American Journal of Physiology. Lung Cellular and Molecular Physiology</SO>
<YR>2013</YR>
<VL>305</VL>
<NO>7</NO>
<PG>L455-66</PG>
<IDENTIFIERS MODIFIED="2013-11-01 14:58:30 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23911436"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cinel-2009" MODIFIED="2009-08-19 01:14:05 +0100" MODIFIED_BY="[Empty name]" NAME="Cinel 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cinel I, Opal SM</AU>
<TI>Molecular biology of inflammation and sepsis: a primer</TI>
<SO>Critical Care Medicine</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>1</NO>
<PG>291-304</PG>
<IDENTIFIERS MODIFIED="2009-06-04 01:11:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-04 01:11:35 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19050640"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cohen--2009" MODIFIED="2009-08-14 22:43:24 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen  2009" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>Non-antibiotic strategies for sepsis</TI>
<SO>Clinical Microbiology and Infection </SO>
<YR>2009</YR>
<VL>15</VL>
<NO>4</NO>
<PG>302-7</PG>
<IDENTIFIERS MODIFIED="2009-08-14 22:43:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-14 22:43:24 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19416301"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cohen-2004" MODIFIED="2009-08-19 01:14:29 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J, Brun-Buisson C, Torres A, Jorgensen J</AU>
<TI>Diagnosis of infection in sepsis: An evidence-based review</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>11</NO>
<PG>466-94</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15542957"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CTU-2011" MODIFIED="2012-10-28 12:30:07 +0000" MODIFIED_BY="[Empty name]" NAME="CTU 2011" TYPE="COMPUTER_PROGRAM">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>Trial Sequential Analysis</TI>
<YR>2011</YR>
<PB>Copenhagen Trial Unit, Centre for Clinical Intervention Research</PB>
<CY>Copenhagen, Denmark</CY>
<MD>http: www.ctu.dk/tsa</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cunneen-2004" MODIFIED="2012-10-28 12:30:24 +0000" MODIFIED_BY="[Empty name]" NAME="Cunneen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cunneen J, Cartwright M</AU>
<TI>The puzzle of sepsis: fitting the pieces of the inflammatory response with treatment</TI>
<SO>AACN Clinical Issues</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>1</NO>
<PG>18-44</PG>
<IDENTIFIERS MODIFIED="2009-08-19 01:17:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-19 01:17:10 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="14767363"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cunnington-2008" MODIFIED="2009-08-17 16:58:30 +0100" MODIFIED_BY="[Empty name]" NAME="Cunnington 2008" TYPE="JOURNAL_ARTICLE">
<AU>Cunnington A, Nadel S</AU>
<TI>New therapies for sepsis</TI>
<SO>Current Topics in Medicinal Chemistry </SO>
<YR>2008</YR>
<VL>8</VL>
<NO>7</NO>
<PG>603-14</PG>
<IDENTIFIERS MODIFIED="2009-08-17 16:58:12 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-17 16:58:12 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18473886"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Danai-2007" MODIFIED="2009-06-03 23:32:55 +0100" MODIFIED_BY="[Empty name]" NAME="Danai 2007" TYPE="JOURNAL_ARTICLE">
<AU>Danai PA, Sinha S, Moss M, Haber MJ, Martin GS</AU>
<TI>Seasonal variation in the epidemiology of sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>2</NO>
<PG>410-5</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="17167351"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Das-2000" NAME="Das 2000" TYPE="JOURNAL_ARTICLE">
<AU>Das UN</AU>
<TI>Critical advances in septicemia and septic shock</TI>
<SO>Critical Care</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>5</NO>
<PG>290-6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11094508"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2003" MODIFIED="2012-11-02 16:21:56 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2003" TYPE="JOURNAL_ARTICLE">
<AU>Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al</AU>
<TI>Evaluating non-randomised intervention studies</TI>
<SO>Health Technology Assessment</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>27</NO>
<PG>iii-x, 1-173</PG>
<IDENTIFIERS MODIFIED="2012-11-02 16:02:57 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="14499048"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dellinger-2008" MODIFIED="2010-06-26 12:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Dellinger 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al</AU>
<TI>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008</TI>
<SO>Intensive Care Medicine</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>1</NO>
<PG>17-60</PG>
<IDENTIFIERS MODIFIED="2009-06-11 01:01:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-11 01:01:44 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18058085"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-EMEA-2005" MODIFIED="2011-03-08 10:50:59 +0000" MODIFIED_BY="Jane Cracknell" NAME="EMEA 2005" TYPE="OTHER">
<AU>European Medicines Agency´s Committee for Medicinal Products for Human Use</AU>
<TI>Drotrecogin alfa (activated) only for use in high risk patients</TI>
<SO>EMEA's post-authorisation summary of opinion for Xigris, EMEA/138447/2005, 21 April 2005. www.emea.europa.eu/ (accessed 29 November 2010)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMEA-2011" MODIFIED="2012-06-21 07:26:11 +0100" MODIFIED_BY="[Empty name]" NAME="EMEA 2011" TYPE="OTHER">
<AU>European Medicines Agency</AU>
<TI>Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy</TI>
<SO>Press Release</SO>
<YR>25 October 2011</YR>
<VL>EMA/856472/2011 Press Office</VL>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Esmon-2006" MODIFIED="2013-11-01 15:13:47 +0000" MODIFIED_BY="[Empty name]" NAME="Esmon 2006" TYPE="JOURNAL_ARTICLE">
<AU>Esmon CT</AU>
<TI>Inflammation and the activated protein C anticoagulant pathway</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>2006</YR>
<VL>32 Suppl 1</VL>
<PG>49-60</PG>
<IDENTIFIERS MODIFIED="2009-08-19 22:09:16 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-19 22:09:16 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16673266"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2001a" MODIFIED="2010-11-29 21:21:20 +0000" MODIFIED_BY="[Empty name]" NAME="FDA 2001a" TYPE="OTHER">
<AU>Food and Drug Administration</AU>
<TI>FDA Anti-Infective Drugs Advisory Committee12 September 2001: Briefing Document for XIGRIS&#8482; for the Treatment of Severe Sepsis. Eli Lilly and Company. 06 August 2001. Available for public disclosure without redaction.</TI>
<SO>http://www.fda.gov/ohrms/dockets/AC/01/briefing/3797b1_01_Sponsor.pdf (accessed 10 June 2009)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2001b" MODIFIED="2010-11-29 21:21:47 +0000" MODIFIED_BY="[Empty name]" NAME="FDA 2001b" TYPE="OTHER">
<AU>Food and Drug Administration</AU>
<TI>FDA Briefing document: Anti-infective Advisory Committee. Drotrecogin alfa (activated)). [Recombinant human activated protein (rhAPC)]. XIGRIS&#8482; BLA # 125029/0.</TI>
<SO>http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.pdf (accessed 21 September 2005)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2005" MODIFIED="2012-10-28 12:31:32 +0000" MODIFIED_BY="Jane Cracknell" NAME="FDA 2005" TYPE="OTHER">
<AU>Food and Drug Administration</AU>
<TI>MedWatch - Xigris [drotrecogin alfa (activated)]</TI>
<SO>www.fda.gov/medwatch/safety/2005/xigris_dearHCP_4-21-05.htm [Posted 01-07-2005] (accessed 21 September 2005)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Finfer-2008" MODIFIED="2012-10-28 12:31:44 +0000" MODIFIED_BY="Jane Cracknell" NAME="Finfer 2008" TYPE="JOURNAL_ARTICLE">
<AU>Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, et al</AU>
<TI>Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock</TI>
<SO>Intensive Care Medicine</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>11</NO>
<PG>1935-47</PG>
<IDENTIFIERS MODIFIED="2009-08-19 16:29:00 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-19 16:29:00 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18839141"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fisher-2000" MODIFIED="2011-03-12 10:47:46 +0000" MODIFIED_BY="[Empty name]" NAME="Fisher 2000" TYPE="JOURNAL_ARTICLE">
<AU>Fisher CJ, Yan SB</AU>
<TI>Protein C levels as a prognostic indicator of outcome in sepsis and related diseases</TI>
<SO>Critical Care Medicine</SO>
<YR>2000</YR>
<VL>28 Suppl 9</VL>
<PG>49-56</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11007198"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garnacho-2003" NAME="Garnacho 2003" TYPE="JOURNAL_ARTICLE">
<AU>Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C</AU>
<TI>Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>12</NO>
<PG>2742-51</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="14668610"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garnacho-2006" MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="Garnacho 2006" TYPE="JOURNAL_ARTICLE">
<AU>Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, Cayuela A, Jiménez R, Barroso S, et al</AU>
<TI>Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis</TI>
<SO>Critical Care</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>4</NO>
<PG>R111</PG>
<IDENTIFIERS MODIFIED="2009-06-03 16:00:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-03 16:00:52 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16859504"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Geroulanos-2006" MODIFIED="2009-08-19 00:26:15 +0100" MODIFIED_BY="[Empty name]" NAME="Geroulanos 2006" TYPE="JOURNAL_ARTICLE">
<AU>Geroulanos S, Douka ET</AU>
<TI>Historical perspective of the word "sepsis"</TI>
<SO>Intensive Care Medicine</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>12</NO>
<PG>2077</PG>
<IDENTIFIERS MODIFIED="2009-08-19 00:26:15 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-19 00:26:15 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17131165"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Girbes-2008" MODIFIED="2009-08-14 22:58:10 +0100" MODIFIED_BY="[Empty name]" NAME="Girbes 2008" TYPE="JOURNAL_ARTICLE">
<AU>Girbes AR, Beishuizen A, Strack van Schijndel RJ</AU>
<TI>Pharmacological treatment of sepsis</TI>
<SO>Fundamental and Clinical Pharmacology </SO>
<YR>2008</YR>
<VL>22</VL>
<NO>4</NO>
<PG>355-61</PG>
<IDENTIFIERS MODIFIED="2009-08-14 22:56:28 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-14 22:56:28 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18705746"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-2005" MODIFIED="2010-06-26 11:24:03 +0100" MODIFIED_BY="[Empty name]" NAME="Goldstein 2005" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein B, Giroir B, Randolph A; International Consensus Conference on Pediatric Sepsis</AU>
<TI>International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics</TI>
<SO>Pediatric Critical Care Medicine</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>1</NO>
<PG>2-8</PG>
<IDENTIFIERS MODIFIED="2010-06-26 11:24:03 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-06-26 11:24:03 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15636651"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guidet-2005" MODIFIED="2009-06-03 17:20:06 +0100" MODIFIED_BY="[Empty name]" NAME="Guidet 2005" TYPE="JOURNAL_ARTICLE">
<AU>Guidet B, Aegerter P, Gauzit R, Meshaka P, Dreyfuss D; CUB-Réa Study Group</AU>
<TI>Incidence and impact of organ dysfunctions associated with sepsis</TI>
<SO>Chest</SO>
<YR>2005</YR>
<VL>127</VL>
<NO>3</NO>
<PG>942-51</PG>
<IDENTIFIERS MODIFIED="2009-06-03 17:19:58 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-03 17:19:58 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15764780"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011" MODIFIED="2012-10-28 12:32:35 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al</AU>
<TI>GRADE guidelines: 2. Framing the question and deciding on important outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>395-400</PG>
<IDENTIFIERS MODIFIED="2012-02-09 20:24:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21194891"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2012-10-28 12:32:51 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS MODIFIED="2012-02-09 20:24:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21195583"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2012-10-28 12:33:04 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS MODIFIED="2012-02-09 20:24:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21247734"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2012-10-28 12:33:21 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 9. Rating up the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1311-6</PG>
<IDENTIFIERS MODIFIED="2012-02-09 20:24:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21802902"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2012-10-28 12:33:34 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence--indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS MODIFIED="2012-02-09 20:24:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21802903"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2012-10-28 12:33:47 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence--inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS MODIFIED="2012-02-09 20:24:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21803546"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011f" MODIFIED="2012-10-28 12:33:59 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011f" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines 6. Rating the quality of evidence--imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS MODIFIED="2012-02-09 20:24:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21839614"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011g" MODIFIED="2012-10-28 12:34:14 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011g" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 5. Rating the quality of evidence--publication bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1277-82</PG>
<IDENTIFIERS MODIFIED="2012-02-09 20:24:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21802904"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Healy-2002" MODIFIED="2009-08-19 00:29:10 +0100" MODIFIED_BY="[Empty name]" NAME="Healy 2002" TYPE="JOURNAL_ARTICLE">
<AU>Healy DP</AU>
<TI>New and emerging therapies for sepsis</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>4</NO>
<PG>648-54</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11918516"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-06-21 13:55:10 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hinds-2001" MODIFIED="2009-08-26 18:50:21 +0100" MODIFIED_BY="[Empty name]" NAME="Hinds 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hinds CJ</AU>
<TI>Treatment of sepsis with activated protein C</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7318</NO>
<PG>881-2</PG>
<IDENTIFIERS MODIFIED="2009-08-26 18:50:21 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-26 18:50:21 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11668121"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Holmes-2003" MODIFIED="2009-06-02 00:22:31 +0100" MODIFIED_BY="[Empty name]" NAME="Holmes 2003" TYPE="JOURNAL_ARTICLE">
<AU>Holmes CL, Russell JA, Walley KR</AU>
<TI>Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy</TI>
<SO>Chest</SO>
<YR>2003</YR>
<VL>124</VL>
<NO>3</NO>
<PG>1103-15</PG>
<IDENTIFIERS MODIFIED="2009-06-02 00:22:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-02 00:22:31 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12970043"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hotchkiss-2010" MODIFIED="2011-03-12 10:49:52 +0000" MODIFIED_BY="[Empty name]" NAME="Hotchkiss 2010" TYPE="JOURNAL_ARTICLE">
<AU>Hotchkiss RS, Opal S</AU>
<TI>Immunotherapy for sepsis - a new approach against an ancient foe</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>363</VL>
<NO>1</NO>
<PG>87-9</PG>
<IDENTIFIERS MODIFIED="2010-07-05 10:36:04 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-05 10:36:04 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20592301"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Iannaro-2009" MODIFIED="2009-06-03 19:01:39 +0100" MODIFIED_BY="[Empty name]" NAME="Iannaro 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ianaro A, Tersigni M, D'Acquisto F</AU>
<TI>New insight in LPS antagonist</TI>
<SO>Mini Reviews in Medicinal Chemistry</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>3</NO>
<PG>306-17</PG>
<IDENTIFIERS MODIFIED="2009-06-03 18:58:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-03 18:58:23 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19275723"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP1997" MODIFIED="2012-07-19 13:47:14 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="ICH-GCP1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>PA 19063-2043, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2010" MODIFIED="2012-06-21 08:26:49 +0100" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP</AU>
<TI>The art of getting it wrong</TI>
<SO>Research Synthesis Methods</SO>
<YR>2010</YR>
<VL>1</VL>
<NO>3-4</NO>
<PG>169-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-I_x00f1_igo-2006" MODIFIED="2009-06-03 22:12:23 +0100" MODIFIED_BY="[Empty name]" NAME="Iñigo 2006" TYPE="JOURNAL_ARTICLE">
<AU>Iñigo J, Sendra JM, Díaz R, Bouza C, Sarría-Santamera A</AU>
<TI>Epidemiology and costs of severe sepsis in Madrid. A hospital discharge study</TI>
<TO>Epidemiología y costes de la sepsis grave en Madrid.Estudio de altas hospitalarias</TO>
<SO>Medicina Intensiva</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>5</NO>
<PG>197-203</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="16938192"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-J_x00f8_rgensen-2006" MODIFIED="2009-09-04 17:47:11 +0100" MODIFIED_BY="[Empty name]" NAME="Jørgensen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jørgensen AW, Hilden J, Gøtzsche PC</AU>
<TI>Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>333</VL>
<NO>7572</NO>
<PG>782-5</PG>
<IDENTIFIERS MODIFIED="2009-09-04 17:47:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-09-04 17:47:11 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17028106"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kalil-2012" MODIFIED="2012-10-19 15:03:45 +0100" MODIFIED_BY="[Empty name]" NAME="Kalil 2012" TYPE="JOURNAL_ARTICLE">
<AU>Kalil AC, LaRosa SP</AU>
<TI>Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression</TI>
<SO>The Lancet Infectious Diseases</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>9</NO>
<PG>678-86</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="22809883"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khan-2008" MODIFIED="2009-08-28 22:54:49 +0100" MODIFIED_BY="[Empty name]" NAME="Khan 2008" TYPE="JOURNAL_ARTICLE">
<AU>Khan SN, Mermer MJ, Myers E, Sandhu HS</AU>
<TI>The roles of funding source, clinical trial outcome, and quality of reporting in orthopedic surgery literature</TI>
<SO>The American Journal of Orthopedic Surgery</SO>
<YR>2008</YR>
<VL>37</VL>
<NO>12</NO>
<PG>205-12</PG>
<IDENTIFIERS MODIFIED="2009-08-28 22:53:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-28 22:53:55 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19212579"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khwannimit-2009" MODIFIED="2009-08-19 00:33:31 +0100" MODIFIED_BY="[Empty name]" NAME="Khwannimit 2009" TYPE="JOURNAL_ARTICLE">
<AU>Khwannimit B, Bhurayanontachai R</AU>
<TI>The epidemiology of, and risk factors for, mortality from severe sepsis and septic shock in a tertiary-care university hospital setting</TI>
<SO>Epidemiology and Infection</SO>
<YR>2009</YR>
<VL>137</VL>
<NO>9</NO>
<PG>1-9</PG>
<IDENTIFIERS MODIFIED="2009-06-04 00:04:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-04 00:04:32 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19192320"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-King-2013" MODIFIED="2013-11-01 15:12:01 +0000" MODIFIED_BY="[Empty name]" NAME="King 2013" TYPE="JOURNAL_ARTICLE">
<AU>King EG, Bauza GJ, Mella JR, Remick DG</AU>
<TI>Pathophysiologic mechanisms in septic shock</TI>
<SO>Laboratory Investigation</SO>
<YR>2013</YR>
<VL>Epub ahead of print</VL>
<PG>Sep 23</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="24061288"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2004" MODIFIED="2009-08-19 00:34:02 +0100" MODIFIED_BY="[Empty name]" NAME="Kumar 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kumar A, Mann HJ</AU>
<TI>Appraisal of four novel approaches to the prevention and treatment of sepsis</TI>
<SO>American Journal of Health-System Pharmacists</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>8</NO>
<PG>765-74</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15127959"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leon-2008" MODIFIED="2009-06-03 18:54:45 +0100" MODIFIED_BY="[Empty name]" NAME="Leon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leon CG, Tory R, Jia J, Sivak O, Wasan KM</AU>
<TI>Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases</TI>
<SO>Pharmaceutical Research</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>8</NO>
<PG>1751-61</PG>
<IDENTIFIERS MODIFIED="2009-06-03 18:54:06 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-03 18:54:06 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18493843"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leone-2010" MODIFIED="2010-05-01 12:26:12 +0100" MODIFIED_BY="[Empty name]" NAME="Leone 2010" TYPE="JOURNAL_ARTICLE">
<AU>Leone M, Textoris J, Michel F, Wiramus S, Martin C</AU>
<TI>Emerging drugs in sepsis</TI>
<SO>Expert Opinion on Emerging Drugs</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>1</NO>
<PG>41-52</PG>
<IDENTIFIERS MODIFIED="2010-05-01 12:26:12 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-05-01 12:26:02 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2010160115"/><IDENTIFIER MODIFIED="2010-05-01 12:26:12 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20055688 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levi-2008" MODIFIED="2009-08-19 21:28:22 +0100" MODIFIED_BY="[Empty name]" NAME="Levi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Levi M</AU>
<TI>The coagulant response in sepsis</TI>
<SO>Clinics in Chest Medicine</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>45</NO>
<PG>627-42</PG>
<IDENTIFIERS MODIFIED="2009-08-19 21:28:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-19 21:28:19 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18954698"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lexchin-2003" NAME="Lexchin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lexchin J, Bero LA, Djulbegovic B, Clark O</AU>
<TI>Pharmaceutical industry sponsorship and research outcome and quality: systematic review</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7400</NO>
<PG>1167-70</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12775614"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lexchin-2005" MODIFIED="2009-08-19 00:36:22 +0100" MODIFIED_BY="[Empty name]" NAME="Lexchin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lexchin JR</AU>
<TI>Implications of pharmaceutical industry funding on clinical research</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>1</NO>
<PG>194-7</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15562137"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mann-2002" MODIFIED="2011-03-12 10:51:17 +0000" MODIFIED_BY="[Empty name]" NAME="Mann 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mann HJ</AU>
<TI>Recombinant human activated protein C in severe sepsis</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2002</YR>
<VL>59 Suppl 1</VL>
<PG>19-23</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11885409"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mann-2009" MODIFIED="2009-08-28 23:51:49 +0100" MODIFIED_BY="[Empty name]" NAME="Mann 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mann HJ, Short MA, Schlichting DE</AU>
<TI>Protein C in critical illness</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>12</NO>
<PG>1089-96</PG>
<IDENTIFIERS MODIFIED="2009-08-28 23:51:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-28 23:51:31 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19498123"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2004" MODIFIED="2011-03-12 10:51:42 +0000" MODIFIED_BY="[Empty name]" NAME="Marshall 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marshall JC, Maier RV, Jimenez M, Dellinger EP</AU>
<TI>Source control in the management of severe sepsis and septic shock: an evidence-based review</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32 Suppl 11</VL>
<PG>513-26</PG>
<IDENTIFIERS MODIFIED="2009-08-19 00:39:58 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-19 00:39:58 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15542959"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2008" MODIFIED="2009-08-19 00:41:11 +0100" MODIFIED_BY="[Empty name]" NAME="Marshall 2008" TYPE="JOURNAL_ARTICLE">
<AU>Marshall JC</AU>
<TI>Sepsis: Rethinking the approach to clinical research</TI>
<SO>Journal of Leukocyte Biology</SO>
<YR>2008</YR>
<VL>83</VL>
<NO>3</NO>
<PG>471-82</PG>
<IDENTIFIERS MODIFIED="2009-08-19 00:41:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-19 00:41:11 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18171697 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Matsuda-2007" MODIFIED="2010-06-26 12:11:55 +0100" MODIFIED_BY="[Empty name]" NAME="Matsuda 2007" TYPE="JOURNAL_ARTICLE">
<AU>Matsuda N, Hattori Y</AU>
<TI>Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction</TI>
<SO>Journal of Smooth Muscle Research</SO>
<YR>2007</YR>
<VL>43</VL>
<NO>4</NO>
<PG>117-37</PG>
<IDENTIFIERS MODIFIED="2009-08-19 21:23:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-19 21:23:40 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17928746"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Melander-2003" NAME="Melander 2003" TYPE="JOURNAL_ARTICLE">
<AU>Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B</AU>
<TI>Evidence b(i)ased medicine --selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7400</NO>
<PG>1171-3</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12775615"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mitka-2011" MODIFIED="2012-10-28 12:36:31 +0000" MODIFIED_BY="[Empty name]" NAME="Mitka 2011" TYPE="OTHER">
<AU>Mitka M</AU>
<TI>Drug for severe sepsis is withdrawn from market, fails to reduce mortality</TI>
<SO>JAMA</SO>
<YR>2011</YR>
<VL>306</VL>
<NO>22</NO>
<PG>2439-40</PG>
<IDENTIFIERS MODIFIED="2012-06-21 06:59:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22166598"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moine-2007" MODIFIED="2009-08-17 23:43:47 +0100" MODIFIED_BY="[Empty name]" NAME="Moine 2007" TYPE="JOURNAL_ARTICLE">
<AU>Moine P</AU>
<TI>Potential benefits of non-anti-infective treatments of septic shock: a critical analysis of literature</TI>
<SO>Annales Francaises D'Anesthesie Et De Reanimation</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>4</NO>
<PG>370-5</PG>
<IDENTIFIERS MODIFIED="2009-08-17 23:43:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-17 23:43:31 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17395418"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parrish-2008" MODIFIED="2009-08-17 17:02:36 +0100" MODIFIED_BY="[Empty name]" NAME="Parrish 2008" TYPE="JOURNAL_ARTICLE">
<AU>Parrish WR, Gallowitsch-Puerta M, Czura CJ, Tracey KJ</AU>
<TI>Experimental therapeutic strategies for severe sepsis: mediators and mechanisms</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2008</YR>
<VL>1144</VL>
<PG>210-36</PG>
<IDENTIFIERS MODIFIED="2009-08-17 17:02:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-17 17:02:10 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19076379"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paul-2009" MODIFIED="2009-08-15 17:33:10 +0100" MODIFIED_BY="[Empty name]" NAME="Paul 2009" TYPE="JOURNAL_ARTICLE">
<AU>Paul M</AU>
<TI>Is there a treatment for sepsis other than antibiotics?</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>4</NO>
<PG>297</PG>
<IDENTIFIERS MODIFIED="2009-08-15 17:33:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-15 17:33:10 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19416299"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Perner-2012" MODIFIED="2012-10-28 12:37:28 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Perner 2012" TYPE="JOURNAL_ARTICLE">
<AU>Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, et al</AU>
<TI>Hydroxyethyl starch 130/0.4 versus Ringer's acetate in severe sepsis</TI>
<SO>The New England journal of medicine</SO>
<YR>2012</YR>
<VL>June 27</VL>
<PG>[Epub ahead of print]</PG>
<IDENTIFIERS MODIFIED="2012-07-04 15:51:42 +0100" MODIFIED_BY="Arturo J Marti-Carvajal"><IDENTIFIER TYPE="PUBMED" VALUE="22738085"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Porta-2008" MODIFIED="2012-06-27 10:05:20 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Porta 2008" TYPE="BOOK">
<AU>Porta M</AU>
<SO>A Dictionary of Epidemiology</SO>
<YR>2008</YR>
<EN>Fifth</EN>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rangel_x002d_Frausto-1995" MODIFIED="2009-08-19 00:46:28 +0100" MODIFIED_BY="[Empty name]" NAME="Rangel-Frausto 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP</AU>
<TI>The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>2</NO>
<PG>117-23</PG>
<IDENTIFIERS MODIFIED="2009-08-19 00:46:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-19 00:46:26 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7799491"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Remick-2007" MODIFIED="2009-06-04 20:11:08 +0100" MODIFIED_BY="[Empty name]" NAME="Remick 2007" TYPE="JOURNAL_ARTICLE">
<AU>Remick DG</AU>
<TI>Pathophysiology of sepsis</TI>
<SO>The American Journal of Pathology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>5</NO>
<PG>1435-44</PG>
<IDENTIFIERS MODIFIED="2009-06-04 20:11:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-04 20:11:08 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17456750"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5.1" MODIFIED="2012-07-20 15:54:20 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 5.1" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre: The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rhodes-2004" MODIFIED="2011-03-12 10:52:52 +0000" MODIFIED_BY="[Empty name]" NAME="Rhodes 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rhodes A, Bennett ED</AU>
<TI>Early goal-directed therapy: An evidence-based review</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32 Suppl 11</VL>
<PG>448-50</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15542954"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rigato-2006" MODIFIED="2009-08-17 23:37:38 +0100" MODIFIED_BY="[Empty name]" NAME="Rigato 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rigato O, Silva E, Salomao R</AU>
<TI>Pathogenesis-oriented targets for adjunctive therapy</TI>
<SO>Endocrine Metabolic &amp; Immune Disorders-Drug Targets</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>2</NO>
<PG>193-200</PG>
<IDENTIFIERS MODIFIED="2009-08-17 23:37:14 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-17 23:37:14 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16787294"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rittirsch-2008" MODIFIED="2009-06-04 01:14:36 +0100" MODIFIED_BY="[Empty name]" NAME="Rittirsch 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rittirsch D, Flierl MA, Ward PA</AU>
<TI>Harmful molecular mechanisms in sepsis</TI>
<SO>Nature Reviews. Inmmunology</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>10</NO>
<PG>776-87</PG>
<IDENTIFIERS MODIFIED="2009-06-04 01:14:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-04 01:14:36 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18802444"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sandrock-2010" MODIFIED="2012-06-25 21:23:32 +0100" MODIFIED_BY="[Empty name]" NAME="Sandrock 2010" TYPE="JOURNAL_ARTICLE">
<AU>Sandrock CE, Albertson TE</AU>
<TI>Controversies in the treatment of sepsis</TI>
<SO>Seminars in Respiratory and Critical Care Medicine</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>1</NO>
<PG>66-78</PG>
<IDENTIFIERS MODIFIED="2010-05-01 12:16:21 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-05-01 12:15:12 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2010112081"/><IDENTIFIER MODIFIED="2010-05-01 12:16:21 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20101549"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schuerholz-2008" MODIFIED="2009-08-17 17:08:25 +0100" MODIFIED_BY="[Empty name]" NAME="Schuerholz 2008" TYPE="JOURNAL_ARTICLE">
<AU>Schuerholz T, Marx G</AU>
<TI>Management of sepsis</TI>
<SO>Minerva Anestesiologica </SO>
<YR>2008</YR>
<VL>74</VL>
<NO>5</NO>
<PG>181-95</PG>
<IDENTIFIERS MODIFIED="2009-08-17 17:07:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-17 17:07:48 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18414361"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shorr-2006" MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="Shorr 2006" TYPE="JOURNAL_ARTICLE">
<AU>Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, et al</AU>
<TI>Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome</TI>
<SO>Critical Care</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>3</NO>
<PG>R92</PG>
<IDENTIFIERS MODIFIED="2009-08-21 14:47:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-21 14:47:10 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16780598"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shorr-2008" MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell" NAME="Shorr 2008" TYPE="JOURNAL_ARTICLE">
<AU>Shorr AF, Nelson DR, Wyncoll DLA, Reinhart K, Brunkhorst F, Vail G, et al</AU>
<TI>Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)</TI>
<SO>Critical Care</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>2</NO>
<PG>R45</PG>
<IDENTIFIERS MODIFIED="2009-08-17 17:23:38 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-17 17:23:38 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18394162"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sibila-2008" MODIFIED="2009-06-10 17:51:25 +0100" MODIFIED_BY="[Empty name]" NAME="Sibila 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sibila O, Agustí C, Torres A</AU>
<TI>Corticosteroids in severe pneumonia</TI>
<SO>The European Respiratory Journal</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>2</NO>
<PG>259-64</PG>
<IDENTIFIERS MODIFIED="2009-06-10 17:51:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-10 17:51:22 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18669784"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sipahi-2006" MODIFIED="2009-06-03 16:22:13 +0100" MODIFIED_BY="[Empty name]" NAME="Sipahi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sipahi T, Pocan H, Akar N</AU>
<TI>Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis</TI>
<SO>Clinical and Applied Thrombosis and Hemostasis</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>1</NO>
<PG>47-54</PG>
<IDENTIFIERS MODIFIED="2009-06-03 16:22:13 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-03 16:22:13 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16444434"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sismondo-2008a" MODIFIED="2009-08-28 23:23:47 +0100" MODIFIED_BY="[Empty name]" NAME="Sismondo 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Sismondo S</AU>
<TI>How pharmaceutical industry funding affects trial outcomes: causal structures and responses</TI>
<SO>Social Science &amp; Medicine</SO>
<YR>2008</YR>
<VL>66</VL>
<NO>9</NO>
<PG>1909-14</PG>
<IDENTIFIERS MODIFIED="2009-08-28 23:19:16 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-28 23:19:16 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18299169"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sismondo-2008b" MODIFIED="2009-08-28 23:23:18 +0100" MODIFIED_BY="[Empty name]" NAME="Sismondo 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Sismondo S</AU>
<TI>Pharmaceutical company funding and its consequences: a qualitative systematic review</TI>
<SO>Contemporary Clinical Trials</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>2</NO>
<PG>109-13</PG>
<IDENTIFIERS MODIFIED="2009-08-28 22:35:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-28 22:35:29 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17919992"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sriskandan-2008" MODIFIED="2009-06-04 01:31:50 +0100" MODIFIED_BY="[Empty name]" NAME="Sriskandan 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sriskandan S, Altmann DM</AU>
<TI>The immunology of sepsis</TI>
<SO>The Journal of Pathology</SO>
<YR>2008</YR>
<VL>214</VL>
<NO>2</NO>
<PG>211-23</PG>
<IDENTIFIERS MODIFIED="2009-06-04 01:31:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-06-04 01:31:50 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18161754"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2012-10-28 12:39:30 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="18824467"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2010" MODIFIED="2012-06-29 13:15:55 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Thorlund 2010" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Anema A, Mills E</AU>
<TI>Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals</TI>
<SO>Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>57-66</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="20865104"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2012-10-28 12:39:49 +0000" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for Trial Sequential Analysis (TSA)</TI>
<SO>http://ctu.dk/tsa/files/tsa_manual.pdf (accessed 30 April 2012).</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Treacher-2009" MODIFIED="2010-04-07 18:28:10 +0100" MODIFIED_BY="[Empty name]" NAME="Treacher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Treacher DF, Alun Brown K</AU>
<TI>The basic science of sepsis</TI>
<SO>Surgery</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>11</NO>
<PG>465-9</PG>
<IDENTIFIERS MODIFIED="2010-04-07 18:28:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-04-07 18:28:10 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2009641439"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vincent-2002" MODIFIED="2012-10-28 12:40:26 +0000" MODIFIED_BY="[Empty name]" NAME="Vincent 2002" TYPE="JOURNAL_ARTICLE">
<AU>Vincent JL, Abraham E, Annane D, Bernard G, Rivers E, Van den Berghe G</AU>
<TI>Reducing mortality in sepsis: new directions</TI>
<SO>Critical Care</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>3 Suppl</NO>
<PG>1-18</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12720570"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vincent-2004" MODIFIED="2009-08-28 23:53:03 +0100" MODIFIED_BY="[Empty name]" NAME="Vincent 2004" TYPE="JOURNAL_ARTICLE">
<AU>Vincent JL</AU>
<TI>Evidence-based medicine in the ICU: important advances and limitations</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>2</NO>
<PG>592-600</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15302748"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vincent-2013" MODIFIED="2013-11-01 17:51:46 +0000" MODIFIED_BY="[Empty name]" NAME="Vincent 2013" TYPE="JOURNAL_ARTICLE">
<AU>Vincent JL, De Backer D</AU>
<TI>Circulatory shock</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>369</VL>
<NO>18</NO>
<PG>1726-34</PG>
<IDENTIFIERS MODIFIED="2013-11-01 17:51:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-11-01 17:51:46 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24171518"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2009a" MODIFIED="2011-03-12 10:57:13 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Wang H, Ward MF, Sama AE</AU>
<TI>Novel HMGB1-Inhibiting therapeutic agents for experimental sepsis</TI>
<SO>Shock</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>4</NO>
<PG>348-57</PG>
<IDENTIFIERS MODIFIED="2009-08-15 19:17:38 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-15 19:17:38 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19333143"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2009b" MODIFIED="2012-10-28 12:40:54 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Wang H, Zhu S, Zhou R, Li W Sama AE</AU>
<TI>Therapeutic potential of HMGB1-targeting agents in sepsis</TI>
<SO>Expert Reviews in Molecular Medicine</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>32</NO>
<PG>1-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wesche_x002d_Soldato-2007" MODIFIED="2009-08-17 23:09:06 +0100" MODIFIED_BY="[Empty name]" NAME="Wesche-Soldato 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A</AU>
<TI>The apoptotic pathway as a therapeutic target in sepsis</TI>
<SO>Current Drug Targets</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>4</NO>
<PG>493-500</PG>
<IDENTIFIERS MODIFIED="2009-08-17 23:09:06 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-17 23:09:06 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17430119"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2012-06-20 13:15:14 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS MODIFIED="2012-06-20 13:15:14 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-06-20 13:15:14 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18083463"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2012-06-29 13:47:33 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="20042080"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wittebole-2008" MODIFIED="2011-03-12 10:57:48 +0000" MODIFIED_BY="[Empty name]" NAME="Wittebole 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wittebole X, Collienne C, Castanares-Zapatero D, Laterre PF</AU>
<TI>Adjunctive therapies for severe sepsis</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2008</YR>
<VL>32 Suppl 1</VL>
<PG>34-8</PG>
<IDENTIFIERS MODIFIED="2009-08-15 20:16:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-15 20:16:55 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18715758"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yan-2001" MODIFIED="2012-10-28 12:41:32 +0000" MODIFIED_BY="[Empty name]" NAME="Yan 2001" TYPE="JOURNAL_ARTICLE">
<AU>Yan SB, Dhainaut JF</AU>
<TI>Activated protein C versus protein C in severe sepsis</TI>
<SO>Critical Care Medicine</SO>
<YR>2001</YR>
<VL>29</VL>
<NO>7 Suppl</NO>
<PG>69-74</PG>
<IDENTIFIERS MODIFIED="2009-08-19 01:02:13 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-08-19 01:02:13 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11445737"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zavala-2006" MODIFIED="2009-08-21 16:25:25 +0100" MODIFIED_BY="[Empty name]" NAME="Zavala 2006" TYPE="COMPUTER_PROGRAM">
<AU>Zavala D, Martí-Carvajal A, Peña-Martí G, Comunián G</AU>
<TI>Data extraction sheet to help manage the characteristics of included studies in Cochrane reviews</TI>
<YR>2006</YR>
<PB>Universidad de Carabobo</PB>
<CY>Valencia</CY>
<MD>(www.cochrane.fcs.edu.ve/hrs)</MD>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-02-06 18:49:23 +0000" MODIFIED_BY="Jane Cracknell">
<REFERENCE ID="REF-Marti_x002d_Carvajal-2012" MODIFIED="2017-02-06 18:49:23 +0000" MODIFIED_BY="Jane Cracknell" NAME="Marti-Carvajal 2012" TYPE="COCHRANE_REVIEW">
<AU>Marti-Carvajal AJ, Sola I, Gluud C, Lathyris D, Cardona AF</AU>
<TI>Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2013-05-29 18:01:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-05-29 18:01:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007175.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2007" MODIFIED="2010-06-11 14:50:50 +0100" MODIFIED_BY="Jane Cracknell" NAME="Martí-Carvajal 2007" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal A, Salanti G, Cardona AF</AU>
<TI>Human recombinant activated protein C for severe sepsis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-06-11 14:50:50 +0100" MODIFIED_BY="Jane Cracknell"><IDENTIFIER MODIFIED="2010-06-11 14:50:50 +0100" MODIFIED_BY="Jane Cracknell" TYPE="DOI" VALUE="10.1002/14651858.CD004388.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2008" MODIFIED="2010-11-29 09:50:12 +0000" MODIFIED_BY="Sera Tort" NAME="Martí-Carvajal 2008" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal A, Salanti G, Cardona AF</AU>
<TI>Human recombinant activated protein C for severe sepsis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-11-29 09:50:12 +0000" MODIFIED_BY="Sera Tort"><IDENTIFIER MODIFIED="2010-11-29 09:50:12 +0000" MODIFIED_BY="Sera Tort" TYPE="DOI" VALUE="10.1002/14651858.CD004388.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2011" MODIFIED="2011-11-25 23:12:03 +0000" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2011" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal Arturo J, Solà I, Lathyris D, Cardona AF</AU>
<TI>Human recombinant activated protein C for severe sepsis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004388.pub4"/><IDENTIFIER TYPE="OTHER" VALUE="CD004388"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2012" MODIFIED="2012-07-11 17:58:15 +0100" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2012" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF</AU>
<TI>Human recombinant activated protein C for severe sepsis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2012-07-11 17:58:15 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-07-11 17:58:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004388.pub5"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-11-01 15:10:33 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-04-04 00:30:53 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-04-04 00:30:53 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-10-28 11:47:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ADDRESS-2005">
<CHAR_METHODS MODIFIED="2012-06-27 12:39:53 +0100" MODIFIED_BY="[Empty name]">
<P>Design: parallel-design (2 arms).<BR/>Multicentre study: 516 centres.<BR/>International: 34 countries.</P>
<P>Follow-up period: 28 days.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-28 11:46:24 +0000" MODIFIED_BY="[Empty name]">
<P>N = 2640 enrolled and randomized patients (1333 patients APC group/1307 placebo group). 2610 patients received one of two interventions (1301 patients APC group/1293 placebo group). 2613 patients completed study and analysed (1316 patients APC group/1297 placebo group).<BR/>
</P>
<P>1. Age (years)</P>
<P>C group: 58.8±16.8</P>
<P>Placebo group: 58.6±16.7</P>
<P>Total group: not reported</P>
<P>Range: not reported<BR/>
</P>
<P>2. Sex</P>
<P>APC group: 58.5% men</P>
<P>Placebo group: 58.5% men</P>
<P>Total group: 1516 men (57.4%)<BR/>
</P>
<P>3. Mean APACHE II score<BR/>
</P>
<P>APC group: 18.2±5.8</P>
<P>Placebo group:18.2±5.9<BR/>
</P>
<P>4. APACHE II score &lt; 25</P>
<P>APC group: 1168 (87.6)<BR/>Placebo group: 1147 (87.8)</P>
<P>5. Inclusion criteria:</P>
<UL>
<LI>patients had severe sepsis, defined as the presence of a suspected or known infection and sepsis-induced dysfunction of at least one organ (cardiovascular, renal, respiratory, haematologic; or unexplained metabolic acidosis) and a low risk of death.</LI>
</UL>
<P>6. Exclusion criteria:</P>
<UL>
<LI>APC contraindicated according to the applicable label in the country in which patients enrolled;</LI>
<LI>increased risk of bleeding;</LI>
<LI>moribund state, not expected to survive for 28 days;</LI>
<LI>disease progressed;</LI>
<LI>investigator determined, in the best interest of patient, to initiate treatment with commercial APC, treatment assignment was unblinded and the study drug was discontinued but follow up of the patient continued;</LI>
<LI>unblinding required to permit investigator to treat the patient appropriately for the indicated duration of therapy (i.e., 96 hrs).</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-28 11:47:25 +0000" MODIFIED_BY="[Empty name]">
<P>1. Activated protein C (APC) (Eli Lilly): APC (manufactured from clones of a single cell) was delivered at dose 24 µg/kg/h intravenously for a total duration of 96 hrs.</P>
<P>2. Placebo (0.9% sodium chloride): delivered at dose of 24 µg/kg/h intravenously for a total duration of 96 hrs.</P>
<P>Co-intervention: all other patient care was at the discretion of the investigators and was not specified in the study protocol.</P>
<P>Patients had to begin treatment with the study drug within 48 hrs of documentation of the first organ dysfunction.</P>
<P>Treatment duration: 96 hrs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-28 11:47:47 +0000" MODIFIED_BY="[Empty name]">
<P>Primary<BR/>Death from any cause, assessed 28 days after the start of the infusion.<BR/>Secondary<BR/>In-hospital mortality within 90 days after the start of the infusion.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 10:17:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. RCT also included high risk patients (12.2% placebo group, 12.4% in APC group).<BR/>2. 1307 patients, placebo group: 1293 received drug/14 did not = 1293 patients (98.9%).<BR/>3. 1333 patients, APC group: 1317 received drug/16 did not = 1317 patients (98.7%).<BR/>4. A priori sample size estimation: yes.<BR/>5. Eli Lilly (sponsor) designed trials together with external executives and steering committees of the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) study group. Sponsor collected and analysed the data. Some authors employees and stockholders of Eli Lilly. One author received lecture fees and research grant from Lilly, Germany. Two authors reported having served as paid consultants for Eli Lilly. Data collected and analysed by the sponsor.<BR/>6. There is a misunderstanding with the final number in the flow chart of this included study (Page 1335).</P>
<P>7. Study required by the FDA to assess the effects of APC in patients with severe sepsis and low risk of death (APACHE II lower than 25 or single organ failure).</P>
<P>8. Early termination for futility.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-04 00:30:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-APROCCHSS-2013">
<CHAR_METHODS MODIFIED="2013-04-04 00:29:09 +0100" MODIFIED_BY="[Empty name]">
<P>Design: 2x2 factorial design<BR/>Multicentre study: 24 hospitals.<BR/>Country: France.</P>
<P>Follow-up period: 180 days</P>
<P>Phase: III</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-04 00:22:32 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria </P>
<UL>
<LI>Were included, patients of both sex, who have reached legal age and with 1) indisputable orprobable septic shock for less than 24 hours, 2) one or more clinically or microbiologicallydocumented outbreaks, 3) at least 2 organ failures, each defined by a SOFA score &#8805; 3 for atleast 6 consecutive hours (E1), 4) treated with catecholamines for at least 6 h and less than 24hours (dopamine &#8805;15 µg/kg /min, or epinephrine or norepinephrine at a rate &#8805;0.25 µg/kg/minor at least equal to 1mg/h), or any other vasoconstrictor to maintain a systolic blood pressure1&#8805; 90 mmHg or mean arterial pressure &#8805; 65 mmHg despite adequate fluid resuscitation,6)giving a free, informed and written consent. Otherwise, the consent will be obtained fromthe person of trust or, if not, from a family member, if present. In the event that neither theperson of trust or a family member would be present on the day of inclusion, the patient maybe still included. It will be informed and its consent will be asked for further possibleresearch and use of their data (Law 2004-806 of August 9, 2004, Article L1122-1-2)</LI>
</UL>
<P>Exclusion criteria</P>
<P>1.- Any previous episode of severe sepsis or septic shock during the current hospitalization<BR/>2- Pregnant or breastfeeding women<BR/>3- Decision of withholding or withdrawing care,<BR/>4- Severe underlying disease with a life-expectancy of one month or less,<BR/>5- Formal indication for corticosteroids (prednisone 30 mg or equivalent, for one month<BR/>or more),<BR/>6- Any surgical procedure within the past 72 hours, or any surgery associated with a high<BR/>risk of bleeding, or a surgical procedure scheduled for the next 24 h,<BR/>7- Gastro-duodenal bleeding in the past 6 weeks.<BR/>8- Chronic liver disease, i.e. Child C.<BR/>9- Recent trauma,<BR/>10- Head trauma in the past 3 months<BR/>11- Stroke in the past 3 months<BR/>12- Any intra-cranial process<BR/>13- Platelets count &lt; 30.000 /mm3<BR/>14- Any formal indication for anticoagulant except prophylactic heparin<BR/>15- Any other risk of bleeding as assessed by patient&#8217;s physician<BR/>16- Known hypersensitivity to drotrecogin alfa activated<BR/>17- No affiliation to a French Social Security</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-04 00:23:25 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Placebo Comparator: 1 placebo of hydrocortisone, placebo of fludrocortisone and placebo of activated protein CIntervention: Drug: placebos</LI>
<LI>Active Comparator: 2 Hydrocortisone plus fludrocortisone and a placebo of activated protein CIntervention: Drug: hydrocortisone and fludrocortisone and placebo</LI>
<LI>Active Comparator: 3 placebo of hydrocortisone, placebo of fludrocortisone and activated protein CIntervention: Drug: recombinant human activated protein C and placebos</LI>
<LI>Active Comparator: 4 hydrocortisone plus fludrocortisone plus activated protein CIntervention: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone</LI>
</UL>
<P>http://clinicaltrials.gov/ct2/show/record/NCT00625209</P>
<P>From <LINK REF="STD-APROCCHSS-2013" TYPE="STUDY">APROCCHSS 2013</LINK>:</P>
<P>Marketed DAA was infused at a constant rate of 24 µg/kg/hour for 96 hours. </P>
<P>Control: placebo (0.9% saline). Infusion was interrupted 2 hours before any percutaneous procedure or major<BR/>surgery and was resumed 1 hour or 12 hours later. Patients, investigators, and sponsor were<BR/>blinded to treatment.</P>
<P>Co-intervention: The use of antibiotics, fluid management, vasopressor therapy and ventilatory support had to<BR/>follow the Surviving Sepsis Campaign guidelines (E2). Compliance to these guidelines was<BR/>checked regularly at each investigator meeting.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-03 23:37:42 +0100" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<OL>
<LI>90-day mortality.</LI>
</OL>
<P>Secondary</P>
<OL>
<LI>Mortality rates at day-28 and 180, and at ICU and hospital discharge;</LI>
<LI>Organ failure-free (SOFA &lt;6) days;</LI>
<LI>Vasopressor- and mechanical ventilation-free days; and</LI>
<LI>Serious adverse events (intracranial hemorrhage, any bleeding requiring surgical haemostasis, or transfusion of more than 2 red blood cell concentrates).</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-04 00:30:53 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical trial registration: NCT00625209.</P>
<P>Official Title: Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS).<BR/>Brief Title: Activated Protein C and Corticosteroids for Human Septic Shock.<BR/>Conducted: September 2, 2008, to October 25, 2011</P>
<P>
Sample size 
</P>
<P>Stopped: On October 25 2011, the trial was suspended following the withdrawal from the market of APC.</P>
<P>Sponsor: University of Versailles</P>
<P>Role of sponsor: Assistance Publique &#8211; Hôpitaux de Paris was the study sponsor and took full administrative<BR/>responsibility. The study sponsor did not take part to trial design, patients&#8217; recruitment, data<BR/>management, analysis, interpretation, and reporting.<BR/>All contributors remained independent from the sponsor.</P>
<P>This trial will remain the only industry-independent trial on drotrecogin alfa activated in adults with septic shock. This trial was performed mainly in centers which used routinely XIGRIS since the drug was available on the French market, and has enrolled adults with septic shock and a baseline risk of death of almost twice of the one observed in PROWESS SHOCK. This trial demonstrated that the drug provided no survival benefit in these sick patients admitted to intensive care units in which physicians had experience with XIGRIS use.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-28 11:53:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dhainaut-2009">
<CHAR_METHODS MODIFIED="2012-06-27 10:16:38 +0100" MODIFIED_BY="[Empty name]">
<P>Design: parallel-design (2 arms).<BR/>Multicentre study: 64 centres.</P>
<P>International: nine countries.<BR/>Follow-up period: 24 days after initiation of the study drug and 28 days after standard drug initiation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-28 11:51:47 +0000" MODIFIED_BY="[Empty name]">
<P>Planned sample size: 270 (135 by arm).</P>
<P>Sample size reduced to 200 ("ensure that the study completed in an acceptable timeframe").</P>
<P>Entered to study: 201 participants.</P>
<P>Randomized: 199 participants (73% of the planned sample size).</P>
<P>Lost post-randomization: 6 participants (3%, 6/199).</P>
<UL>
<LI>Experimental arm: 4 ("owing to entry criteria exclusion").</LI>
<LI>Placebo arm: 2 ("owing to entry criteria exclusion and death").</LI>
</UL>
<P>Received study drug, 193 participants (71.5%, 193/270): 94 (70%) experimental arm versus 99 (73.3%) placebo arm.</P>
<P>1. Age (years)<BR/>Mean (± SD): 62.0 ±13.4 (APC arm) versus 62.7 ±13.0 (placebo arm).<BR/>
</P>
<P>2. Sex (male): 61.7% (APC arm) versus 59.6% (placebo arm).<BR/>
<BR/>
</P>
<P>3. Inclusion criteria:</P>
<UL>
<LI>age: &#8805;18 years;</LI>
<LI>severe sepsis;</LI>
<LI>continued to require vasopressor support (having been treated with at least 84 hrs of a planned 96 hr infusion of standard DAA).</LI>
</UL>
<P>4. Exclusion criteria:</P>
<UL>
<LI>required extensive or multiple surgical procedures within the next 3 days;</LI>
<LI>platelet count &lt;30,000/mm<SUP>3</SUP>;</LI>
<LI>receiving therapeutic heparin (&gt;15,000 IU/day of unfractionated heparin or larger doses of low molecular weight heparin than used for prophylaxis of deep venous thrombosis, or &gt;15 IU/kg/hr for renal replacement purposes);</LI>
<LI>not expected to survive 24 days given their pre-existing uncorrectable medical condition;</LI>
<LI>had received treatment within the last 30 days with any drug that had not received regulatory approval;</LI>
<LI>pregnant or breastfeeding;</LI>
<LI>contraindicated for treatment with APC;</LI>
<LI>not given written informed consent;</LI>
<LI>were no longer vasopressor dependent;</LI>
<LI>patients whose family or primary physician had not committed to aggressive management of the patients.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-28 11:52:43 +0000" MODIFIED_BY="[Empty name]">
<P>Experimental<BR/>APC 24 µg/kg/hr. Maximum of 72hr extended infusion. "There was to be no time interval between the standard and study infusions; however, a maximum of 2 hr was allowed in case of unforeseen circumstances. Interruptions were acceptable as long as infusions were restarted within 24 hr and within the 72-hr treatment period. If a patient resolved their need for vasopressor support for 12 continuous hours before completion of treatment, the infusion was discontinued and not restarted".<BR/>Placebo<BR/>Sterile 0.9% sodium chloride.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-28 11:53:45 +0000" MODIFIED_BY="[Empty name]">
<P>Primary<BR/>Time to resolution of vasopressor-dependent hypotension (dopamine &#8805;5 &#956;g/kg/min; or epinephrine, phenylephrine, vasopressin, or norepinephrine at any dose) within 72 hrs.<BR/>Secondary<BR/>1. 28-day all-cause mortality.<BR/>2. 90-day in-hospital mortality.<BR/>3. Organ function (sequential organ failure assessment, SOFA) and biomarker evaluations (protein C, D-dimers, prothrombin time).</P>
<P>Safety: serious adverse events and adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-23 13:23:17 +0100" MODIFIED_BY="[Empty name]">
<P>A priori sample size estimation: 270 patients (power: 81% "to detect a difference between treatment groups using the log rank statistic with a two sided significance level of 0.1 if the true hazard ratio was 0.63. This corresponds to a difference of about 16.5% in time to resolution of vasopressor-dependent cardiovascular organ failure") (Page 1189).</P>
<P>Official title: 'A Phase IIIb Study to Determine Efficacy and Safety of Extended DrotrecoginAlfa (Activated) Therapy in Patients With Persistent Requirement for Vasopressor Support After 96 Hour Infusion With Commercial Drotrecogin Alfa (Activated)'.<BR/>
</P>
<P>ClinicalTrials.gov identifier: NCT00190788.<BR/>Sponsors and Collaborators: Eli Lilly and Company.<BR/>Role: not described.<BR/>First received: September 12, 2005. <BR/>Last updated: October 10, 2007.<BR/>Conducted between 2004 and 2007.</P>
<P>Sample size reduced by 25% due to the slow recruitment.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-28 12:00:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PROWESS-2001">
<CHAR_METHODS MODIFIED="2012-06-27 10:31:12 +0100" MODIFIED_BY="[Empty name]">
<P>Design: parallel-design (2 arms).</P>
<P>Multicentre study: 164 centres.</P>
<P>International: 11 countries.<BR/>
</P>
<P>Follow-up period: 28 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-28 12:00:02 +0000" MODIFIED_BY="[Empty name]">
<P>Planned sample size: 2280.</P>
<P>N = 1728 randomized patients; 1690 patients (APC 850/placebo group 840) for the efficacy and safety analysis.</P>
<P>1. Age: APC group 60.5 ±17.2 yrs; placebo group 60.6±16.5 yrs. Range: 18-96.</P>
<P>2. Sex APC group: 56.1% men; placebo group 58.0% men.</P>
<P>3. Plasma protein C activity (median level) APC group (n = 799): 47%; placebo group (n= 775) 50%.</P>
<P>Protein C deficiency (Yes): APC group 83.4%; placebo group 79.8%.</P>
<P>
<BR/>4. Inclusion criteria:</P>
<UL>
<LI>patients with a known or suspected infection on the basis of clinical data at the time of screening;</LI>
<LI>to meet the following criteria within a 24-hour period: 3 or more signs of systematic inflammation; and sepsis-induced dysfunction of at least one organ system that lasted no longer than 24 hrs.</LI>
</UL>
<P>5. Exclusion criteria:</P>
<UL>
<LI>pregnancy or breastfeeding;</LI>
<LI>age &lt;18 yr or weight &gt;135 kg;</LI>
<LI>platelet count &lt;30,000/mm<SUP>3</SUP>;</LI>
<LI>conditions that increased the risk of bleeding: surgery requiring general or spinal anesthesia within 12 hours before the infusion, the potential need for such surgery during the infusion, or evidence of active bleeding postoperatively; a history of severe head trauma requiring hospitalization, intracranial surgery, or stroke within 3 months before the study or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or mass lesions of the central nervous system; a history of congenital bleeding diatheses; gastrointestinal bleeding within 6 weeks before the study unless corrective surgery had been performed; and trauma considered to increase the risk of bleeding;</LI>
</UL>
<UL>
<LI>known hypercoagulable condition, including resistance to activated protein C; hereditary deficiency;</LI>
<LI>of protein C, protein S, or antithrombin III; presence of anticardiolipin antibody, antiphospholipid antibody, lupus anticoagulant, or homocysteinemia; or recently documented (within 3 months before the study) or highly suspected deep-vein thrombosis or pulmonary embolism;</LI>
<LI>patient&#8217;s family, physician, or both, not in favour of aggressive treatment of patient; or presence of an</LI>
<LI>advanced directive to withhold life-sustaining treatment;</LI>
<LI>patient not expected to survive 28 days because of uncorrectable medical condition; such as poorly</LI>
<LI>controlled neoplasm or other end-stage disease;</LI>
<LI>moribund state in which death was perceived to be imminent;</LI>
<LI>human immunodeficiency virus infection in association with a last known CD4 count of &#8804;50/mm<SUP>3</SUP>;</LI>
<LI>history of bone marrow, lung, liver, pancreas, or small-bowel transplantation;</LI>
<LI>chronic renal failure requiring haemodialysis or peritoneal dialysis;</LI>
<LI>known or suspected portosystemic hypertension, chronic jaundice, cirrhosis, or chronic ascites;</LI>
<LI>acute pancreatitis with no established source of infection;</LI>
<LI>participation in another investigational study within 30 days before the current study;</LI>
</UL>
<UL>
<LI>use of any of the following medications or treatment regimens: unfractionated heparin to treat an active thrombotic event within 8 hours before the infusion&#8224;; low-molecular-weight heparin at a higher dose than recommended for prophylactic use (as specified in the package insert) within 12 hours before the infusion; warfarin (if used within 7 days before study entry and if the prothrombin time exceeded the upper limit of the normal range for the institution); acetylsalicylic acid at a dose of more than 650 mg/day within 3 days before the study; thrombolytic therapy within 3 days before the study&#8225;; glycoprotein IIb/IIIa antagonists within 7 days before study entry; antithrombin III at a dose of more than 10,000 U within 12 hours before the study; or protein C within 24 hours before the study.</LI>
</UL>
<P>Notes</P>
<UL>
<LI>Acute renal failure was not an exclusion criterion.</LI>
<LI>Prophylactic treatment with a dose of unfractionated heparin of up to 15,000 U per day was permitted.</LI>
<LI>Thrombolytic agents were permitted for the treatment of thromboses within a catheter.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-28 12:00:35 +0000" MODIFIED_BY="[Empty name]">
<P>1. Activated protein C (APC) (Xigris, Eli Lilly, Indianapolis).<BR/>APC (product from an established mammalian cell line into which the complementary DNA for human protein C was delivered) at doses of 24 µg per kilogram of body weight per hour intravenously at a constant rate from foil-wrapped bags for a total duration of 96 hrs.</P>
<P>2. Placebo (0.9% saline with or without 0.1% human serum albumin).<BR/>Placebo was delivered at doses of 24 µg per kilogram of body weight per hour intravenously at a constant rate from foil-wrapped bags for a total duration of 96 hrs.</P>
<P>Co-intervention: not standardised approach to critical care (e.g., antibiotics, fluids, vasopressors, or ventilatory support).</P>
<P>The infusion was stopped 1 hour before any percutaneous procedure or major surgery and was resumed 1 hour and 12 hrs later, respectively, in the absence of bleeding complications.</P>
<P>Treatment duration: 96 hrs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death from any cause.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-23 13:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. A priori sample size estimation<BR/>Parameters: "Assuming that the true placebo 28-day all-cause mortality rate in the primary analysis population was 30%, this planned sample size was sufficient to ensure greater than 80% power to conclude efficacy if drotrecogin alfa (activated), in truth, was associated with an 18% relative risk reduction in 28-day all-cause mortality" (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>).</P>
<P>17/38 (placebo group) and 21/38 (APC group) never received study drug. APC group: 14/21 met at least one exclusion criterion, 4/21 became moribund before the infusion could be started, 3/21 consent was withdrawn before start of infusion. Placebo group: 15/17 did not meet the entry criteria, and 2/17 became moribund before start of infusion.</P>
<P>Eli Lilly supplied intervention, employed three of the trial authors, and five trial authors have served as consultants.<BR/>Eli Lilly supplied intervention, employed two persons for helping in analysis and interpretation of the data, and three clinical research associates.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-28 12:04:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012">
<CHAR_METHODS MODIFIED="2012-07-23 13:24:20 +0100" MODIFIED_BY="[Empty name]">
<P>Design: parallel-design (2 arms).<BR/>Multicentre study: 104 centres.</P>
<P>International: 18 countries.<BR/>Follow-up period: 28 days.</P>
<P>Intention-to-treat analysis: yes (Quote &#8216;&#8216;Intention-to-treat&#8217;&#8217; conducted by Independent Academic Statistical Center and Sponsor) (<LINK REF="REF-Finfer-2008" TYPE="REFERENCE">Finfer 2008</LINK>).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-28 12:03:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized: 1697 patients (852 patients APC group/845 placebo group).<BR/>Received APC: 1666 patients (833 (97.8%) APC group/ 833 (98.6%) (placebo group).</P>
<P>1. Median age (interquartile range): APC group 2.3 (0.7-7.8) months; placebo group 2.8 (0.7-9.4) months. Total group: 38 weeks corrected gestational age and 17 years.<BR/>
</P>
<P>2. Sex: APC group, male 59.6%; placebo group, male 48.5%.<BR/>
</P>
<P>3. Inclusion criteria (<LINK REF="REF-Finfer-2008" TYPE="REFERENCE">Finfer 2008</LINK>):</P>
<P>Inclusion criteria to obtain informed consent:</P>
<UL>
<LI>aged C 18 years old;</LI>
<LI>must have an infection requiring intravenous antimicrobial therapy;</LI>
<LI>must meet at least two of the four systemic inflammatory response syndrome (SIRS) criteria;</LI>
<LI>must have septic shock, defined as: (a) The patient must have received intravenous fluid resuscitation of &#8805; 30 mL/kg administered within the time period spanning the 4 hours before and 4 hours after initiation of vasopressor therapy, (b) The patient must have a continuous requirement for at least one of the vasopressors listed below at the dose shown below for at least four hours: norepinephrine &#8805; 5 mcg/min, dopamine &#8805; 10 mcg/kg/min, phenylephrine &#8805; 25 mcg/min, epinephrine &#8805; 5 mcg/min, vasopressin &#8805; 0.03 units/min, and (c) The patient must meet at least 1 of the following criteria consistent with hypoperfusion during the 36 hours prior to study entry: metabolic acidosis: base deficit &#8805; 5.0 mmol/L or venous bicarbonate\18 mmol/L or lactate &lt;2.5 mMol/L; urine output &lt;0.5 mL/kg h-1 for 1 hour or a 50% increase in creatinine from a known baseline level, acute hepatic dysfunction: AST or ALT&gt; 500 IU/dL or bilirubin &gt;2 g/dL.</LI>
</UL>
<P>Inclusion criterion to proceed to randomization</P>
<UL>
<LI>Patients must remain vasopressor dependent throughout the pretreatment period and through the time of randomization with the goal of maintaining a systolic blood pressure of approximately 90 mm Hg or higher or a mean arterial pressure of 65 mm Hg or higher with reasonable attempts made to wean the patient from vasopressor support, if applicable. (Note: dopamine at doses\5 mcg/kg/min does not fulfil the criteria for vasopressor dependency.)</LI>
</UL>
<P>4. Exclusion criteria:</P>
<UL>
<LI>high risk of intracranial bleeding;</LI>
<LI>expected to die before the end of the 28 days of the study from pre-existing conditions;</LI>
<LI>end-stage renal or liver disease;</LI>
<LI>patients with co-existing illnesses with a high risk of death (e.g., metastatic cancer).</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-25 21:13:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Activated protein C (APC) (Eli Lilly, Indianapolis) 24 µg/kg/hr intravenously for 96 hrs.</P>
<P>2. Placebo: 0.9% saline solution intravenously.</P>
<P>Treatment duration: 96 hrs.<BR/>
</P>
<P>All other treatments were at the discretion of treating clinicians.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-28 12:04:12 +0000" MODIFIED_BY="[Empty name]">
<P>Primary<BR/>Death from any cause 28 days.</P>
<P>Secondary</P>
<OL>
<LI>28-day mortality in patients with severe protein C deficiency (plasma concentration, &#8804;50% of the lower limit of the normal range).</LI>
<LI>90-day mortality.</LI>
<LI>Measures of organ dysfunction.</LI>
<LI>Safety.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-28 12:04:59 +0000" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov number, NCT00604214<BR/>A priori sample size estimation: yes. Quote: "We determined that the planned enrolment of 1500 patients would provide a power of 80% at a significance level of 0.05 to detect an absolute difference of 7 percentage points (20% relative risk reduction) in the primary outcome of 28-day mortality from the placebo rate of 35%. An independent data and safety monitoring board conducted interim analyses, as described previously.* The protocol specified an increase in sample size if the 28-day mortality for 750 patients was less than 30%." Page 2057 from <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK> and * page 1941 from <LINK REF="REF-Finfer-2008" TYPE="REFERENCE">Finfer 2008</LINK>.</P>
<P>Sponsor: Eli Lilly.</P>
<P>Disclosure forms provided by the authors are available with the full text of this article at NEJM.org and the protocol of this trial (<LINK REF="REF-Finfer-2008" TYPE="REFERENCE">Finfer 2008</LINK>).</P>
<P>We contacted to the main author for asking data on 28-day all-cause mortality by APACHE II score, 28-day all-cause mortality by protein C deficiency class, 28-Day all-cause mortality by number of organ dysfunction, and In-hospital mortality. This information was sent by <LINK REF="STD-PROWESS_x002d_SHOCK-2012" TYPE="STUDY">PROWESS-SHOCK 2012</LINK> Steering Committee (12 July 2012).</P>
<P>This trial was not stopped for futility. This information was supplied by the main author, 27 June 2012.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-28 12:07:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RESOLVE-2007">
<CHAR_METHODS MODIFIED="2012-06-27 12:39:38 +0100" MODIFIED_BY="[Empty name]">
<P>Design: parallel-design (2 arms).<BR/>Multicentre study: 104 centres.</P>
<P>International: 18 countries.<BR/>Follow-up period: 28 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-28 12:06:23 +0000" MODIFIED_BY="[Empty name]">
<P>N = 477 patients (240 patients APC group/237 placebo group). Median age (interquartile range): APC group 2.3 (0.7-7.8) months; placebo group 2.8 (0.7-9.4) months. Total group: 38 weeks corrected gestational age and 17 years.<BR/>1. Age (years), median (IQR)<BR/>APC group: 2.3 (0.7 and 7.8)<BR/>Placebo group: 2·8 (0.7 and 9.4)<BR/>
</P>
<P>2. Sex<BR/>APC group, male 59.6%<BR/>Placebo group, male 48.5%<BR/>
</P>
<P>3. Inclusion criteria:</P>
<UL>
<LI>suspected or proven infection, and systemic inflammation;</LI>
<LI>sepsis-induced cardiovascular;</LI>
<LI>respiratory organ dysfunction within 12 hrs before entering the study.</LI>
</UL>
<P>4. Exclusion criteria:</P>
<UL>
<LI>high risk of intracranial bleeding;</LI>
<LI>expected to die before the end of the 28 days of the study from pre-existing conditions;</LI>
<LI>end-stage renal or liver disease;</LI>
<LI>(see web panel 1 for full inclusion criteria and web panel 2 for full exclusion criteria).</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-28 12:06:44 +0000" MODIFIED_BY="[Empty name]">
<P>1. Activated protein C (APC) (Eli Lilly, Indianapolis) 24 µg/kg/hr intravenously for 96 hrs.</P>
<P>2. Placebo: 0·9% saline.</P>
<P>Treatment duration: 96 hrs.<BR/>
</P>
<P>The study drug was to be started within 42 hrs of the first documented organ dysfunction and within 24 hrs of dual cardiovascular and respiratory organ dysfunction.<BR/>Standard of care was at the discretion of the primary physician and not dictated by the trial protocol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-28 12:07:06 +0000" MODIFIED_BY="[Empty name]">
<P>Primary<BR/>Composite time to complete organ failure resolution (CTCOFR) score.</P>
<P>Secondary</P>
<OL>
<LI>28-day mortality.</LI>
<LI>Major amputations.</LI>
<LI>Safety.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-28 12:07:35 +0000" MODIFIED_BY="[Empty name]">
<P>NCT00049764.</P>
<P>Date for conducting trial: Enrolment of the patients was between November 2002 and March 2005. Follow up of the enrolled patients (N: 477) was until 3 April 2005.</P>
<P>A priori sample size estimation: Yes. Quote "We calculated that a sample size of 600 patients would provide 80% power for a clinically relevant 1·2-day reduction" (Page 839).</P>
<P>Rol of founding sources: This trial was funded by Eli Lilly, and the authors from the funding company were involved in all aspects of the study. The decision to stop the study, which was made by the sponsors at the recommendation of the Data Safety Monitoring Board (Page 840)</P>
<P>Early termination for futility.</P>
<P>Quote "... enrolment was suspended after the second planned interim analysis suggested there was little chance of reaching the efficacy endpoint by completion of the trial." (Page 840).</P>
<P>Data from April 21, 2005 re: Discontinuation of Study F1K-MC-EVBP, Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in paediatric Severe Sepsis (http://www.fda.gov/medwatch/safety/2005/xigris_dearHCP_4-21-05.htm).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-28 12:12:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-rhAPC-Sepsis-Study-2001">
<CHAR_METHODS MODIFIED="2012-06-27 13:45:36 +0100" MODIFIED_BY="[Empty name]">
<P>Design: Parallel-design (2 arms).</P>
<P>Phase: II<BR/>International multicentre study: 40 centres (USA and Canada).</P>
<P>Follow-up period: 28 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-28 12:10:48 +0000" MODIFIED_BY="[Empty name]">
<P>N = 135 randomized patients; 131 patients (90 APC group/41 placebo group) for the efficacy and safety analysis.</P>
<P>1. Age<BR/>APC group 58 ±14 yrs<BR/>Placebo group 62±16 yrs<BR/>Total group: 60±15 yrs<BR/>Range: 19-89 yrs</P>
<P>2. Sex (men)<BR/>APC group: 63%<BR/>Placebo group: 66%<BR/>Total group: 64%</P>
<P>3. Plasma protein C activity (mean level)<BR/>APC group (N = 88): 43±21%<BR/>Placebo group (N= 37): 36±17%<BR/>Total group (N= 125): 41±20%<BR/>% lower than 40% protein C activity<BR/>APC group: 47%<BR/>placebo group: 60%<BR/>Total group: 50%<BR/>
<BR/>
</P>
<P>131 patients who received study drug (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>): 90 received APC (Stage 1: 46 patients; Stage 2: 44 patients); 41 received placebo (Stage 1: 26 patients; Stage 2: 15 patients).<BR/>Post-randomization loss: 4 (one withdrew consent, and three did not meet entry criteria).<BR/>
</P>
<P>
<BR/>Inclusion criteria:</P>
<UL>
<LI>&#8805;18 years;</LI>
<LI>severe sepsis;</LI>
<LI>known or suspected site of infection;</LI>
<LI>evidence of infection: modified definition of systematic inflammatory response syndrome - SIRS (ACCP/SCCM consensus conference), and cardiovascular, renal, or respiratory organ failure;</LI>
<LI>no more than 24 hrs between meeting SIRS and organ failure entry criteria;</LI>
<LI>no more than 36 hrs between meeting entry criteria and study drug infusion.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>activated partial thromboplastin time (APTT) more than 2 times the upper limit of references range for that institution or platelet count lower than 30,000/mm<SUP>3</SUP>;</LI>
<LI>active bleeding likely to become life threatening or an increased risk for bleeding;</LI>
<LI>therapeutic doses of heparin within the previous 8 hrs, acetylsalicylic acid (ASA) doses higher than 650 mg/day within the previous 7 days, or warfarin or thrombolytic treatment within the past month;</LI>
<LI>anticipated requirement for therapeutic heparin, warfarin or ASA higher than 650 mg/day during the infusion period;</LI>
<LI>not expected to live more than 6 hr, or not expected to survive 28 days given their pre-existing; medical condition, or known or suspected to have sustained irreversible cessation of all brain function;</LI>
<LI>end-stage renal disease, receiving either haemodialysis or peritoneal dialysis.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-28 12:11:13 +0000" MODIFIED_BY="[Empty name]">
<P>1. Activated protein C (APC) (Eli Lilly, Indianapolis). APC (from an established mammalian cell culture) was delivered at two stages. Stage 1: 4 dose tiers of 48 hrs duration infusion, as a continuous intravenous infusion; 18 patients enrolled in each tier. Doses studied in this stage: 12, 18, 24, and 30 µg/kg/hr. Stage 2: 3 dose tiers of 96 hrs duration of infusion, as continuous intravenous infusion; 20 patients in each tier. Doses studied in this stage: 12, 18, and 24 µg/kg/hr.</P>
<P>2. Placebo (saline) Stage 1: 4 dose tiers of 48 hrs duration infusion, as a continuous intravenous infusion; 18 patients enrolled in each tier. Doses studied in this stage: 12, 18, 24, and 30 µg/kg/hr. Stage 2: 3 dose tiers of 96 hrs duration of infusion, as continuous intravenous infusion; 20 patients in each tier. Doses studied in this stage: 12, 18, and 24 µg/kg/hr.</P>
<P>3. Co-intervention: use of antimicrobial agents, intravenous fluids, cardiovascular and respiratory support and surgical intervention left up to treating physician, not prespecified in the protocol. Appropriateness of antimicrobial therapy: not assessed.<BR/>Infusion rates for individual patients could be decreased from 25% to 75% when bedside whole blood APTT measurements were consistently 95 sec.</P>
<P>Treatment duration: 48 hrs (Stage 1); 96 hr (Stage 2).</P>
<P>1. Activated protein C (APC) (Xigris, Eli Lilly, Indianapolis). APC (from an established mammalian cell line using complementary DNA for human protein C) at doses of 24 µg/kg/hr intravenously at a constant rate from foil-wrapped bags for a total duration of 96 hrs.<BR/>2. Placebo (0.9% saline with or without 0.1% human serum albumin). Placebo delivered at doses of 24 µg/kg/hr intravenously at a constant rate from foil-wrapped bags for a total duration of 96 hrs. Co-intervention: non standardized approach to critical care (e.g. antibiotics, fluids, vasopressors, or ventilatory support).<BR/>The infusion was stopped 1 hr before any percutaneous procedure or major surgery and was resumed 1 hr and 12 hrs later, respectively, in the absence of bleeding complications.<BR/>
</P>
<P>Treatment duration: 96 hrs.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-28 12:12:13 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Primary</LI>
</UL>
<P>1. Safety (serious adverse events, serious bleeding events).<BR/>2. Assessment of antiAPC antibody response.</P>
<UL>
<LI>Secondary</LI>
</UL>
<P>1. IL-6 blood levels.<BR/>2. Organ failure-free and other.<BR/>3. All-cause 28-day mortality.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-28 12:12:22 +0000" MODIFIED_BY="[Empty name]">
<P>1. It did not distinguish APC from endogenous plasma APC.</P>
<P>2. A priori sample estimation: no.</P>
<P>3. This study was funded by Eli Lilly and Company.</P>
<P>4. Disclosure: not given.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Dr Gordon Bernard supplied some data from <LINK REF="STD-PROWESS-2001" TYPE="STUDY">PROWESS 2001</LINK> (February 2, 2003).<BR/>Dr Jonathan Janes from Ely Liily supplied some data from <LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK> (December 8, 2005).<BR/>Dr Jonathan Janes from Ely Lilly supplied some data from <LINK REF="STD-ADDRESS-2005" TYPE="STUDY">ADDRESS 2005</LINK> (April 16, 2007).<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-10-28 12:13:19 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:39:16 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Alaniz-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:39:16 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:44:41 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Barie-2011a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:44:41 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-23 13:25:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barton-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-23 13:25:36 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomized clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 13:59:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bearden-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 13:59:27 +0100" MODIFIED_BY="[Empty name]">
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-23 13:25:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernard-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-23 13:25:38 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomized clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 13:59:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bertolini-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 13:59:30 +0100" MODIFIED_BY="[Empty name]">
<P>Survey.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:36:19 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Boyle-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:36:19 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:47:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casey-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:47:15 +0100" MODIFIED_BY="[Empty name]">
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 13:59:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Costa-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 13:59:35 +0100" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:13:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Decruyenaere-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:13:00 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled clinical trial open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:36:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferrer-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:36:27 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:38:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freeman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:38:48 +0100" MODIFIED_BY="[Empty name]">
<P>Meta-analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:13:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldstein-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:13:06 +0000" MODIFIED_BY="[Empty name]">
<P>Non-controlled clinical trial open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:39:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Green-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:39:41 +0100" MODIFIED_BY="[Empty name]">
<P>Systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:40:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heslet-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:40:21 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical practice guidelines.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:41:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Houston-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:41:54 +0100" MODIFIED_BY="[Empty name]">
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:55:50 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Kalil-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:55:50 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Meta-analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:13:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kanji-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:13:19 +0000" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:42:10 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Khan-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:42:10 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 16:02:36 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Kylat-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 16:02:36 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Cochrane review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-23 13:25:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-23 13:25:45 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial assessing prophylactic heparin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:36:58 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Lopez-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:36:58 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 14:00:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lucioni-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 14:00:09 +0100" MODIFIED_BY="[Empty name]">
<P>Cost-effectiveness analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:43:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marraro-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:43:04 +0100" MODIFIED_BY="[Empty name]">
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:43:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCoy-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:43:55 +0100" MODIFIED_BY="[Empty name]">
<P>Narrative review.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:44:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCoy-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:44:32 +0100" MODIFIED_BY="[Empty name]">
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-23 13:25:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neilson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-23 13:25:51 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomized clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:37:13 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Sadique-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:37:13 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:37:24 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Sanchez-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:37:24 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:37:31 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Sanchez_x002d_Garcia-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:37:31 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-23 13:25:56 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" STUDY_ID="STD-Shorr-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-23 13:25:56 +0100" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Randomized clinical trial comparing two regimens of APC.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 16:54:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Doorn-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 16:54:29 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-23 13:25:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vincent-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-23 13:25:59 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomized clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-29 05:37:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wheeler-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-29 05:37:43 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 17:00:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wiedermann-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 17:00:29 +0100" MODIFIED_BY="[Empty name]">
<P>Meta-analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-06-27 12:10:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-06-21 11:19:19 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-04-04 00:28:04 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-04-03 23:38:28 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 12:17:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ADDRESS-2005">
<DESCRIPTION>
<P>Quote: "We used block randomization stratified according to investigative site and within a site in terms of whether the patient received or was intended to receive low-dose heparin for prophylaxis against deep-vein thrombosis at the start of infusion of the study drug".</P>
<P> Comment: Insufficient information to permit judgment of 'Low risk' or 'High risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-03 23:38:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-APROCCHSS-2013">
<DESCRIPTION>
<P>Quote "Randomization was centralized, performed through a secured Website, and stratified<BR/>according to centre, using permutation blocks."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-04 13:45:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dhainaut-2009">
<DESCRIPTION>
<P>Quote: &#8216;[...] pharmacist or designee who obtained treatment assignments from an interactive voice response system [...]&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-23 13:24:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PROWESS-2001">
<DESCRIPTION>
<P>Quote: "Block randomization stratified according to site was used, and all assignments were made through a central randomization centre".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 12:38:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012">
<DESCRIPTION>
<P>Quote " A centralized system randomly assigned..." (Page 2056).</P>
<P>Insufficient information to permit judgment of 'Low risk' or 'High risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-23 13:24:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RESOLVE-2007">
<DESCRIPTION>
<P>Quote: "block randomization (block size of 4)." (Page 837).</P>
<P>Insufficient information to permit judgment of 'Low risk' or 'High risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 13:50:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-rhAPC-Sepsis-Study-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgment of 'Low risk' or 'High risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-04-03 23:38:53 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 12:17:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ADDRESS-2005">
<DESCRIPTION>
<P>Insufficient information to permit judgment of 'Low risk' or 'High risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-03 23:38:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-APROCCHSS-2013">
<DESCRIPTION>
<P>Quote "Randomization was centralized, performed through a secured Website..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-28 09:08:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dhainaut-2009">
<DESCRIPTION>
<P>Quote: &#8216;[...] pharmacist or designee who obtained treatment assignments from an interactive voice response system [...]&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-23 13:24:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PROWESS-2001">
<DESCRIPTION>
<P>"An unblinded pharmacist at each site will obtain the patient's treatment code from the central randomization centre and prepare the study medication according to the pharmacist's instruction brochure. There are very few anticipated reasons for breaking the randomization code. Given that there is no known treatment to increase the clearance or counter the effects of APC, incidences where unblinding could be beneficial will be extremely rare. The investigator must contact the VCC prior to unblinding a patient's therapy assignment."</P>
<P>Information supplied by Bridget Swindell, RN, Clinical Trials Manager, Vanderbilt Coordinating Center (bridget.swindell@Vanderbilt.Edu).</P>
<P>Quote from <LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>: "The patient treatment assignments were provided to investigators by Covance, a contract research organization, via a central randomization centre. The code for the treatment assignment was retained by Covance".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 12:38:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012">
<DESCRIPTION>
<P>Quote " A centralized system randomly assigned..."</P>
<P>Insufficient information to permit judgment of 'Low risk' or 'High risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 13:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RESOLVE-2007">
<DESCRIPTION>
<P>Insufficient information to permit judgment of 'Low risk' or 'High risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 13:50:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-rhAPC-Sepsis-Study-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgment of 'Low risk' or 'High risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-04-03 23:40:29 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Blinding of outcome assessment?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Blinding of providers or participants?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-28 11:49:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADDRESS-2005">
<DESCRIPTION>
<P>Quote "Patients, investigators, and all others involved in conducting the study remained blinded to the treatment assignments for the duration of the study" (Page 1333).<BR/>Quote: &#8216;All delivery systems for the study drug were covered to ensure blinding&#8217; (Page 1333).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-06-28 09:08:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ADDRESS-2005">
<DESCRIPTION>
<P>Data were not provided to judge if outcome measurement was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-03 23:40:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-APROCCHSS-2013">
<DESCRIPTION>
<P>Patients, investigators, and sponsor were blinded to treatment. (ask how?)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-04-03 23:40:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-APROCCHSS-2013">
<DESCRIPTION>
<P>Patients, investigators, and sponsor were blinded to treatment.(ask how)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-12 09:42:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dhainaut-2009">
<DESCRIPTION>
<P>Quote: &#8216;Patients and study personnel remained blinded to treatment throughout the study, apart from a pharmacist [...] prepared the drug (covered to maintain the blinding)&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-06-28 09:17:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dhainaut-2009">
<DESCRIPTION>
<P>Data were not provided to judge if outcome measurement was blinded.</P>
<P>IInsufficient information to permit judgment of 'Low risk' or 'High risk'.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-28 09:13:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PROWESS-2001">
<DESCRIPTION>
<P>&#8220;The patients, investigators, VCC and Lilly (with the possible exception of study drug coordination and Global Safety Monitoring personnel) were blinded to the study therapy until all patients have completed the protocol and the study has ended.&#8221;</P>
<P>Information supplied by Bridget Swindell, RN, Clinical Trials Manager, Vanderbilt Coordinating Center (bridget.swindell@Vanderbilt.Edu).</P>
<P>Comments: trial did not report the appearance of the drug preparations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-07-23 13:24:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PROWESS-2001">
<DESCRIPTION>
<P>Quote: "All measurements were performed by a central laboratory".</P>
<P>Quote from <LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>: &#8216;All deaths and serious adverse events were reviewed by Lilly in a blinded manner&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-28 09:16:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012">
<DESCRIPTION>
<P>Quote " patients, care-givers, data collectors, statisticians, the study steering committee,<BR/>and the clinical coordinating centre will be blinded"</P>
<P>Comment: trial did not report the appearance of the drug preparations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-06-28 09:10:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012">
<DESCRIPTION>
<P>Data were not provided to judge if outcome measurement was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-28 09:13:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RESOLVE-2007">
<DESCRIPTION>
<P>Quote: "All study personnel, except the pharmacist responsible for dispensing study drug, remained unaware of treatment assignment".</P>
<P>Comments: trial did not report the appearance of the drug preparations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-06-28 09:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RESOLVE-2007">
<DESCRIPTION>
<P>Data were not provided to judge if outcome measurement was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-28 09:15:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-rhAPC-Sepsis-Study-2001">
<DESCRIPTION>
<P>Double blind infusion with the use of a saline.</P>
<P>Comment: trial did not report the appearance of the drug preparations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2012-06-28 09:15:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-rhAPC-Sepsis-Study-2001">
<DESCRIPTION>
<P>Data were not provided to judge if outcome measurement was blinded.</P>
<P>Insufficient information to permit judgment of 'Low risk' or 'High risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" NO="12">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" NO="13">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-04-03 23:31:49 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-23 15:53:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADDRESS-2005">
<DESCRIPTION>
<P>Quote: "was analysed in the intention-to-treat population, defined as all patients who were randomly assigned to treatment, even if the patient did not receive the assigned or correct treatment, did not follow the protocol, or received commercial DrotAA as a result of the investigator&#8217;s decision".</P>
<P>Data for primary outcome available for 98.97% of the randomized sample, with balanced reasons for withdrawals or losses to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-APROCCHSS-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-23 15:53:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dhainaut-2009">
<DESCRIPTION>
<P>Quote: "Analyses used the intention to treat (ITT) population".</P>
<P>Data for primary outcome available for 96.01% of the randomized sample but reasons for withdrawals or losses to follow up remain unclear.</P>
<P>27.5% of patients had protocol violations due to drug discontinuation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-12-03 16:41:27 +0000" MODIFIED_BY="Jane Cracknell" RESULT="YES" STUDY_ID="STD-PROWESS-2001">
<DESCRIPTION>
<P>Complete data for primary outcome available. 38 patients did not receive the allocated drug, with balanced reasons between groups. One patient allocated to the intervention did not receive the drug and was imputed as a negative outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-23 15:53:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012">
<DESCRIPTION>
<P>Data for primary outcome available for the 98.9% of the randomized sample, with balanced reasons for withdrawals or losses to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-23 13:24:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RESOLVE-2007">
<DESCRIPTION>
<P>Quote: "Analysis was by intention to treat".</P>
<P>Data for primary outcome available for the 96.16% of the randomized sample, with balanced reasons for withdrawals or losses to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-23 13:25:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-rhAPC-Sepsis-Study-2001">
<DESCRIPTION>
<P>135 patients randomized, 131 analysed (1 consent withdrawn, 3 did not fit inclusion criteria).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-04-03 23:40:34 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:57:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADDRESS-2005">
<DESCRIPTION>
<P>No protocol available. All the outcomes listed in the method section described in results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-03 23:40:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-APROCCHSS-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 16:00:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dhainaut-2009">
<DESCRIPTION>
<P>No protocol available. All the outcomes listed in the method section described in results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:55:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PROWESS-2001">
<DESCRIPTION>
<P>FDA data available. All outcomes available in the trial publication and reported in results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 07:56:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012">
<DESCRIPTION>
<P>All outcomes available in the trial publication and reported in results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:58:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RESOLVE-2007">
<DESCRIPTION>
<P>Registration data available [NCT00049764]. All outcomes available in the trial publication and reported in results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:53:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-rhAPC-Sepsis-Study-2001">
<DESCRIPTION>
<P>No protocol available. All the outcomes listed in the method section described in results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-04-04 00:28:04 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 13:31:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ADDRESS-2005">
<DESCRIPTION>
<P>Sponsor bias.</P>
<P>Bias in the presentation of data (<LINK REF="REF-Porta-2008" TYPE="REFERENCE">Porta 2008</LINK>).<BR/>Comment: this trial has a misunderstanding with the final number in the flow chart of this included study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-04 00:28:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-APROCCHSS-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 11:54:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dhainaut-2009">
<DESCRIPTION>
<P>Sponsor bias.</P>
<P>Design bias (<LINK REF="REF-Porta-2008" TYPE="REFERENCE">Porta 2008</LINK>).</P>
<P>Comment: The trial has a considerable number of imbalances at baseline: lower protein C levels, more admissions to acute care hospitals, more cancer histories, higher SOFA cardiovascular scores for the intervention group, and more myocardial infarction histories in the placebo group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-23 15:53:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-PROWESS-2001">
<DESCRIPTION>
<P>Sponsor bias.</P>
<P>Design bias (<LINK REF="REF-Porta-2008" TYPE="REFERENCE">Porta 2008</LINK>).</P>
<P>Trial was stopped early for benefit.</P>
<P>Quote: "At the time of the second interim analysis of data from 1520 patients, enrolment was suspended because the differences in the mortality rate between the two groups exceeded the a priori guideline for stopping the trial". (Page 701). This trial was not supplied the stopping criteria.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 13:32:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012">
<DESCRIPTION>
<P>Sponsor bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 13:31:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-RESOLVE-2007">
<DESCRIPTION>
<P>Sponsor bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 13:51:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-rhAPC-Sepsis-Study-2001">
<DESCRIPTION>
<P>Sponsor bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2010-10-28 15:52:17 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Free of academic bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2010-10-28 15:52:17 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Free of imbalance bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2010-10-28 15:52:17 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Free of drug company bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2010-10-28 15:52:17 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Free of early stopping bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2010-10-28 15:52:17 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Free attrition bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-10-28 12:15:35 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-10-28 12:15:35 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-07-13 09:33:00 +0100" MODIFIED_BY="Grade Profiler">Human recombinant activated protein C compared to placebo for severe sepsis or septic shock</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>Human recombinant activated protein C compared to placebo for severe sepsis or septic shock</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with severe sepsis or septic shock<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> Human recombinant activated protein C<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Human recombinant activated protein C</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>28-Day all-cause mortality (adult and paediatric patients)</B>
<BR/>Follow up: 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.00 </B>
<BR/>(0.86 to 1.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>6781<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>229 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>229 per 1000</B>
<BR/>(197 to 266)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>In-hospital mortality (adult and paediatric patients)</B>
<BR/>Follow up: 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.04 </B>
<BR/>(0.94 to 1.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>4307<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>272 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>283 per 1000</B>
<BR/>(256 to 313)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Serious bleeding events in adult and paediatric patients (days 0 to 28) </B>
<BR/>Follow up: 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.45 </B>
<BR/>(1.08 to 1.94)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>6767<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 1000</B>
<BR/>(24 to 43)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Serious adverse events (adult and paediatric patients)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.04 </B>
<BR/>(0.92 to 1.18)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>6636<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>133 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>138 per 1000</B>
<BR/>(122 to 157)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Limitations related to the completion of the original trial protocols in most of the trials (ADDRESS, RESOLVE, PROWESS and <LINK REF="STD-Dhainaut-2009" TYPE="STUDY">Dhainaut 2009</LINK>). All RCTs were sponsored by a drug company (Eli Lilly).<BR/>
<SUP>2</SUP> I<SUP>2</SUP>: 56%.<BR/>
<SUP>3</SUP> I<SUP>2</SUP>: 11%.<BR/>
<SUP>4</SUP> I<SUP>2</SUP>: 0%.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-06-29 14:27:25 +0100" MODIFIED_BY="Jane Cracknell"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-10-06 20:02:25 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-10-06 20:02:25 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>APC versus placebo</NAME>
<DICH_OUTCOME CHI2="11.76009962502848" CI_END="1.1423234380962506" CI_START="0.8832329976229495" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0044589361863954" ESTIMABLE="YES" EVENTS_1="856" EVENTS_2="837" I2="48.98002405327864" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.057789087703660716" LOG_CI_START="-0.05392471405117383" LOG_EFFECT_SIZE="0.001932186826243421" METHOD="MH" MODIFIED="2013-04-03 18:16:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06753979887762507" P_Q="1.0" P_Z="0.9459460022607021" Q="0.0" RANDOM="YES" SCALE="24.08" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.013147580732355764" TOTALS="YES" TOTAL_1="3643" TOTAL_2="3549" WEIGHT="100.0" Z="0.06779854469818933">
<NAME>28-Day all-cause mortality (paediatric and adult patients)</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2845219181164225" CI_START="0.9225583416160911" EFFECT_SIZE="1.088598369715391" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="220" LOG_CI_END="0.10874151914016467" LOG_CI_START="-0.035006159975665994" LOG_EFFECT_SIZE="0.03686767958224932" ORDER="1591" O_E="0.0" SE="0.08443809827512648" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1316" TOTAL_2="1297" VAR="0.007129792440319917" WEIGHT="21.236217932367452"/>
<DICH_DATA CI_END="1.3753860897576198" CI_START="0.816341514339057" EFFECT_SIZE="1.0596153846153846" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="70" LOG_CI_END="0.13842462770408667" LOG_CI_START="-0.08812811727011488" LOG_EFFECT_SIZE="0.025148255216985892" MODIFIED="2013-04-03 18:14:41 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.13307820385202018" STUDY_ID="STD-APROCCHSS-2013" TOTAL_1="208" TOTAL_2="203" VAR="0.017709808340479843" WEIGHT="13.954995180391363"/>
<DICH_DATA CI_END="1.8469896098484095" CI_START="0.8555202430089714" EFFECT_SIZE="1.257035003431709" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="31" LOG_CI_END="0.2664644523443053" LOG_CI_START="-0.06776970988315816" LOG_EFFECT_SIZE="0.09934737123057359" MODIFIED="2012-06-28 10:47:35 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.19633080137819825" STUDY_ID="STD-Dhainaut-2009" TOTAL_1="94" TOTAL_2="99" VAR="0.03854578356980553" WEIGHT="8.330173932457285"/>
<DICH_DATA CI_END="0.9356326516364017" CI_START="0.6862058444174828" EFFECT_SIZE="0.8012718600953895" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="259" LOG_CI_END="-0.028894630622955306" LOG_CI_START="-0.16354558737653188" LOG_EFFECT_SIZE="-0.09622010899974362" MODIFIED="2013-04-03 18:16:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1593" O_E="0.0" SE="0.07909463853003652" STUDY_ID="STD-PROWESS-2001" TOTAL_1="850" TOTAL_2="840" VAR="0.0062559618441971375" WEIGHT="22.192582312841864"/>
<DICH_DATA CI_END="1.283035251685488" CI_START="0.9231234289172425" EFFECT_SIZE="1.0883013833298223" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="202" LOG_CI_END="0.10823858887856508" LOG_CI_START="-0.03474022647806092" LOG_EFFECT_SIZE="0.036749181200252064" MODIFIED="2012-05-30 21:06:08 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.08398646389703267" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="846" TOTAL_2="834" VAR="0.007053726117927572" WEIGHT="21.316181125422702"/>
<DICH_DATA CI_END="1.457587126378768" CI_START="0.6632929766576896" EFFECT_SIZE="0.9832635983263598" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.1636345238939113" LOG_CI_START="-0.17829460124671415" LOG_EFFECT_SIZE="-0.007330038676401435" MODIFIED="2012-06-28 10:39:45 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.20085086068407038" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="239" TOTAL_2="235" VAR="0.04034106823753184" WEIGHT="8.05058127441776"/>
<DICH_DATA CI_END="1.44392933272895" CI_START="0.4957096577162526" EFFECT_SIZE="0.846031746031746" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.15954593896986358" LOG_CI_START="-0.3047726198238825" LOG_EFFECT_SIZE="-0.07261334042700944" ORDER="1592" O_E="0.0" SE="0.2727430198493808" STUDY_ID="STD-rhAPC-Sepsis-Study-2001" TOTAL_1="90" TOTAL_2="41" VAR="0.07438875487655974" WEIGHT="4.919268242101561"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.861411214539242" CI_END="1.1274629292575118" CI_START="0.9065488009372541" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0109896965941847" ESTIMABLE="YES" EVENTS_1="955" EVENTS_2="931" I2="40.98509972051487" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.052102271274099415" LOG_CI_START="-0.042608812189213335" LOG_EFFECT_SIZE="0.004746729542443078" METHOD="MH" MODIFIED="2013-04-04 00:56:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10520958045427664" P_Q="0.8522657744893589" P_Z="0.844250977276131" Q="0.034680987174282404" RANDOM="YES" SCALE="2.29" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.00910992846419468" TOTALS="SUB" TOTAL_1="3851" TOTAL_2="3752" WEIGHT="200.0" Z="0.19645892766382375">
<NAME>Any-Day all cause mortality (paediatric and adults patients)</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APC</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.760099625028479" CI_END="1.1423234380962506" CI_START="0.8832329976229496" DF="6" EFFECT_SIZE="1.0044589361863954" ESTIMABLE="YES" EVENTS_1="856" EVENTS_2="837" I2="48.980024053278626" ID="CMP-001.02.01" LOG_CI_END="0.057789087703660716" LOG_CI_START="-0.05392471405117377" LOG_EFFECT_SIZE="0.001932186826243421" MODIFIED="2013-04-04 00:56:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06753979887762518" P_Z="0.9459460022607022" STUDIES="7" TAU2="0.01314758073235576" TOTAL_1="3643" TOTAL_2="3549" WEIGHT="100.0" Z="0.06779854469818922">
<NAME>28-Day all-cause mortality</NAME>
<DICH_DATA CI_END="1.2845219181164225" CI_START="0.9225583416160911" EFFECT_SIZE="1.088598369715391" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="220" LOG_CI_END="0.10874151914016467" LOG_CI_START="-0.035006159975665994" LOG_EFFECT_SIZE="0.03686767958224932" MODIFIED="2013-04-04 00:56:54 +0100" MODIFIED_BY="[Empty name]" ORDER="1591" O_E="0.0" SE="0.08443809827512648" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1316" TOTAL_2="1297" VAR="0.007129792440319917" WEIGHT="21.236217932367456"/>
<DICH_DATA CI_END="1.3753860897576198" CI_START="0.816341514339057" EFFECT_SIZE="1.0596153846153846" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="70" LOG_CI_END="0.13842462770408667" LOG_CI_START="-0.08812811727011488" LOG_EFFECT_SIZE="0.025148255216985892" MODIFIED="2013-04-04 00:56:07 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.13307820385202018" STUDY_ID="STD-APROCCHSS-2013" TOTAL_1="208" TOTAL_2="203" VAR="0.017709808340479843" WEIGHT="13.95499518039136"/>
<DICH_DATA CI_END="1.8469896098484095" CI_START="0.8555202430089714" EFFECT_SIZE="1.257035003431709" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="31" LOG_CI_END="0.2664644523443053" LOG_CI_START="-0.06776970988315816" LOG_EFFECT_SIZE="0.09934737123057359" MODIFIED="2013-04-04 00:56:08 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.19633080137819825" STUDY_ID="STD-Dhainaut-2009" TOTAL_1="94" TOTAL_2="99" VAR="0.03854578356980553" WEIGHT="8.330173932457287"/>
<DICH_DATA CI_END="0.9356326516364017" CI_START="0.6862058444174828" EFFECT_SIZE="0.8012718600953895" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="259" LOG_CI_END="-0.028894630622955306" LOG_CI_START="-0.16354558737653188" LOG_EFFECT_SIZE="-0.09622010899974362" MODIFIED="2013-04-04 00:56:55 +0100" MODIFIED_BY="[Empty name]" ORDER="1593" O_E="0.0" SE="0.07909463853003652" STUDY_ID="STD-PROWESS-2001" TOTAL_1="850" TOTAL_2="840" VAR="0.0062559618441971375" WEIGHT="22.192582312841864"/>
<DICH_DATA CI_END="1.283035251685488" CI_START="0.9231234289172425" EFFECT_SIZE="1.0883013833298223" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="202" LOG_CI_END="0.10823858887856508" LOG_CI_START="-0.03474022647806092" LOG_EFFECT_SIZE="0.036749181200252064" MODIFIED="2013-04-04 00:56:56 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.08398646389703267" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="846" TOTAL_2="834" VAR="0.007053726117927572" WEIGHT="21.316181125422702"/>
<DICH_DATA CI_END="1.457587126378768" CI_START="0.6632929766576896" EFFECT_SIZE="0.9832635983263598" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.1636345238939113" LOG_CI_START="-0.17829460124671415" LOG_EFFECT_SIZE="-0.007330038676401435" MODIFIED="2013-04-04 00:56:10 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.20085086068407038" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="239" TOTAL_2="235" VAR="0.04034106823753184" WEIGHT="8.05058127441776"/>
<DICH_DATA CI_END="1.44392933272895" CI_START="0.4957096577162526" EFFECT_SIZE="0.846031746031746" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.15954593896986358" LOG_CI_START="-0.3047726198238825" LOG_EFFECT_SIZE="-0.07261334042700944" MODIFIED="2013-04-04 00:56:10 +0100" MODIFIED_BY="[Empty name]" ORDER="1592" O_E="0.0" SE="0.2727430198493808" STUDY_ID="STD-rhAPC-Sepsis-Study-2001" TOTAL_1="90" TOTAL_2="41" VAR="0.07438875487655974" WEIGHT="4.91926824210156"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2625167841951208" CI_START="0.836840956998901" DF="0" EFFECT_SIZE="1.0278743862520459" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="94" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.10123716044208213" LOG_CI_START="-0.07735707254547687" LOG_EFFECT_SIZE="0.011940043948302637" MODIFIED="2013-04-04 00:49:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7932678139585763" STUDIES="1" TAU2="0.0" TOTAL_1="208" TOTAL_2="203" WEIGHT="100.0" Z="0.26206956093737704">
<NAME>90-Day all-cause mortality</NAME>
<DICH_DATA CI_END="1.2625167841951208" CI_START="0.836840956998901" EFFECT_SIZE="1.0278743862520459" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="94" LOG_CI_END="0.10123716044208213" LOG_CI_START="-0.07735707254547687" LOG_EFFECT_SIZE="0.011940043948302637" MODIFIED="2013-04-04 00:49:47 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.10490713651260329" STUDY_ID="STD-APROCCHSS-2013" TOTAL_1="208" TOTAL_2="203" VAR="0.011005507291273982" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.760099625028483" CI_END="1.1423234380962506" CI_START="0.8832329976229495" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0044589361863954" ESTIMABLE="YES" EVENTS_1="856" EVENTS_2="837" I2="48.98002405327864" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.057789087703660716" LOG_CI_START="-0.05392471405117383" LOG_EFFECT_SIZE="0.001932186826243421" METHOD="MH" MODIFIED="2013-04-04 00:46:47 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="3" P_CHI2="0.06753979887762485" P_Q="0.9080735211007255" P_Z="0.9459460022607021" Q="0.013333052513166417" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.013147580732355767" TOTALS="YES" TOTAL_1="3643" TOTAL_2="3549" WEIGHT="99.99999999999999" Z="0.0677985446981893">
<NAME>28-Day all-cause mortality by age of the participants</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.457587126378768" CI_START="0.6632929766576896" DF="0" EFFECT_SIZE="0.9832635983263598" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.1636345238939113" LOG_CI_START="-0.17829460124671415" LOG_EFFECT_SIZE="-0.007330038676401435" MODIFIED="2012-07-10 17:48:21 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="1" P_CHI2="1.0" P_Z="0.933030442105849" STUDIES="1" TAU2="0.0" TOTAL_1="239" TOTAL_2="235" WEIGHT="8.050581274417763" Z="0.08403268838314895">
<NAME>28-Day all-cause mortality (paediatric patients)</NAME>
<DICH_DATA CI_END="1.457587126378768" CI_START="0.6632929766576896" EFFECT_SIZE="0.9832635983263598" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.1636345238939113" LOG_CI_START="-0.17829460124671415" LOG_EFFECT_SIZE="-0.007330038676401435" MODIFIED="2012-06-28 11:09:33 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="99" O_E="0.0" SE="0.20085086068407038" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="239" TOTAL_2="235" VAR="0.04034106823753184" WEIGHT="8.050581274417763"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.758628010815656" CI_END="1.1632037429715436" CI_START="0.8732184600509553" DF="5" EFFECT_SIZE="1.0078347985474199" ESTIMABLE="YES" EVENTS_1="815" EVENTS_2="796" I2="57.478032340159324" ID="CMP-001.03.02" LOG_CI_END="0.06565579099542337" LOG_CI_START="-0.05887709177471333" LOG_EFFECT_SIZE="0.0033893496103549955" MODIFIED="2013-04-04 00:46:47 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="2" P_CHI2="0.03824910946245541" P_Z="0.9150375085794091" STUDIES="6" TAU2="0.01653566916655506" TOTAL_1="3404" TOTAL_2="3314" WEIGHT="91.94941872558222" Z="0.10668673236405214">
<NAME>28-Day all-cause mortality (adult patients)</NAME>
<DICH_DATA CI_END="1.2845219181164225" CI_START="0.9225583416160911" EFFECT_SIZE="1.088598369715391" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="220" LOG_CI_END="0.10874151914016467" LOG_CI_START="-0.035006159975665994" LOG_EFFECT_SIZE="0.03686767958224932" MODIFIED="2012-06-28 11:09:59 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="100" O_E="0.0" SE="0.08443809827512648" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1316" TOTAL_2="1297" VAR="0.007129792440319917" WEIGHT="21.236217932367452"/>
<DICH_DATA CI_END="1.3753860897576198" CI_START="0.816341514339057" EFFECT_SIZE="1.0596153846153846" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="70" LOG_CI_END="0.13842462770408667" LOG_CI_START="-0.08812811727011488" LOG_EFFECT_SIZE="0.025148255216985892" MODIFIED="2013-04-04 00:46:47 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.13307820385202018" STUDY_ID="STD-APROCCHSS-2013" TOTAL_1="208" TOTAL_2="203" VAR="0.017709808340479843" WEIGHT="13.95499518039136"/>
<DICH_DATA CI_END="1.8469896098484095" CI_START="0.8555202430089714" EFFECT_SIZE="1.257035003431709" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="31" LOG_CI_END="0.2664644523443053" LOG_CI_START="-0.06776970988315816" LOG_EFFECT_SIZE="0.09934737123057359" MODIFIED="2012-06-28 11:10:24 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="101" O_E="0.0" SE="0.19633080137819825" STUDY_ID="STD-Dhainaut-2009" TOTAL_1="94" TOTAL_2="99" VAR="0.03854578356980553" WEIGHT="8.330173932457287"/>
<DICH_DATA CI_END="0.9356326516364017" CI_START="0.6862058444174828" EFFECT_SIZE="0.8012718600953895" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="259" LOG_CI_END="-0.028894630622955306" LOG_CI_START="-0.16354558737653188" LOG_EFFECT_SIZE="-0.09622010899974362" MODIFIED="2012-06-28 11:10:58 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="102" O_E="0.0" SE="0.07909463853003652" STUDY_ID="STD-PROWESS-2001" TOTAL_1="850" TOTAL_2="840" VAR="0.0062559618441971375" WEIGHT="22.192582312841864"/>
<DICH_DATA CI_END="1.283035251685488" CI_START="0.9231234289172425" EFFECT_SIZE="1.0883013833298223" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="202" LOG_CI_END="0.10823858887856508" LOG_CI_START="-0.03474022647806092" LOG_EFFECT_SIZE="0.036749181200252064" MODIFIED="2012-06-28 11:11:24 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="103" O_E="0.0" SE="0.08398646389703267" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="846" TOTAL_2="834" VAR="0.007053726117927572" WEIGHT="21.316181125422702"/>
<DICH_DATA CI_END="1.44392933272895" CI_START="0.4957096577162526" EFFECT_SIZE="0.846031746031746" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.15954593896986358" LOG_CI_START="-0.3047726198238825" LOG_EFFECT_SIZE="-0.07261334042700944" MODIFIED="2012-06-28 11:13:01 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="104" O_E="0.0" SE="0.2727430198493808" STUDY_ID="STD-rhAPC-Sepsis-Study-2001" TOTAL_1="90" TOTAL_2="41" VAR="0.07438875487655974" WEIGHT="4.919268242101561"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.483679640435868" CI_END="1.1587689242789145" CI_START="0.8581973522327482" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9972223536733191" ESTIMABLE="YES" EVENTS_1="780" EVENTS_2="767" I2="56.45994875724152" I2_Q="32.67583363731192" ID="CMP-001.04" LOG_CI_END="0.06399683983241959" LOG_CI_START="-0.06641282971534963" LOG_EFFECT_SIZE="-0.0012079949414650114" METHOD="MH" MODIFIED="2013-04-04 00:46:26 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="4" P_CHI2="0.04259012463922973" P_Q="0.2229395679433568" P_Z="0.9710346990933085" Q="1.4853507351473316" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.017333049189534513" TOTALS="YES" TOTAL_1="3435" TOTAL_2="3346" WEIGHT="100.00000000000003" Z="0.036310598546692816">
<NAME>28-Day all-cause mortality by treatment duration</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.850091438662934" CI_END="1.1366458392831087" CI_START="0.82870596426578" DF="4" EFFECT_SIZE="0.9705386062758119" ESTIMABLE="YES" EVENTS_1="743" EVENTS_2="736" I2="59.39123991987058" ID="CMP-001.04.01" LOG_CI_END="0.05562516653035308" LOG_CI_START="-0.08159953549152883" LOG_EFFECT_SIZE="-0.012987184480587874" MODIFIED="2012-06-28 11:58:10 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="1" P_CHI2="0.04303008128233776" P_Z="0.7106458736731549" STUDIES="5" TAU2="0.01708597835253628" TOTAL_1="3341" TOTAL_2="3247" WEIGHT="89.49859356576039" Z="0.37098880110478627">
<NAME>96 hours</NAME>
<DICH_DATA CI_END="1.2845219181164225" CI_START="0.9225583416160911" EFFECT_SIZE="1.088598369715391" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="220" LOG_CI_END="0.10874151914016467" LOG_CI_START="-0.035006159975665994" LOG_EFFECT_SIZE="0.03686767958224932" MODIFIED="2012-06-28 11:56:42 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="105" O_E="0.0" SE="0.08443809827512648" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1316" TOTAL_2="1297" VAR="0.007129792440319917" WEIGHT="23.987660254506004"/>
<DICH_DATA CI_END="0.9356326516364017" CI_START="0.6862058444174828" EFFECT_SIZE="0.8012718600953895" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="259" LOG_CI_END="-0.028894630622955306" LOG_CI_START="-0.16354558737653188" LOG_EFFECT_SIZE="-0.09622010899974362" MODIFIED="2012-06-28 11:57:10 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="106" O_E="0.0" SE="0.07909463853003652" STUDY_ID="STD-PROWESS-2001" TOTAL_1="850" TOTAL_2="840" VAR="0.0062559618441971375" WEIGHT="24.87625840004979"/>
<DICH_DATA CI_END="1.283035251685488" CI_START="0.9231234289172425" EFFECT_SIZE="1.0883013833298223" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="202" LOG_CI_END="0.10823858887856508" LOG_CI_START="-0.03474022647806092" LOG_EFFECT_SIZE="0.036749181200252064" MODIFIED="2012-06-28 11:57:33 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="107" O_E="0.0" SE="0.08398646389703267" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="846" TOTAL_2="834" VAR="0.007053726117927572" WEIGHT="24.062481672071577"/>
<DICH_DATA CI_END="1.457587126378768" CI_START="0.6632929766576896" EFFECT_SIZE="0.9832635983263598" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.1636345238939113" LOG_CI_START="-0.17829460124671415" LOG_EFFECT_SIZE="-0.007330038676401435" MODIFIED="2012-06-28 11:57:54 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="108" O_E="0.0" SE="0.20085086068407038" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="239" TOTAL_2="235" VAR="0.04034106823753184" WEIGHT="10.174517791603812"/>
<DICH_DATA CI_END="1.44392933272895" CI_START="0.4957096577162526" EFFECT_SIZE="0.846031746031746" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.15954593896986358" LOG_CI_START="-0.3047726198238825" LOG_EFFECT_SIZE="-0.07261334042700944" MODIFIED="2012-06-28 11:58:10 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="109" O_E="0.0" SE="0.2727430198493808" STUDY_ID="STD-rhAPC-Sepsis-Study-2001" TOTAL_1="90" TOTAL_2="41" VAR="0.07438875487655974" WEIGHT="6.397675447529188"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8469896098484095" CI_START="0.8555202430089714" DF="0" EFFECT_SIZE="1.257035003431709" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="31" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.2664644523443053" LOG_CI_START="-0.06776970988315816" LOG_EFFECT_SIZE="0.09934737123057359" MODIFIED="2012-06-28 11:58:36 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="2" P_CHI2="1.0" P_Z="0.24395635741436594" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="99" WEIGHT="10.501406434239637" Z="1.1651548020883629">
<NAME>&gt;96 hours</NAME>
<DICH_DATA CI_END="1.8469896098484095" CI_START="0.8555202430089714" EFFECT_SIZE="1.257035003431709" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="31" LOG_CI_END="0.2664644523443053" LOG_CI_START="-0.06776970988315816" LOG_EFFECT_SIZE="0.09934737123057359" MODIFIED="2012-06-28 11:58:36 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="110" O_E="0.0" SE="0.19633080137819825" STUDY_ID="STD-Dhainaut-2009" TOTAL_1="94" TOTAL_2="99" VAR="0.03854578356980553" WEIGHT="10.501406434239637"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1721580809222156" CI_END="0.9403410168709001" CI_START="0.6892474708677482" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8050637661896569" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="259" I2="68.47571985727527" I2_Q="68.44836868945602" ID="CMP-001.05" LOG_CI_END="-0.026714619924451732" LOG_CI_START="-0.16162481882421434" LOG_EFFECT_SIZE="-0.09416971937433298" METHOD="MH" MODIFIED="2013-04-04 00:46:22 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.07490345581792301" P_Q="0.07502966981067105" P_Z="0.0062157115653555285" Q="3.1694082317253054" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02739575101992459" TOTALS="SUB" TOTAL_1="850" TOTAL_2="840" WEIGHT="200.0" Z="2.7361794721697836">
<NAME>28-Day all-cause mortality (according to PROWESS first and second protocol)</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1743315240270686" CI_START="0.745687096938006" DF="0" EFFECT_SIZE="0.9357798165137615" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="109" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.069790719339526" LOG_CI_START="-0.12744337169693812" LOG_EFFECT_SIZE="-0.02882632617870605" MODIFIED="2012-07-10 17:47:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5667065316883395" STUDIES="1" TAU2="0.0" TOTAL_1="360" TOTAL_2="360" WEIGHT="100.00000000000001" Z="0.5729086773992098">
<NAME>First protocol</NAME>
<DICH_DATA CI_END="1.1743315240270686" CI_START="0.745687096938006" EFFECT_SIZE="0.9357798165137615" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="109" LOG_CI_END="0.069790719339526" LOG_CI_START="-0.12744337169693812" LOG_EFFECT_SIZE="-0.02882632617870605" ORDER="1595" O_E="0.0" SE="0.11585628139931559" STUDY_ID="STD-PROWESS-2001" TOTAL_1="360" TOTAL_2="360" VAR="0.0134226779396774" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.872667431361029" CI_START="0.5700415857025533" DF="0" EFFECT_SIZE="0.7053061224489796" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="150" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-0.059151231944501774" LOG_CI_START="-0.24409346049881417" LOG_EFFECT_SIZE="-0.15162234622165796" MODIFIED="2012-07-10 17:47:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0013103690931913783" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="480" WEIGHT="100.0" Z="3.213699112083972">
<NAME>Second protocol</NAME>
<DICH_DATA CI_END="0.872667431361029" CI_START="0.5700415857025533" EFFECT_SIZE="0.7053061224489796" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="150" LOG_CI_END="-0.059151231944501774" LOG_CI_START="-0.24409346049881417" LOG_EFFECT_SIZE="-0.15162234622165796" ORDER="1596" O_E="0.0" SE="0.10863598053159912" STUDY_ID="STD-PROWESS-2001" TOTAL_1="490" TOTAL_2="480" VAR="0.011801776266061981" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="51.322557681098615" CI_END="1.1112114614063187" CI_START="0.8848415716956741" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9915876643025637" ESTIMABLE="YES" EVENTS_1="1610" EVENTS_2="1565" I2="74.67000752227179" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.045796712211064294" LOG_CI_START="-0.053134481502857565" LOG_EFFECT_SIZE="-0.0036688846458966563" METHOD="MH" MODIFIED="2013-04-04 00:46:19 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.7651976391697133E-6" P_Q="0.6722074760874861" P_Z="0.8844176650131299" Q="0.17903081332633813" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.040807326731808036" TOTALS="SUB" TOTAL_1="6926" TOTAL_2="6618" WEIGHT="200.0" Z="0.14537137376878734">
<NAME>28-Day all-cause mortality all trials compared to all trials excluding PROWESS first protocol)</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.760099625028479" CI_END="1.1423234380962506" CI_START="0.8832329976229496" DF="6" EFFECT_SIZE="1.0044589361863954" ESTIMABLE="YES" EVENTS_1="856" EVENTS_2="837" I2="48.980024053278626" ID="CMP-001.06.01" LOG_CI_END="0.057789087703660716" LOG_CI_START="-0.05392471405117377" LOG_EFFECT_SIZE="0.001932186826243421" MODIFIED="2013-04-03 18:21:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06753979887762518" P_Z="0.9459460022607021" STUDIES="7" TAU2="0.01314758073235576" TOTAL_1="3643" TOTAL_2="3549" WEIGHT="100.0" Z="0.06779854469818936">
<NAME>Adult and paediatric patients</NAME>
<DICH_DATA CI_END="1.2845219181164225" CI_START="0.9225583416160911" EFFECT_SIZE="1.088598369715391" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="220" LOG_CI_END="0.10874151914016467" LOG_CI_START="-0.035006159975665994" LOG_EFFECT_SIZE="0.03686767958224932" MODIFIED="2011-11-25 23:33:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1597" O_E="0.0" SE="0.08443809827512648" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1316" TOTAL_2="1297" VAR="0.007129792440319917" WEIGHT="21.236217932367456"/>
<DICH_DATA CI_END="1.3753860897576198" CI_START="0.816341514339057" EFFECT_SIZE="1.0596153846153846" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="70" LOG_CI_END="0.13842462770408667" LOG_CI_START="-0.08812811727011488" LOG_EFFECT_SIZE="0.025148255216985892" MODIFIED="2013-04-03 18:21:53 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.13307820385202018" STUDY_ID="STD-APROCCHSS-2013" TOTAL_1="208" TOTAL_2="203" VAR="0.017709808340479843" WEIGHT="13.95499518039136"/>
<DICH_DATA CI_END="1.8469896098484095" CI_START="0.8555202430089714" EFFECT_SIZE="1.257035003431709" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="31" LOG_CI_END="0.2664644523443053" LOG_CI_START="-0.06776970988315816" LOG_EFFECT_SIZE="0.09934737123057359" MODIFIED="2011-11-25 23:34:38 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.19633080137819825" STUDY_ID="STD-Dhainaut-2009" TOTAL_1="94" TOTAL_2="99" VAR="0.03854578356980553" WEIGHT="8.330173932457287"/>
<DICH_DATA CI_END="0.9356326516364017" CI_START="0.6862058444174828" EFFECT_SIZE="0.8012718600953895" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="259" LOG_CI_END="-0.028894630622955306" LOG_CI_START="-0.16354558737653188" LOG_EFFECT_SIZE="-0.09622010899974362" MODIFIED="2012-07-10 17:52:34 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="1599" O_E="0.0" SE="0.07909463853003652" STUDY_ID="STD-PROWESS-2001" TOTAL_1="850" TOTAL_2="840" VAR="0.0062559618441971375" WEIGHT="22.192582312841864"/>
<DICH_DATA CI_END="1.283035251685488" CI_START="0.9231234289172425" EFFECT_SIZE="1.0883013833298223" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="202" LOG_CI_END="0.10823858887856508" LOG_CI_START="-0.03474022647806092" LOG_EFFECT_SIZE="0.036749181200252064" MODIFIED="2012-05-30 21:08:06 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.08398646389703267" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="846" TOTAL_2="834" VAR="0.007053726117927572" WEIGHT="21.316181125422702"/>
<DICH_DATA CI_END="1.457587126378768" CI_START="0.6632929766576896" EFFECT_SIZE="0.9832635983263598" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.1636345238939113" LOG_CI_START="-0.17829460124671415" LOG_EFFECT_SIZE="-0.007330038676401435" MODIFIED="2012-06-25 21:35:49 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.20085086068407038" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="239" TOTAL_2="235" VAR="0.04034106823753184" WEIGHT="8.05058127441776"/>
<DICH_DATA CI_END="1.44392933272895" CI_START="0.4957096577162526" EFFECT_SIZE="0.846031746031746" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.15954593896986358" LOG_CI_START="-0.3047726198238825" LOG_EFFECT_SIZE="-0.07261334042700944" MODIFIED="2011-11-25 23:34:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1598" O_E="0.0" SE="0.2727430198493808" STUDY_ID="STD-rhAPC-Sepsis-Study-2001" TOTAL_1="90" TOTAL_2="41" VAR="0.07438875487655974" WEIGHT="4.91926824210156"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="39.01924492947449" CI_END="1.2091092163001556" CI_START="0.7404192642749355" DF="6" EFFECT_SIZE="0.9461753306660479" ESTIMABLE="YES" EVENTS_1="754" EVENTS_2="728" I2="84.62297255919553" ID="CMP-001.06.02" LOG_CI_END="0.08246553154249955" LOG_CI_START="-0.1305222902710202" LOG_EFFECT_SIZE="-0.02402837936426034" MODIFIED="2013-04-03 18:22:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="7.095742569074304E-7" P_Z="0.6583230798621227" STUDIES="7" TAU2="0.08552559797812254" TOTAL_1="3283" TOTAL_2="3069" WEIGHT="99.99999999999999" Z="0.44222958627230063">
<NAME>Adult and paediatric patients (excluding PROWESS 2001 first protocol)</NAME>
<DICH_DATA CI_END="1.2845219181164225" CI_START="0.9225583416160911" EFFECT_SIZE="1.088598369715391" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="220" LOG_CI_END="0.10874151914016467" LOG_CI_START="-0.035006159975665994" LOG_EFFECT_SIZE="0.03686767958224932" MODIFIED="2012-07-05 16:30:27 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="1597" O_E="0.0" SE="0.08443809827512648" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1316" TOTAL_2="1297" VAR="0.007129792440319917" WEIGHT="16.89328301516196"/>
<DICH_DATA CI_END="1.3753860897576198" CI_START="0.816341514339057" EFFECT_SIZE="1.0596153846153846" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="70" LOG_CI_END="0.13842462770408667" LOG_CI_START="-0.08812811727011488" LOG_EFFECT_SIZE="0.025148255216985892" MODIFIED="2013-04-03 18:22:04 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.13307820385202018" STUDY_ID="STD-APROCCHSS-2013" TOTAL_1="208" TOTAL_2="203" VAR="0.017709808340479843" WEIGHT="15.16198549544552"/>
<DICH_DATA CI_END="1.8469896098484095" CI_START="0.8555202430089714" EFFECT_SIZE="1.257035003431709" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="31" LOG_CI_END="0.2664644523443053" LOG_CI_START="-0.06776970988315816" LOG_EFFECT_SIZE="0.09934737123057359" MODIFIED="2012-07-05 16:30:27 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="49" O_E="0.0" SE="0.19633080137819825" STUDY_ID="STD-Dhainaut-2009" TOTAL_1="94" TOTAL_2="99" VAR="0.03854578356980553" WEIGHT="12.615751623708851"/>
<DICH_DATA CI_END="0.6503515466553025" CI_START="0.4302586962679549" EFFECT_SIZE="0.5289795918367347" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="150" LOG_CI_END="-0.1868518225863434" LOG_CI_START="-0.3662703430735724" LOG_EFFECT_SIZE="-0.27656108282995795" MODIFIED="2012-07-05 16:39:57 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="1599" O_E="0.0" SE="0.10539132707019841" STUDY_ID="STD-PROWESS-2001" TOTAL_1="490" TOTAL_2="360" VAR="0.011107331821617536" WEIGHT="16.197933111030277"/>
<DICH_DATA CI_END="1.283035251685488" CI_START="0.9231234289172425" EFFECT_SIZE="1.0883013833298223" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="202" LOG_CI_END="0.10823858887856508" LOG_CI_START="-0.03474022647806092" LOG_EFFECT_SIZE="0.036749181200252064" MODIFIED="2012-07-05 16:30:27 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="42" O_E="0.0" SE="0.08398646389703267" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="846" TOTAL_2="834" VAR="0.007053726117927572" WEIGHT="16.907163111227074"/>
<DICH_DATA CI_END="1.457587126378768" CI_START="0.6632929766576896" EFFECT_SIZE="0.9832635983263598" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.1636345238939113" LOG_CI_START="-0.17829460124671415" LOG_EFFECT_SIZE="-0.007330038676401435" MODIFIED="2012-07-05 16:30:27 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="48" O_E="0.0" SE="0.20085086068407038" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="239" TOTAL_2="235" VAR="0.04034106823753184" WEIGHT="12.43580830636475"/>
<DICH_DATA CI_END="1.44392933272895" CI_START="0.4957096577162526" EFFECT_SIZE="0.846031746031746" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.15954593896986358" LOG_CI_START="-0.3047726198238825" LOG_EFFECT_SIZE="-0.07261334042700944" MODIFIED="2012-07-05 16:30:27 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="1598" O_E="0.0" SE="0.2727430198493808" STUDY_ID="STD-rhAPC-Sepsis-Study-2001" TOTAL_1="90" TOTAL_2="41" VAR="0.07438875487655974" WEIGHT="9.788075337061551"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.95913207940355" CI_END="1.175945404182602" CI_START="0.9135350898985501" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0364687117929516" ESTIMABLE="YES" EVENTS_1="675" EVENTS_2="681" I2="68.66997544025045" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.07038715914434428" LOG_CI_START="-0.03927476625711724" LOG_EFFECT_SIZE="0.015556196443613595" METHOD="MH" MODIFIED="2013-04-04 00:34:21 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.006961741990597736" P_Q="0.6233725126950376" P_Z="0.5781663546265656" Q="0.24115593011803713" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03013143903191132" TOTALS="SUB" TOTAL_1="3008" TOTAL_2="2969" WEIGHT="200.0" Z="0.5560651001574752">
<NAME>28-Day all-cause mortality by APACHE II score</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.280487761852999" CI_END="1.2024529062150915" CI_START="0.9162290692908187" DF="2" EFFECT_SIZE="1.0496296047308753" ESTIMABLE="YES" EVENTS_1="355" EVENTS_2="334" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.08006807633782569" LOG_CI_START="-0.037995933437121605" LOG_EFFECT_SIZE="0.021036071450352065" MODIFIED="2012-07-12 19:47:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8691462507305664" P_Z="0.4849060032926702" STUDIES="3" TAU2="0.0" TOTAL_1="2012" TOTAL_2="1987" WEIGHT="100.0" Z="0.6984337140080783">
<NAME>APACHE &lt; 25</NAME>
<DICH_DATA CI_END="1.2719588664773211" CI_START="0.8791830148826238" EFFECT_SIZE="1.0574897782183126" ESTIMABLE="YES" EVENTS_1="195" EVENTS_2="182" LOG_CI_END="0.10447306701147682" LOG_CI_START="-0.055920710727883585" LOG_EFFECT_SIZE="0.024276178141796605" ORDER="1600" O_E="0.0" SE="0.09421609900610498" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1153" TOTAL_2="1138" VAR="0.008876673311928176" WEIGHT="54.18262294371277"/>
<DICH_DATA CI_END="1.3034232276204012" CI_START="0.7522738394442527" EFFECT_SIZE="0.9902177517409085" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="83" LOG_CI_END="0.11508545606228457" LOG_CI_START="-0.12362404064332749" LOG_EFFECT_SIZE="-0.004269292290521422" ORDER="1601" O_E="0.0" SE="0.14021913999594232" STUDY_ID="STD-PROWESS-2001" TOTAL_1="436" TOTAL_2="437" VAR="0.019661407221201674" WEIGHT="24.462208510491696"/>
<DICH_DATA CI_END="1.4775597194259578" CI_START="0.8204642799183814" EFFECT_SIZE="1.1010381334155617" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="69" LOG_CI_END="0.16954504305110482" LOG_CI_START="-0.0859403218284702" LOG_EFFECT_SIZE="0.04180236061131732" MODIFIED="2012-07-12 19:47:26 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.15007336800321494" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="423" TOTAL_2="412" VAR="0.02252201578382838" WEIGHT="21.355168545795536"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.032561563672337" CI_END="1.346196544825411" CI_START="0.6809587348971932" DF="2" EFFECT_SIZE="0.9574467588786775" ESTIMABLE="YES" EVENTS_1="320" EVENTS_2="347" I2="84.6538227329391" ID="CMP-001.07.02" LOG_CI_END="0.12910847155337923" LOG_CI_START="-0.16687920489989128" LOG_EFFECT_SIZE="-0.018885366673256045" MODIFIED="2012-07-12 19:51:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0014791672325477068" P_Z="0.8025028074905117" STUDIES="3" TAU2="0.07460030759754942" TOTAL_1="996" TOTAL_2="982" WEIGHT="100.0" Z="0.2501093218335972">
<NAME>APACHE &gt;= 25</NAME>
<DICH_DATA CI_END="1.7124726274532214" CI_START="0.8311292896124552" EFFECT_SIZE="1.1930155733836716" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="39" LOG_CI_END="0.23362363835948258" LOG_CI_START="-0.08033141256037692" LOG_EFFECT_SIZE="0.07664611289955285" ORDER="1602" O_E="0.0" SE="0.18441875101289176" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="163" TOTAL_2="158" VAR="0.03401027572515497" WEIGHT="27.83237816939488"/>
<DICH_DATA CI_END="0.849038877610996" CI_START="0.5903049657551103" EFFECT_SIZE="0.7079490557751428" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="176" LOG_CI_END="-0.07107242289462067" LOG_CI_START="-0.22892356339752118" LOG_EFFECT_SIZE="-0.14999799314607093" MODIFIED="2012-07-12 19:51:36 +0100" MODIFIED_BY="[Empty name]" ORDER="1603" O_E="0.0" SE="0.0927225413071511" STUDY_ID="STD-PROWESS-2001" TOTAL_1="414" TOTAL_2="403" VAR="0.008597469666456341" WEIGHT="36.333793133003425"/>
<DICH_DATA CI_END="1.330275800773716" CI_START="0.9031743114677846" EFFECT_SIZE="1.0961162942069864" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="132" LOG_CI_END="0.12394169084426307" LOG_CI_START="-0.04422842332671743" LOG_EFFECT_SIZE="0.03985663375877282" MODIFIED="2012-07-12 19:51:07 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.09878395751952475" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="419" TOTAL_2="421" VAR="0.009758270263219269" WEIGHT="35.83382869760171"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.538800133596925" CI_END="1.0716034029275354" CI_START="0.7038261377781403" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8684598345993899" ESTIMABLE="YES" EVENTS_1="374" EVENTS_2="418" I2="38.8266972797096" I2_Q="8.615146599012395" ID="CMP-001.08" LOG_CI_END="0.03003408406112872" LOG_CI_START="-0.15253460893868667" LOG_EFFECT_SIZE="-0.06125026243877893" METHOD="MH" MODIFIED="2013-04-04 00:34:18 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.16236209205491747" P_Q="0.3347830758875938" P_Z="0.18847532352214938" Q="2.1885464883597283" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.016318449318697876" TOTALS="SUB" TOTAL_1="1517" TOTAL_2="1502" WEIGHT="300.0" Z="1.3151028958043163">
<NAME>28-Day all-cause mortality by protein C deficiency class</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.92804499131085" CI_END="1.168984900945525" CI_START="0.7025057175448436" DF="1" EFFECT_SIZE="0.9062111104140271" ESTIMABLE="YES" EVENTS_1="338" EVENTS_2="362" I2="74.54204312292553" ID="CMP-001.08.01" LOG_CI_END="0.06780890168503138" LOG_CI_START="-0.15335013677794176" LOG_EFFECT_SIZE="-0.04277061754645517" MODIFIED="2012-07-12 19:56:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04748718265779428" P_Z="0.44839904863627333" STUDIES="2" TAU2="0.025201336076645806" TOTAL_1="1333" TOTAL_2="1280" WEIGHT="100.0" Z="0.758086764802279">
<NAME>Protein C deficiency (less than 80% of normal value)</NAME>
<DICH_DATA CI_END="0.9451531069919895" CI_START="0.6770501284961713" EFFECT_SIZE="0.7999475186144914" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="215" LOG_CI_END="-0.02449783367510687" LOG_CI_START="-0.16937917515043446" LOG_EFFECT_SIZE="-0.09693850441277065" ORDER="1610" O_E="0.0" SE="0.08510401715681415" STUDY_ID="STD-PROWESS-2001" TOTAL_1="709" TOTAL_2="670" VAR="0.007242693736227317" WEIGHT="52.01753863292484"/>
<DICH_DATA CI_END="1.2616806546729835" CI_START="0.8530128504914751" EFFECT_SIZE="1.0374149659863945" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="147" LOG_CI_END="0.10094944408098427" LOG_CI_START="-0.0690444262117272" LOG_EFFECT_SIZE="0.015952508934628514" MODIFIED="2012-07-12 19:56:14 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.09985524089316794" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="624" TOTAL_2="610" VAR="0.009971069133832599" WEIGHT="47.98246136707516"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.41515050737673104" CI_END="1.0400368927700778" CI_START="0.4084424533208355" DF="1" EFFECT_SIZE="0.6517631625269944" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="40" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.0170487451086718" LOG_CI_START="-0.3888691238702281" LOG_EFFECT_SIZE="-0.18591018938077816" MODIFIED="2012-07-12 19:57:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5193668359025154" P_Z="0.0726019133631461" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="157" WEIGHT="100.0" Z="1.7953251304848903">
<NAME>No protein C deficiency (more than 80% of normal value)</NAME>
<DICH_DATA CI_END="1.0381835969799995" CI_START="0.3277626219173768" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="28" LOG_CI_END="0.01627416286170056" LOG_CI_START="-0.4844405749284364" LOG_EFFECT_SIZE="-0.23408320603336796" ORDER="1611" O_E="0.0" SE="0.29412231555585255" STUDY_ID="STD-PROWESS-2001" TOTAL_1="90" TOTAL_2="105" VAR="0.0865079365079365" WEIGHT="65.71970283020195"/>
<DICH_DATA CI_END="1.790974420743853" CI_START="0.3629091137870154" EFFECT_SIZE="0.8062015503875969" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.253089383163869" LOG_CI_START="-0.4402021251648062" LOG_EFFECT_SIZE="-0.09355637100046861" MODIFIED="2012-07-12 19:57:02 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="125" O_E="0.0" SE="0.40724286384057823" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="43" TOTAL_2="52" VAR="0.16584675014907574" WEIGHT="34.28029716979805"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.065804008985258" CI_START="0.6020233710165035" DF="0" EFFECT_SIZE="1.1151960784313726" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.3150891158990859" LOG_CI_START="-0.22038664876462094" LOG_EFFECT_SIZE="0.04735123356723247" MODIFIED="2012-07-12 13:22:08 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="3" P_CHI2="1.0" P_Z="0.7288672562055889" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="65" WEIGHT="100.0" Z="0.3466327275282191">
<NAME>Unknown protein C concentration</NAME>
<DICH_DATA CI_END="2.065804008985258" CI_START="0.6020233710165035" EFFECT_SIZE="1.1151960784313726" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.3150891158990859" LOG_CI_START="-0.22038664876462094" LOG_EFFECT_SIZE="0.04735123356723247" ORDER="1612" O_E="0.0" SE="0.3145411148112455" STUDY_ID="STD-PROWESS-2001" TOTAL_1="51" TOTAL_2="65" VAR="0.09893611290670114" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.619141283735735" CI_END="1.2139637847031057" CI_START="0.9615357188234941" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0804024899777815" ESTIMABLE="YES" EVENTS_1="465" EVENTS_2="422" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.08420573094170841" LOG_CI_START="-0.017034578092361967" LOG_EFFECT_SIZE="0.033585576424673254" METHOD="MH" MODIFIED="2013-04-04 00:34:16 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6550575493458098" P_Q="0.3777260282067706" P_Z="0.1934634277178372" Q="0.7780897953360076" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2154" TOTAL_2="2127" WEIGHT="199.99999999999997" Z="1.300401407708554">
<NAME>28-Day all-cause mortality, subgroup analysis by baseline organ dysfunction category</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.020501031943483385" CI_END="1.4490670067897795" CI_START="0.9459777581578966" DF="1" EFFECT_SIZE="1.1708053461201693" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="134" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.16108846829119794" LOG_CI_START="-0.02411907461601825" LOG_EFFECT_SIZE="0.06848469683758987" MODIFIED="2012-07-12 20:04:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8861466012244401" P_Z="0.1472029046853027" STUDIES="2" TAU2="0.0" TOTAL_1="872" TOTAL_2="906" WEIGHT="99.99999999999999" Z="1.4494824258973567">
<NAME>Single organ dysfunction (&lt;2) in patients with low and high risk of death</NAME>
<DICH_DATA CI_END="1.4556804178495402" CI_START="0.9459848497760469" EFFECT_SIZE="1.1734784281789463" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="131" LOG_CI_END="0.16306603981305878" LOG_CI_START="-0.02411581889561709" LOG_EFFECT_SIZE="0.06947511045872085" MODIFIED="2010-11-09 16:19:56 +0000" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.10995155037062028" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="853" TOTAL_2="886" VAR="0.01208934342890305" WEIGHT="97.90160896235395"/>
<DICH_DATA CI_END="4.587204179482223" CI_START="0.24154870758822392" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6615480712959129" LOG_CI_START="-0.6169952818736083" LOG_EFFECT_SIZE="0.022276394711152208" MODIFIED="2012-07-12 20:04:43 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.751022694543446" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="19" TOTAL_2="20" VAR="0.5640350877192981" WEIGHT="2.0983910376460337"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8203969191066482" CI_END="1.1999546226411961" CI_START="0.9083695378320322" DF="1" EFFECT_SIZE="1.0440317169454163" ESTIMABLE="YES" EVENTS_1="314" EVENTS_2="288" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.07916482312333425" LOG_CI_START="-0.04173743827141207" LOG_EFFECT_SIZE="0.01871369242596108" MODIFIED="2012-07-13 08:38:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.365064203737661" P_Z="0.544022990775195" STUDIES="2" TAU2="0.0" TOTAL_1="1282" TOTAL_2="1221" WEIGHT="99.99999999999999" Z="0.6067407300660723">
<NAME>Multiple organ dysfunction (=&gt;2) in patients with low and high risk of death</NAME>
<DICH_DATA CI_END="1.221850274073981" CI_START="0.730505900941138" EFFECT_SIZE="0.9447586121743425" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="89" LOG_CI_END="0.08701799058132577" LOG_CI_START="-0.1363762715355387" LOG_EFFECT_SIZE="-0.02467914047710648" MODIFIED="2010-11-09 16:19:26 +0000" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.1312228953868781" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="455" TOTAL_2="407" VAR="0.01721944827371555" WEIGHT="29.290367459006802"/>
<DICH_DATA CI_END="1.2840382054713784" CI_START="0.9221446554200368" EFFECT_SIZE="1.088149331907421" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="199" LOG_CI_END="0.1085779459902713" LOG_CI_START="-0.035200946491963064" LOG_EFFECT_SIZE="0.036688499749154106" MODIFIED="2012-07-12 20:06:52 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.08445643316106062" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="827" TOTAL_2="814" VAR="0.0071328891022887" WEIGHT="70.70963254099318"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.957683289624002" CI_END="1.218214490588181" CI_START="0.7166628520648316" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9343709494904215" ESTIMABLE="YES" EVENTS_1="431" EVENTS_2="461" I2="66.5091977132636" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.08572376110289871" LOG_CI_START="-0.14468510642955004" LOG_EFFECT_SIZE="-0.029480672663325644" METHOD="MH" MODIFIED="2013-04-04 00:34:14 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="10" P_CHI2="0.029858862088709248" P_Q="0.6431941415340938" P_Z="0.6159824333656418" Q="0.21458899779149257" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.029016566752577327" TOTALS="SUB" TOTAL_1="1695" TOTAL_2="1674" WEIGHT="200.0" Z="0.50155236887309">
<NAME>28-Day all-cause mortality, subgroup analysis by baseline organ dysfunction category</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.751584173118675" CI_END="1.8558018576558097" CI_START="0.5963780529113745" DF="1" EFFECT_SIZE="1.0520263772634617" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="132" I2="73.34459380745537" ID="CMP-001.10.01" LOG_CI_END="0.2685316051153837" LOG_CI_START="-0.22447834723591822" LOG_EFFECT_SIZE="0.02202662893973272" MODIFIED="2012-07-13 08:30:26 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="1" P_CHI2="0.052757757501240676" P_Z="0.8609743528532985" STUDIES="2" TAU2="0.12713577415276867" TOTAL_1="617" TOTAL_2="607" WEIGHT="100.0" Z="0.17513398752624496">
<NAME>&lt; 3 dysfuntional organs</NAME>
<DICH_DATA CI_END="1.0509257517223336" CI_START="0.6499667759638" EFFECT_SIZE="0.8264785675529028" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="114" LOG_CI_END="0.02157203405266023" LOG_CI_START="-0.18710884241000966" LOG_EFFECT_SIZE="-0.0827684041786747" MODIFIED="2012-07-13 08:26:20 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="1613" O_E="0.0" SE="0.1225801798211706" STUDY_ID="STD-PROWESS-2001" TOTAL_1="485" TOTAL_2="476" VAR="0.015025900484990522" WEIGHT="58.993484128373424"/>
<DICH_DATA CI_END="2.5678789377234743" CI_START="0.8629839166425426" EFFECT_SIZE="1.4886363636363635" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="18" LOG_CI_END="0.40957454512968083" LOG_CI_START="-0.06399729811848964" LOG_EFFECT_SIZE="0.1727886235055956" MODIFIED="2012-07-13 08:26:20 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="70" O_E="0.0" SE="0.2781784449424065" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="132" TOTAL_2="131" VAR="0.07738324723057548" WEIGHT="41.00651587162657"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.19940969387877" CI_END="1.2202155116838838" CI_START="0.6695980119231273" DF="1" EFFECT_SIZE="0.9039103278209017" ESTIMABLE="YES" EVENTS_1="308" EVENTS_2="329" I2="80.7670474366101" ID="CMP-001.10.02" LOG_CI_END="0.08643654155121926" LOG_CI_START="-0.17418584445938598" LOG_EFFECT_SIZE="-0.04387465145408337" MODIFIED="2012-07-13 08:30:26 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="2" P_CHI2="0.0225946057370493" P_Z="0.5093161348547903" STUDIES="2" TAU2="0.03788792621856182" TOTAL_1="1078" TOTAL_2="1067" WEIGHT="100.0" Z="0.6599029193198479">
<NAME>&gt;=3 dysfuntional organs</NAME>
<DICH_DATA CI_END="0.9426833663947883" CI_START="0.6328986901065098" EFFECT_SIZE="0.7724137931034483" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="145" LOG_CI_END="-0.025634155957390575" LOG_CI_START="-0.198665803172196" LOG_EFFECT_SIZE="-0.11214997956479329" MODIFIED="2012-07-13 08:26:23 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="1614" O_E="0.0" SE="0.10163964609444419" STUDY_ID="STD-PROWESS-2001" TOTAL_1="364" TOTAL_2="364" VAR="0.010330617658203863" WEIGHT="48.605402705954326"/>
<DICH_DATA CI_END="1.2458186803141913" CI_START="0.8829495399385078" EFFECT_SIZE="1.0488064791133844" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="184" LOG_CI_END="0.09545483857580897" LOG_CI_START="-0.0540641153946307" LOG_EFFECT_SIZE="0.02069536159058913" MODIFIED="2012-07-13 08:26:23 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" ORDER="72" O_E="0.0" SE="0.08782817369299507" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="714" TOTAL_2="703" VAR="0.007713788094246912" WEIGHT="51.394597294045674"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.475720807600515" CI_END="1.1459903380000165" CI_START="0.9403093248478671" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0380681100038545" ESTIMABLE="YES" EVENTS_1="609" EVENTS_2="578" I2="10.628920525888535" I2_Q="9.2781153825785" ID="CMP-001.11" LOG_CI_END="0.05918095605112151" LOG_CI_START="-0.026729257063976882" LOG_EFFECT_SIZE="0.016225849493572305" METHOD="MH" MODIFIED="2013-04-04 00:34:11 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.34543619301408635" P_Q="0.35346493260819856" P_Z="0.45908387763691283" Q="4.409079481613714" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0014486738147016136" TOTALS="YES" TOTAL_1="2182" TOTAL_2="2125" WEIGHT="99.99999999999999" Z="0.7403562271079986">
<NAME>In-hospital mortality</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1673320665439847E-30" CI_END="1.0991810154104478" CI_START="0.6643563923014207" DF="0" EFFECT_SIZE="0.8545454545454545" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="82" I2="100.00000000000001" ID="CMP-001.11.01" LOG_CI_END="0.04106921882966321" LOG_CI_START="-0.17759888194671603" LOG_EFFECT_SIZE="-0.0682648315585264" NO="1" P_CHI2="0.0" P_Z="0.22104979419594062" STUDIES="1" TAU2="0.0" TOTAL_1="275" TOTAL_2="235" WEIGHT="14.189505116899069" Z="1.2237414674601494">
<NAME>PROWESS data</NAME>
<DICH_DATA CI_END="1.0991810154104478" CI_START="0.6643563923014207" EFFECT_SIZE="0.8545454545454545" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="82" LOG_CI_END="0.04106921882966321" LOG_CI_START="-0.17759888194671603" LOG_EFFECT_SIZE="-0.0682648315585264" ORDER="1622" O_E="0.0" SE="0.1284467248206011" STUDY_ID="STD-PROWESS-2001" TOTAL_1="275" TOTAL_2="235" VAR="0.01649856111713922" WEIGHT="14.189505116899069"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1997480021108138" CI_START="0.8539715536928857" DF="0" EFFECT_SIZE="1.0122009017001057" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="213" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.07909003539298039" LOG_CI_START="-0.06855659568098184" LOG_EFFECT_SIZE="0.00526671985599924" MODIFIED="2012-07-12 20:35:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8887957328507374" STUDIES="1" TAU2="0.0" TOTAL_1="1159" TOTAL_2="1141" WEIGHT="28.388927749047184" Z="0.13982819871114416">
<NAME>Patients with low risk of death</NAME>
<DICH_DATA CI_END="1.1997480021108138" CI_START="0.8539715536928857" EFFECT_SIZE="1.0122009017001057" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="213" LOG_CI_END="0.07909003539298039" LOG_CI_START="-0.06855659568098184" LOG_EFFECT_SIZE="0.00526671985599924" ORDER="1623" O_E="0.0" SE="0.08672836195545641" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1159" TOTAL_2="1141" VAR="0.007521808767476659" WEIGHT="28.388927749047184"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.457587126378768" CI_START="0.6632929766576896" DF="0" EFFECT_SIZE="0.9832635983263598" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="0.1636345238939113" LOG_CI_START="-0.17829460124671415" LOG_EFFECT_SIZE="-0.007330038676401435" NO="3" P_CHI2="1.0" P_Z="0.933030442105849" STUDIES="1" TAU2="0.0" TOTAL_1="239" TOTAL_2="235" WEIGHT="6.09389695636886" Z="0.08403268838314895">
<NAME>Paediatric patients</NAME>
<DICH_DATA CI_END="1.457587126378768" CI_START="0.6632929766576896" EFFECT_SIZE="0.9832635983263598" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.1636345238939113" LOG_CI_START="-0.17829460124671415" LOG_EFFECT_SIZE="-0.007330038676401435" ORDER="1624" O_E="0.0" SE="0.20085086068407038" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="239" TOTAL_2="235" VAR="0.04034106823753184" WEIGHT="6.09389695636886"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6719333396101785" CI_START="0.9332525064931865" DF="0" EFFECT_SIZE="1.2491340920336467" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="43" I2="0.0" ID="CMP-001.11.04" LOG_CI_END="0.22321895802131106" LOG_CI_START="-0.03000083498890884" LOG_EFFECT_SIZE="0.09660906151620108" MODIFIED="2009-08-18 00:03:15 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.1347733287228359" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="99" WEIGHT="10.803127907402397" Z="1.4955409204076442">
<NAME>Patients with prolonged septic shock</NAME>
<DICH_DATA CI_END="1.6719333396101785" CI_START="0.9332525064931864" EFFECT_SIZE="1.2491340920336467" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="43" LOG_CI_END="0.22321895802131106" LOG_CI_START="-0.030000834988908893" LOG_EFFECT_SIZE="0.09660906151620108" MODIFIED="2009-08-18 00:03:15 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.1487425598723941" STUDY_ID="STD-Dhainaut-2009" TOTAL_1="94" TOTAL_2="99" VAR="0.022124349117392743" WEIGHT="10.803127907402397"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2439163872794679" CI_START="0.9471312372077509" DF="0" EFFECT_SIZE="1.085427135678392" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="199" I2="0.0" ID="CMP-001.11.05" LOG_CI_END="0.09479118922655831" LOG_CI_START="-0.02358983974410984" LOG_EFFECT_SIZE="0.03560067474122426" MODIFIED="2012-07-12 20:19:09 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.23846262571386578" STUDIES="1" TAU2="0.0" TOTAL_1="415" TOTAL_2="415" WEIGHT="40.52454227028248" Z="1.178838212927058">
<NAME>Patients with high risk of death</NAME>
<DICH_DATA CI_END="1.2439163872794679" CI_START="0.9471312372077509" EFFECT_SIZE="1.085427135678392" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="199" LOG_CI_END="0.09479118922655831" LOG_CI_START="-0.02358983974410984" LOG_EFFECT_SIZE="0.03560067474122426" MODIFIED="2012-07-12 20:19:09 +0100" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.06953760241291469" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="415" TOTAL_2="415" VAR="0.004835478149336599" WEIGHT="40.52454227028248"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7875971019567296" CI_END="1.1319642314406109" CI_START="0.9264185903278319" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0240472194155592" ESTIMABLE="YES" EVENTS_1="575" EVENTS_2="550" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.053832703942893995" LOG_CI_START="-0.033192738595280116" LOG_EFFECT_SIZE="0.010319982673806955" METHOD="MH" MODIFIED="2014-10-06 19:52:59 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.7326917700378295" P_Q="0.7495757799394717" P_Z="0.6420404293608343" Q="0.10188788637231073" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3542" TOTAL_2="3505" WEIGHT="99.99999999999997" Z="0.46484783694989823">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.69125576728032" CI_END="1.141411649577756" CI_START="0.9271067424496084" DF="4" EFFECT_SIZE="1.0286935579821948" ESTIMABLE="YES" EVENTS_1="531" EVENTS_2="505" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.05744230077077818" LOG_CI_START="-0.03287026047464793" LOG_EFFECT_SIZE="0.01228602014806507" MODIFIED="2014-10-06 19:52:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6107457981658788" P_Z="0.5938517941291221" STUDIES="5" TAU2="0.0" TOTAL_1="3302" TOTAL_2="3268" WEIGHT="92.8530476668874" Z="0.5332626308338837">
<NAME>Adult patients</NAME>
<DICH_DATA CI_END="1.1810694174707197" CI_START="0.8072176927506922" EFFECT_SIZE="0.9764118650186091" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="183" LOG_CI_END="0.07227542406440311" LOG_CI_START="-0.09300932771789204" LOG_EFFECT_SIZE="-0.010366951826744448" ORDER="1635" O_E="0.0" SE="0.09708908136963686" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1317" TOTAL_2="1293" VAR="0.009426289721199965" WEIGHT="27.722149483887353"/>
<DICH_DATA CI_END="1.1760481080392193" CI_START="0.8245754606974904" EFFECT_SIZE="0.9847539847539848" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="111" LOG_CI_END="0.07042508758079245" LOG_CI_START="-0.08376959391284133" LOG_EFFECT_SIZE="-0.0066722531660244385" MODIFIED="2014-10-06 19:52:59 +0100" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.09057471918534384" STUDY_ID="STD-APROCCHSS-2013" TOTAL_1="208" TOTAL_2="203" VAR="0.008203779755503893" WEIGHT="31.853245762018343"/>
<DICH_DATA CI_END="2.0215567370452296" CI_START="0.4675246725550312" EFFECT_SIZE="0.972176759410802" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.3056859347569441" LOG_CI_START="-0.3301954652796655" LOG_EFFECT_SIZE="-0.012254765261360693" MODIFIED="2009-08-18 00:14:37 +0100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.3735198820451995" STUDY_ID="STD-Dhainaut-2009" TOTAL_1="94" TOTAL_2="99" VAR="0.13951710228305972" WEIGHT="1.873010609117744"/>
<DICH_DATA CI_END="1.3247290673062517" CI_START="0.7961685935171086" EFFECT_SIZE="1.0269896193771626" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="102" LOG_CI_END="0.12212706574046331" LOG_CI_START="-0.09899495803958006" LOG_EFFECT_SIZE="0.011566053850441592" ORDER="1636" O_E="0.0" SE="0.1298881713400682" STUDY_ID="STD-PROWESS-2001" TOTAL_1="850" TOTAL_2="840" VAR="0.01687093705406691" WEIGHT="15.489181892628967"/>
<DICH_DATA CI_END="1.5934779698036872" CI_START="0.9642849599402239" EFFECT_SIZE="1.2395833333333333" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="96" LOG_CI_END="0.20234606363100616" LOG_CI_START="-0.01579460692508146" LOG_EFFECT_SIZE="0.09327572835296231" MODIFIED="2012-05-30 21:25:02 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.12813690969838012" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="833" TOTAL_2="833" VAR="0.01641906762705082" WEIGHT="15.915459919235001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4045600463407242" CI_START="0.6637648089827815" DF="0" EFFECT_SIZE="0.9655555555555555" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="45" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.14754031045607408" LOG_CI_START="-0.17798577643739094" LOG_EFFECT_SIZE="-0.015222732990658431" MODIFIED="2012-07-11 10:38:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8545551987212173" STUDIES="1" TAU2="0.0" TOTAL_1="240" TOTAL_2="237" WEIGHT="7.146952333112569" Z="0.1833094772384535">
<NAME>Paediatric patients</NAME>
<DICH_DATA CI_END="1.4045600463407242" CI_START="0.6637648089827815" EFFECT_SIZE="0.9655555555555555" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="45" LOG_CI_END="0.14754031045607408" LOG_CI_START="-0.17798577643739094" LOG_EFFECT_SIZE="-0.015222732990658431" ORDER="1637" O_E="0.0" SE="0.1912156348213395" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="240" TOTAL_2="237" VAR="0.03656341900012786" WEIGHT="7.146952333112569"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.114581648224196" CI_END="1.6715639987091837" CI_START="0.9447646919617243" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2566760307791305" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="103" I2="15.666158649010606" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.22312300895979556" LOG_CI_START="-0.024676345678963187" LOG_EFFECT_SIZE="0.09922333164041619" METHOD="MH" MODIFIED="2014-10-06 20:02:25 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.3103809316559939" P_Q="0.46557272198427535" P_Z="0.11650590082925731" Q="0.5324643269725787" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.023242617406805773" TOTALS="YES" TOTAL_1="3632" TOTAL_2="3546" WEIGHT="100.0" Z="1.5696098702500116">
<NAME>Serious bleeding events (days 0 to 90)</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9284663035083671" CI_START="0.505664137468176" DF="0" EFFECT_SIZE="0.9875" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.28521205475081457" LOG_CI_START="-0.29613784615381883" LOG_EFFECT_SIZE="-0.005462895701502138" MODIFIED="2012-07-11 10:38:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9706163831504393" STUDIES="1" TAU2="0.0" TOTAL_1="240" TOTAL_2="237" WEIGHT="15.149306828204836" Z="0.03683523058860654">
<NAME>Paediatric patients</NAME>
<DICH_DATA CI_END="1.9284663035083671" CI_START="0.505664137468176" EFFECT_SIZE="0.9875" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.28521205475081457" LOG_CI_START="-0.29613784615381883" LOG_EFFECT_SIZE="-0.005462895701502138" ORDER="1627" O_E="0.0" SE="0.3414878095198025" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="240" TOTAL_2="237" VAR="0.11661392405063291" WEIGHT="15.149306828204836"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.470915653823723" CI_END="1.8168961684544485" CI_START="0.9360355591664563" DF="5" EFFECT_SIZE="1.3041010010680352" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="87" I2="22.731182610216" ID="CMP-001.13.02" LOG_CI_END="0.2593301090605102" LOG_CI_START="-0.02870765248365384" LOG_EFFECT_SIZE="0.11531122828842816" MODIFIED="2014-10-06 20:02:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2630535431871045" P_Z="0.1165828636532029" STUDIES="6" TAU2="0.038103729593458924" TOTAL_1="3392" TOTAL_2="3309" WEIGHT="84.85069317179516" Z="1.569279342033372">
<NAME>Adult patients</NAME>
<DICH_DATA CI_END="2.8173462733693" CI_START="1.135035803161738" EFFECT_SIZE="1.7882362512203058" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="28" LOG_CI_END="0.44984022837428234" LOG_CI_START="0.05500956097437243" LOG_EFFECT_SIZE="0.2524248946743274" ORDER="1628" O_E="0.0" SE="0.23192548847403155" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1317" TOTAL_2="1293" VAR="0.053789432203918144" WEIGHT="27.50452141903455"/>
<DICH_DATA CI_END="1.4322359545493994" CI_START="0.5345662476689295" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="0.15601457196434437" LOG_CI_START="-0.271998465919718" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2014-10-06 20:02:25 +0100" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.25141697715180567" STUDY_ID="STD-APROCCHSS-2013" TOTAL_1="208" TOTAL_2="203" VAR="0.06321049640015158" WEIGHT="24.507268335079708"/>
<DICH_DATA CI_END="5.711498181349512" CI_START="0.04855172312257637" EFFECT_SIZE="0.526595744680851" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7567500428429358" LOG_CI_START="-1.3137953521751957" LOG_EFFECT_SIZE="-0.27852265466612997" MODIFIED="2009-08-18 00:09:28 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="1.2162486143986555" STUDY_ID="STD-Dhainaut-2009" TOTAL_1="94" TOTAL_2="99" VAR="1.4792606920266493" WEIGHT="1.4101331059757811"/>
<DICH_DATA CI_END="3.137580973694994" CI_START="0.9693273006487553" EFFECT_SIZE="1.7439446366782008" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="17" LOG_CI_END="0.4965949427680202" LOG_CI_START="-0.013529555390065303" LOG_EFFECT_SIZE="0.24153269368897745" ORDER="1630" O_E="0.0" SE="0.29964965537505056" STUDY_ID="STD-PROWESS-2001" TOTAL_1="850" TOTAL_2="840" VAR="0.08978991596638657" WEIGHT="18.74442335530969"/>
<DICH_DATA CI_END="3.151449328849488" CI_START="0.4958036246041842" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.49851032863505174" LOG_CI_START="-0.304690302618939" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2012-05-30 21:26:46 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.47180402670584143" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="833" TOTAL_2="833" VAR="0.22259903961584634" WEIGHT="8.61826951595541"/>
<DICH_DATA CI_END="3.026733274743639" CI_START="0.19046099224575572" EFFECT_SIZE="0.7592592592592593" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.48097415124701043" LOG_CI_START="-0.7201939574534765" LOG_EFFECT_SIZE="-0.119609903103233" ORDER="1629" O_E="0.0" SE="0.7055720929286979" STUDY_ID="STD-rhAPC-Sepsis-Study-2001" TOTAL_1="90" TOTAL_2="41" VAR="0.4978319783197832" WEIGHT="4.066077440440022"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.558060652203598" CI_END="3.395484013882439" CI_START="0.9585275325051582" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8040689880066794" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="23" I2="15.684405263242962" I2_Q="7.85837195128474" ID="CMP-001.14" LOG_CI_END="0.5309016901262844" LOG_CI_START="-0.01839540804065672" LOG_EFFECT_SIZE="0.2562531410428138" METHOD="MH" MODIFIED="2013-04-04 00:34:04 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.31330970652593626" P_Q="0.2975185411004405" P_Z="0.06744613115794845" Q="1.0852857944633887" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07833392772995597" TOTALS="YES" TOTAL_1="1840" TOTAL_2="1836" WEIGHT="100.0" Z="1.8286895344804324">
<NAME>Serious bleeding during infusion</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.327864286620016" CI_END="5.832086582994066" CI_START="0.9201289934456859" DF="2" EFFECT_SIZE="2.316521521009123" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="16" I2="14.084338528860911" ID="CMP-001.14.01" LOG_CI_END="0.7658239628814931" LOG_CI_START="-0.03615128437763982" LOG_EFFECT_SIZE="0.36483633925192666" MODIFIED="2009-08-22 02:01:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.31225597461508514" P_Z="0.07454362614341949" STUDIES="3" TAU2="0.17969145538232417" TOTAL_1="1639" TOTAL_2="1638" WEIGHT="69.03031779272258" Z="1.7832622331650647">
<NAME>Adult patients</NAME>
<DICH_DATA CI_END="3.7404476617346294" CI_START="1.1006336516511608" EFFECT_SIZE="2.0290053151100986" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="15" LOG_CI_END="0.5729235822503735" LOG_CI_START="0.041642787144029796" LOG_EFFECT_SIZE="0.3072831846972017" ORDER="1631" O_E="0.0" SE="0.31207696892781633" STUDY_ID="STD-ADDRESS-2005" TOTAL_1="1317" TOTAL_2="1293" VAR="0.09739203453517323" WEIGHT="59.24529732288402"/>
<DICH_DATA CI_END="16.59703263661807" CI_START="0.0668319655416392" EFFECT_SIZE="1.053191489361702" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.22003044799553" LOG_CI_START="-1.1750157659998275" LOG_EFFECT_SIZE="0.02250734099785122" MODIFIED="2009-08-18 00:10:49 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="1.406862001770838" STUDY_ID="STD-Dhainaut-2009" TOTAL_1="94" TOTAL_2="99" VAR="1.9792606920266493" WEIGHT="5.059760937253518"/>
<DICH_DATA CI_END="281.6810194211418" CI_START="0.929282751288169" EFFECT_SIZE="16.179039301310045" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4497575838037333" LOG_CI_START="-0.031852123852815835" LOG_EFFECT_SIZE="1.208952729975459" ORDER="1632" O_E="0.0" SE="1.4577098264436266" STUDY_ID="STD-PROWESS-2001" TOTAL_1="228" TOTAL_2="246" VAR="2.1249179381103076" WEIGHT="4.725259532585038"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.04562650533156" CI_START="0.41614580041607185" DF="0" EFFECT_SIZE="1.1257995735607675" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="0.4836766433798425" LOG_CI_START="-0.38075448374238463" LOG_EFFECT_SIZE="0.05146107981872897" MODIFIED="2012-07-11 10:39:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8154818010104968" STUDIES="1" TAU2="0.0" TOTAL_1="201" TOTAL_2="198" WEIGHT="30.969682207277422" Z="0.23336009055117782">
<NAME>Paediatric patients</NAME>
<DICH_DATA CI_END="3.04562650533156" CI_START="0.41614580041607185" EFFECT_SIZE="1.1257995735607675" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4836766433798425" LOG_CI_START="-0.38075448374238463" LOG_EFFECT_SIZE="0.05146107981872897" ORDER="1633" O_E="0.0" SE="0.5077711230746864" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="201" TOTAL_2="198" VAR="0.2578315134285284" WEIGHT="30.969682207277422"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6360259577272719" CI_END="4.1245782379638065" CI_START="0.7201807805911153" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.723497019152021" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.6153795460278304" LOG_CI_START="-0.14255847279339132" LOG_EFFECT_SIZE="0.23641053661721956" METHOD="MH" MODIFIED="2013-04-04 00:34:02 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.4251537665920877" P_Q="1.0" P_Z="0.2214522928590229" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1073" TOTAL_2="1070" WEIGHT="100.0" Z="1.222675537654569">
<NAME>Central nervous system bleeding events in pediatric and adult patients</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors APC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.940268061467446" CI_START="0.2024181658885454" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6937505146033283" LOG_CI_START="-0.6937505146033283" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-06-21 10:58:27 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.8150249727968542" STUDY_ID="STD-PROWESS_x002d_SHOCK-2012" TOTAL_1="833" TOTAL_2="833" VAR="0.6642657062825129" WEIGHT="29.840133138578025"/>
<DICH_DATA CI_END="6.157409534360504" CI_START="0.7665165397334877" EFFECT_SIZE="2.1725" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7893980398344617" LOG_CI_START="-0.11547846959305363" LOG_EFFECT_SIZE="0.33695978512070407" MODIFIED="2012-06-21 10:58:27 +0100" MODIFIED_BY="[Empty name]" ORDER="1634" O_E="0.0" SE="0.531528940848684" STUDY_ID="STD-RESOLVE-2007" TOTAL_1="240" TOTAL_2="237" VAR="0.2825230149597238" WEIGHT="70.15986686142197"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-05-29 17:55:59 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-05-29 17:55:59 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram from June 2012 to May 2013.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWoAAAliCAYAAADsZNzpAACAAElEQVR42uydD6RV2d+4v4wxxhiJ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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-04-04 00:28:05 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvEAAAEACAMAAAANwNnyAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-04-04 00:28:05 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXgAAAK6CAIAAAC8N9DTAAAkhklEQVR42u3dMW8USd7H8ZGQEAEB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</FILE>
</FIGURE>
<FIGURE FILENAME="28-day mortality 6 RCT with APC-20%.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-04-04 01:01:12 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis of human recombinant activated protein C (APC) versus placebo on all-cause mortality at 28-days based on the diversity-adjusted required information size (DARIS) of 7230 patients. This DARIS was calculated based upon a proportion of patients dying within 28 days out of 23.3% in the control group; a RRR of 20% in the experimental intervention group; an alpha (&#945;) of 5%; a beta (&#946;) of 20%; and a diversity of 71%. The cumulative Z-curve (blue line) crosses temporally the conventional alpha of 5%, but reverts to insignificant values. The cumulative Z-curve never crosses the trial sequential alpha-spending monitoring boundaries. After the third trial, the cumulative Z-curve crosses the trial sequential beta-spending monitoring boundary, showing that the area of futility has been reached. This suggests that no more trials may be needed for disproving an intervention effect of 20% relative risk reduction. Smaller risk reductions might still require further trials.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uzdB3Cc933nf00yc5n5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=
</FILE>
</FIGURE>
<FIGURE FILENAME="In-hospital mortality 12%.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-04-04 01:01:19 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis of human recombinant activated protein C (APC) versus placebo in-hospital mortality based on the diversity-adjusted required information size (DARIS) of 6584 patients. This DARIS was calculated based upon a proportion of patients dying in-hospital out of 27.2% in the control group; a RRR of 12% in the experimental intervention group; an alpha (&#945;) of 5%; a beta (&#946;) of 20%; and a diversity of 15%. The cumulative Z-curve (blue line) crossed the trial sequential beta-spending monitoring boundary, showing that the area of futility has been reached. This suggests that no more trials may be needed for disproving an intervention effect of 12% relative risk reduction. Smaller risk reductions might still require further trials.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uy9B5QUZdq+757/nvP7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</FILE>
</FIGURE>
<FIGURE FILENAME="APC Adverse Events.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-04-04 01:01:25 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis of human recombinant activated protein C (APC) versus placebo on adverse events based on the diversity-adjusted required information size (DARIS) of 11480 patients. This DARIS was calculated based upon a proportion of patients developing adverse events out of 13.2% in the control group; a RRR of 13% in the experimental intervention group; an alpha an alpha (&#945;) of 5%; a beta (&#946;) of 20%; and a diversity of 0%. The cumulative Z-curve (blue line) crossed the trials sequential beta-spending monitoring boundary, showing that the area of futility has been reached. This suggest that no more trials are needed for disproving and intervention effect of 13% relative risk reduction.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uy9B5QVZb6vzbfm3Hvu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</FILE>
</FIGURE>
<FIGURE FILENAME="Bleeding.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2013-04-04 01:01:31 +0100" MODIFIED_BY="Arturo J Marti-Carvajal" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis of human recombinant activated protein C (APC) versus placebo on serious bleeding based on the diversity-adjusted required information size (DARIS) of 6665 patients. This DARIS was calculated based upon a proportion of patients with serious bleeding out of 2.2% in the control group; a RRR of 41% in the experimental intervention group; an alpha (&#945;) of 5%; a beta (&#946;) of 20%; and a diversity of 0%. The cumulative Z-curve (blue line) crossed the lower conventional alpha of 5% and the lower trial sequential alpha-spending monitoring boundaries, showing that we have robust data for significant harm.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uy9CZAWdZ6n7+7GbEzs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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-10-08 18:28:43 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2012-10-08 18:28:43 +0100" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2012-10-08 18:23:11 +0100" MODIFIED_BY="Jane Cracknell">Comment from Dr Peter Gøtzsche</TITLE>
<DATE_SUBMITTED>
<DATE DAY="10" MONTH="8" YEAR="2007"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2012-10-08 18:23:24 +0100" MODIFIED_BY="Jane Cracknell">
<P>I wish to congratulate the authors for a very fine review. The authors conclude that activated protein C (APC) should not be used in sepsis with an APACHE II score of less than 25 or in pediatric patients and that there is very weak evidence supporting APC use in patients with severe sepsis and at high-risk of death.</P>
<P>I believe the conclusion should be stronger than this. This drug should not be used at all. The division after a score of 25 was not preplanned, and the overall result, including all randomized patients, was not statistically significant. In such circumstances, subgroup analyses are inappropriate and dangerously misleading, as the authors also point out. I have compared the results for patients below and above 25 and got P = 0.59, confirming the lack of a difference between the effect in these two subgroups.<BR/>We have been fooled so often in the past into believing that various, very expensive drugs for the treatment of sepsis were effective because of their presumed beneficial effects on the coagulation processes. Sadly, the only thing that has been effective with APC was its marketing.</P>
<P>Submitter agrees with default conflict of interest statement:</P>
<P>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2012-10-08 18:28:41 +0100" MODIFIED_BY="Jane Cracknell">
<P>Thank you for your comments about our Cochrane review "Human recombinant activated protein C for severe sepsis" <SUP>1</SUP>.</P>
<P>Overall, we agree with your comments. The exaggeration of the effectiveness of protein C is further highlighted in the discussion of our review, regarding the methodological concerns and the poorly documented amendment of the protocol of the PROWESS study <SUP>2</SUP>.</P>
<P>In summary, this review found no evidence suggesting that APC should be used for treating patients with severe sepsis or septic shock. Additionally, APC seems to be associated with a higher risk of bleeding. Unless additional RCTs provide evidence of a treatment effect, policy-makers, clinicians and academics should not promote the use of APC.</P>
<P>References<BR/>1. <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2007" TYPE="REFERENCE">Martí-Carvajal 2007</LINK> </P>
<P>2. <LINK REF="REF-Bernard-2001" TYPE="REFERENCE">Bernard 2001</LINK>
</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-10-08 18:28:43 +0100" MODIFIED_BY="Jane Cracknell">
<P>Summary: Dr Peter Gøtzsche 10th August 2007.</P>
<P>Reply: Prof Arturo Martí-Carvajal, on behalf of the authors, 10th September 2007.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2012-10-28 12:48:16 +0000" MODIFIED_BY="Jane Cracknell">
<APPENDIX ID="APP-01" MODIFIED="2012-10-28 12:43:24 +0000" MODIFIED_BY="Jane Cracknell" NO="1">
<TITLE MODIFIED="2012-10-28 12:43:24 +0000" MODIFIED_BY="Jane Cracknell">Acute Physiology And Chronic Health Evaluation (APACHE)</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-03 16:10:01 +0000" MODIFIED_BY="Jane Cracknell">
<TABLE COLS="4" ROWS="2">
<TR>
<TH>
<P>Definition</P>
</TH>
<TH>
<P>APACHE I</P>
</TH>
<TH>
<P>APACHE II</P>
</TH>
<TH>
<P>Score interpretation</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Scale for measuring the severity of disease of hospitalized patients. It was created by Dr William A Knaus in June 1978.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>System original with 33 physiologic measurements. (June 1978).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Simplified version with 12 physiologic measurements and more precisely represented the complex interactions of diseases and severity of prognosis (released 1985).</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Score interpretation 0-4 ~4% death rate; 5-9 ~8% death rate;10-14 ~15% death rate; 15-19 ~25% death rate; 20-24 ~40% death rate; 25-29 ~55% death rate; 30-34 ~75% death rate; over 34 ~85% death rate. http://<A HREF="http://www.emedicine.com/splash/etools_xml.pl?file=apache_ii_score_for_adults&amp;prog=edecision">www.emedicine.com/splash/etools_xml.pl?file=apache_ii_score_for_adults&amp;prog=edecision</A>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-07-11 10:33:05 +0100" MODIFIED_BY="Jane Cracknell" NO="2">
<TITLE MODIFIED="2010-12-03 16:11:48 +0000" MODIFIED_BY="Jane Cracknell">Sepsis-related organ failure (SOFA) score</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-11 10:33:05 +0100" MODIFIED_BY="Jane Cracknell">
<TABLE COLS="2" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P>The SOFA score is composed of scores from six organ systems: respiratory, cardiovascular, hepatic, coagulation, renal, and neurological graded from 0 to 4 according to the degree of dysfunction or failure.<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>1.Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Medicine. 1996;22:707-10.</P>
<P>2. Janssens U, Dujardin R, Graf J, Lepper W, J Ortlepp,<BR/>Merx M, et al . Value of SOFA (Sequential Organ Failure<BR/>Assessment) score and total maximum SOFA score in 812 patients with acute cardiovascular disorders. Critical Care 2001; 5 Suppl:225.<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-12-03 16:39:33 +0000" MODIFIED_BY="Jane Cracknell" NO="3">
<TITLE MODIFIED="2008-05-12 16:09:50 +0100" MODIFIED_BY="Karen Hovhannisyan">Search strategy for CENTRAL, <I>The Cochrane Library</I>
</TITLE>
<APPENDIX_BODY MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell">
<P>#1 MeSH descriptor Anticoagulants explode all trees<BR/>#2 anticoagulant*<BR/>#3 MeSH descriptor Protein C explode all trees<BR/>#4 protein next C<BR/>#5 MeSH descriptor Recombinant Proteins explode all trees<BR/>#6 recombinant near protein*<BR/>#7 MeSH descriptor Blood Coagulation Factor Inhibitors explode all trees<BR/>#8 blood coagulation factor inhibitor*<BR/>#9 MeSH descriptor Disseminated Intravascular Coagulation explode all trees<BR/>#10 disseminated intravascular coagulation<BR/>#11 drotrecogin near alfa<BR/>#12 apc or rh?APC or rhAPC<BR/>#13 recombinant human activated protein c<BR/>#14 (#1 OR #2 OR #3 OR #4 OR #5 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)<BR/>#15 MeSH descriptor Sepsis explode all trees<BR/>#16 MeSH descriptor Shock, Septic explode all trees<BR/>#17 MeSH descriptor Systemic Inflammatory Response Syndrome explode all trees<BR/>#18 Septicemia:ab,ti<BR/>#19 seps* or (sept* near shock*) or (sepsis next syndrome) or septic?em* <BR/>#20 (#15 OR #16 OR #17 OR #18 OR #19)<BR/>#21 (#14 AND #20)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-10-28 12:45:16 +0000" MODIFIED_BY="Jane Cracknell" NO="4">
<TITLE MODIFIED="2012-10-28 12:45:16 +0000" MODIFIED_BY="[Empty name]">Search strategy for MEDLINE (OvidSP)</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-12 14:03:44 +0100" MODIFIED_BY="Jane Cracknell">
<P>1. exp Anticoagulants/ or exp Protein-C/ or exp Blood-Coagulation-Factor-Inhibitors/ or exp Recombinant-Proteins/ or exp Disseminated-Intravascular-Coagulation/<BR/>2. anticoagulant*.ti,ab. or (APC alfa or APC or rh?APC or rhAPC or protein C or recombinant protein* or blood coagulation factor inhibitor* or disseminated intravascular coagulation or recombinant human activated protein C).mp.<BR/>3. 1 or 2<BR/>4. (((seps* or sept*) adj3 shock*) or sepsis syndrome or septic?em*).mp.<BR/>5. exp Sepsis-Syndrome/ or Sepsis/ or exp SHOCK SEPTIC/ or exp SEPSIS SYNDROME/ or exp SEPTICEMIA/<BR/>6. 4 or 5<BR/>7. 6 and 3<BR/>8. ((randomised controlled trial or controlled clinical trial).pt. or randomised.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab. or trial.ti.) not (animals not (humans and animals)).sh.<BR/>9. 8 and 7</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2012-10-28 12:45:25 +0000" MODIFIED_BY="Jane Cracknell" NO="5">
<TITLE MODIFIED="2012-10-28 12:45:25 +0000" MODIFIED_BY="[Empty name]">Search strategy for EMBASE (OvidSP)</TITLE>
<APPENDIX_BODY MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell">
<P>1. exp anticoagulant-agent/ or exp activated-protein-C/ or exp protein-C/ or exp blood-clotting-inhibitor/ or exp disseminated-intravascular-clotting/<BR/>2. (Protein?C or recombinant protein* or blood coagulation factor inhibitor* or disseminated intravascular coagulat* or drotrecogin alfa or APC or rh?APC or rhAPC or recombinant human activated protein C).mp. or anticoagulant*.ti,ab.<BR/>3. 1 or 2<BR/>4. sepsis/ or exp septic-shock/ or exp septicemia/<BR/>5. (((seps* or sept*) adj3 shock*) or sepsis syndrome or septic?em*).mp.<BR/>6. 4 or 5<BR/>7. 6 and 3<BR/>8. (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab. or ((singl* or doubl* or tripl*) adj3 (blind* or mask*)).mp.) not (animals not (humans and animals)).sh.<BR/>9. 8 and 7 </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2012-06-28 16:41:08 +0100" MODIFIED_BY="Jane Cracknell" NO="6">
<TITLE MODIFIED="2009-08-21 15:49:23 +0100" MODIFIED_BY="[Empty name]">Search strategy for LILACS (accessed through Biblioteca Virtual em Saúde)</TITLE>
<APPENDIX_BODY MODIFIED="2012-06-28 16:41:08 +0100" MODIFIED_BY="Jane Cracknell">
<P>1. Sepsis OR septic shock<BR/>2.- Drotrecogin<BR/>3.- 1 AND 2<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2012-10-28 12:45:42 +0000" MODIFIED_BY="Jane Cracknell" NO="7">
<TITLE MODIFIED="2012-10-28 12:45:42 +0000" MODIFIED_BY="[Empty name]">Search strategy for BIOSIS Previews (OvidSP)</TITLE>
<APPENDIX_BODY MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell">
<P>1. anticoagulant*.ti,ab. or (APC alfa or APC or rh?APC or rhAPC or protein C or recombinant protein* or blood coagulation factor inhibitor* or disseminated intravascular coagulation or recombinant human activated protein C).mp.<BR/>2. (((seps* or sept*) adj3 shock*) or sepsis syndrome or septic?em*).mp. or (seps* or sept*).ti,ab.<BR/>3. 1 and 2<BR/>4. (controlled study.ab. or random*.ti,ab. or trial*.ti,ab. or ((singl* or doubl* or tripl*) adj3 (blind* or mask*)).mp.) not (animals not (humans and animals)).mp.<BR/>5. 4 and 3</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2010-12-03 16:39:22 +0000" MODIFIED_BY="Jane Cracknell" NO="8">
<TITLE MODIFIED="2009-08-21 15:35:54 +0100" MODIFIED_BY="[Empty name]">Search strategy for CINAHL (EBSCOhost)</TITLE>
<APPENDIX_BODY MODIFIED="2010-07-08 16:12:28 +0100" MODIFIED_BY="Jane Cracknell">
<P>S1 (MH "Anticoagulants")<BR/>S2 (MM "C-Reactive Protein")<BR/>S3 (MH "Blood Coagulation Factors")<BR/>S4 (MH "Recombinant Proteins")<BR/>S5 (MM "Disseminated Intravascular Coagulation")<BR/>S6 TI anticoagulant* or AB anticoagulant* or TX ( APC alfa or APC or rh?APC or rhAPC ) or TX ( (protein C) or (recombinant protein*) or (blood coagulation factor inhibitor*) or (disseminated intravascular coagulation) or (recombinant human activated protein C) )<BR/>S7 S1 or S2 or S3 or S4 or S5 or S6<BR/>S8 (MM "Systemic Inflammatory Response Syndrome")<BR/>S9 (MH "Sepsis")<BR/>S10 (MH "Shock, Septic+")<BR/>S11 TX ( (seps* or sept*) and shock* ) or AB sepsis syndrome or AB septic?em*<BR/>S12 S8 or S9 or S10 or S11<BR/>S13 S7 and S12<BR/>S14 TI random* or AB random* or TI trial* or TX ( (single or double or triple) and (blind* or mask*) ) or TX ( multicenter or crossover ) or AB placebo*<BR/>S15 S13 and S14<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2012-10-28 12:48:16 +0000" MODIFIED_BY="Jane Cracknell" NO="9">
<TITLE MODIFIED="2012-07-11 10:34:13 +0100" MODIFIED_BY="Jane Cracknell">Secondary objectives first and the second protocol PROWESS 2001</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-28 12:48:16 +0000" MODIFIED_BY="Jane Cracknell">
<TABLE COLS="2" ROWS="11">
<TR>
<TD>
<P>First protocol (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>)</P>
</TD>
<TD>
<P>Second protocol (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>)</P>
</TD>
</TR>
<TR>
<TD>
<P>1.To evaluate the effects of APC on organ function (cardiovascular (shock), respiratory, renal, haematologic, and hepatic).</P>
</TD>
<TD>
<P>1. "Simplify the primary objective to clarify that there would be a single primary analysis that included all patients meeting the diagnosis of severe sepsis.<BR/>To this end, references to the protein C deficient subpopulation and the shock subpopulation were removed".</P>
</TD>
</TR>
<TR>
<TD>
<P>2.To evaluate the health economic impact of APC administration in patients with severe sepsis and/or septic shock.</P>
</TD>
<TD>
<P>2. "Clarify exclusion criteria for patients with oesophageal varices"</P>
</TD>
</TR>
<TR>
<TD>
<P>3.To further characterize pharmacokinetics of APC administration.</P>
</TD>
<TD>
<P>3. "Add exclusion criteria for patients having undergone bone marrow, lung, liver, pancreas, or small bowel transplantation".</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>4. "Add exclusion criteria for patients who were considered moribund and<BR/>where death was imminent (within 24 hours)".</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>5. "Add exclusion criteria for patients whose family had not committed to aggressive management of the patient".</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>6. "Add exclusion criteria for patients with acute pancreatitis without known infection".</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>7. "Clarify exclusion criteria for patients with a history of malignancy".</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>8. "Add exclusion criteria for patients having organ failure for greater than 24 hours at the time of meeting all inclusion criteria".</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>9. "Change placebo from normal saline to 0.1% human serum albumin".</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>10. "Replace &#8220;septic shock status&#8221; with &#8220;Protein C activity class&#8221; as a covariate for the primary analysis".</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2012-07-11 10:35:33 +0100" MODIFIED_BY="Jane Cracknell" NO="10">
<TITLE MODIFIED="2012-07-11 08:39:48 +0100" MODIFIED_BY="Jane Cracknell">Baseline characteristics by PROWESS 2001 first protocol compared second protocol</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-11 10:35:33 +0100" MODIFIED_BY="Jane Cracknell">
<TABLE COLS="3" ROWS="8">
<TR>
<TD>
<P>Characteristics</P>
<P>(<LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>)</P>
</TD>
<TD>
<P>First</P>
<P>(N = 720)</P>
</TD>
<TD>
<P>Second</P>
<P>(N= 970)</P>
</TD>
</TR>
<TR>
<TD>
<P>Patients with &gt; 1 condition</P>
</TD>
<TD>
<P>321 (45%)</P>
</TD>
<TD>
<P>260 (27%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Patients with no condition</P>
</TD>
<TD>
<P>399 (55%)</P>
</TD>
<TD>
<P>710 (73%)</P>
</TD>
</TR>
<TR>
<TD>
<P>History of allergic reaction</P>
</TD>
<TD>
<P>80 (11%)</P>
</TD>
<TD>
<P>1 (0%)</P>
</TD>
</TR>
<TR>
<TD>
<P>History of pneumonia</P>
</TD>
<TD>
<P>46 (6%)</P>
</TD>
<TD>
<P>17 (2%)</P>
</TD>
</TR>
<TR>
<TD>
<P>1<SUP>st</SUP> induced organ failure multiple</P>
</TD>
<TD>
<P>105 (15%)</P>
</TD>
<TD>
<P>87 (9%)</P>
</TD>
</TR>
<TR>
<TD>
<P>1<SUP>st</SUP> induced organ failure acidosis</P>
</TD>
<TD>
<P>87 (12%)</P>
</TD>
<TD>
<P>40 (4%)</P>
</TD>
</TR>
<TR>
<TD>
<P>28-day all-cause mortality</P>
</TD>
<TD>
<P>211 (29.3%)</P>
</TD>
<TD>
<P>258 (26.5%)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-11" MODIFIED="2012-07-11 10:37:11 +0100" MODIFIED_BY="Jane Cracknell" NO="11">
<TITLE MODIFIED="2012-07-11 10:36:08 +0100" MODIFIED_BY="Jane Cracknell">Primary objectives according to first and the second protocol of PROWESS 2001</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-11 10:37:11 +0100" MODIFIED_BY="Jane Cracknell">
<TABLE COLS="2" ROWS="3">
<TR>
<TD>
<P>First protocol (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>)</P>
</TD>
<TD>
<P>Second protocol (<LINK REF="REF-FDA-2001a" TYPE="REFERENCE">FDA 2001a</LINK>; <LINK REF="REF-FDA-2001b" TYPE="REFERENCE">FDA 2001b</LINK>)</P>
</TD>
</TR>
<TR>
<TD>
<P>1.To demonstrate that APC reduces 28-day mortality in patients with severe sepsis and/or septic shock.</P>
</TD>
<TD>
<P>1.To demonstrate that APC reduces 28-day mortality in patients with severe sepsis</P>
</TD>
</TR>
<TR>
<TD>
<P>2.To demonstrate that APC reduces 28-day mortality in protein C deficient patients with severe sepsis and/or septic shock.</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-12" MODIFIED="2012-10-28 12:47:54 +0000" MODIFIED_BY="Jane Cracknell" NO="12">
<TITLE MODIFIED="2010-12-03 16:21:38 +0000" MODIFIED_BY="Jane Cracknell">Exclusion criteria of the patients in the PROWESS trial from PROWESS 2001</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-28 12:47:54 +0000" MODIFIED_BY="Jane Cracknell">
<TABLE COLS="1" ROWS="16">
<TR>
<TD>
<P>
<B>Reason</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>1. Pregnancy or breastfeeding.</P>
</TD>
</TR>
<TR>
<TD>
<P>2. Age &lt;18 yr or weight &gt;135 kg.</P>
</TD>
</TR>
<TR>
<TD>
<P>3. Platelet count &lt;30,000/mm3.</P>
</TD>
</TR>
<TR>
<TD>
<P>4. Patient with conditions that increased the risk of bleeding.</P>
</TD>
</TR>
<TR>
<TD>
<P>5. Patient with known hypercoagulable condition.</P>
</TD>
</TR>
<TR>
<TD>
<P>6. Patient's family, physician, or both not in favour of aggressive treatment of patient or presence of an advanced directive to withhold life-sustaining treatment.</P>
</TD>
</TR>
<TR>
<TD>
<P>Patient not expected to survive 28 days because of uncorrectable medical condition, such as poorly controlled neoplasm or other end-stage disease.</P>
</TD>
</TR>
<TR>
<TD>
<P>7. Moribund state in which death was perceived to be imminent.</P>
</TD>
</TR>
<TR>
<TD>
<P>8. Human immunodeficiency virus infection in association with a last known CD4 count of 50/mm3 or more.</P>
</TD>
</TR>
<TR>
<TD>
<P>9. History of bone marrow, lung, liver, pancreas, or small-bowel transplantation.</P>
</TD>
</TR>
<TR>
<TD>
<P>10. Chronic renal failure requiring haemodialysis or peritoneal dialysis (acute renal failure was not an exclusion criterion).</P>
</TD>
</TR>
<TR>
<TD>
<P>11. Known or suspected systemic hypertension, chronic jaundice, cirrhosis, or chronic ascites.</P>
</TD>
</TR>
<TR>
<TD>
<P>12. Acute pancreatitis with no established source of infection.</P>
</TD>
</TR>
<TR>
<TD>
<P>13. Participation in another investigational study within 30 days before the current study.</P>
</TD>
</TR>
<TR>
<TD>
<P>14. Use of any of the following medications or treatment regimens: warfarin, acetylsalicylic acid, glycoprotein IIb/IIIa antagonists, and low-molecular weight heparin at a higher dose than recommended for prophylactic use.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-13" MODIFIED="2010-12-03 16:23:20 +0000" MODIFIED_BY="Jane Cracknell" NO="13">
<TITLE MODIFIED="2010-12-03 16:23:07 +0000" MODIFIED_BY="Jane Cracknell">RESOLVE trial resolution organ dysfunction definitions</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-03 16:23:20 +0000" MODIFIED_BY="Jane Cracknell">
<TABLE COLS="4" ROWS="2">
<TR>
<TH>
<P>General</P>
</TH>
<TH>
<P>Cardiovascular</P>
</TH>
<TH>
<P>Respiratory</P>
</TH>
<TH>
<P>Renal</P>
</TH>
</TR>
<TR>
<TD>
<P>The last day the patient needed vasoactive agents, invasive<BR/>mechanical ventilation, or renal replacement therapy.</P>
</TD>
<TD>
<P>Requiring less than 5 µg/kg/min dopamine or dobutamine, or cessation of epinephrine, norepinephrine, phenylephrine, or any other vasoactive agent used for<BR/>haemodynamic support.</P>
</TD>
<TD>
<P>Cessation of invasive mechanical ventilation (i.e., not requiring intermittent positive pressure) including continuous positive airway pressure or bimodal positive airway pressure.</P>
</TD>
<TD>
<P>Cessation of renal replacement therapy (peritoneal dialysis,<BR/>haemodialysis, ultrafiltration, or haemofiltration).</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 RCTs included in quantitative synthesis (meta-analysis).&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 (38 references) RCTs included in qualitative synthesis: 6 (38 references).&lt;br&gt;* Included RCTs in previous versions: 5&lt;br&gt;* Included RCT for this update: 1&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 new randomised clinical trial (RCTs).&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt; 11 full-text articles assessed for eligibility.&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;519 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;519 records after duplicates removed.&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt; 542 records identified through database searching: &lt;br&gt;CENTRAL (121), MEDLINE (66), &lt;span&gt;EMBASE (317), &lt;/span&gt;CINHAL(37), BIOSIS (0), LILACS (1).&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt; 509 records excluded.&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt; 35 full-text articles excluded, with reasons:&lt;br&gt;Previous versions (25), this update (10).&lt;br&gt;&lt;/p&gt;&lt;p&gt;Narrative review (9), Observational study (8), No randomized clinical trial (4),&lt;br&gt;Cost effectiveness (2), Survey (1), Non controlled clinical trial open label (2),&lt;br&gt;Meta-analysis (3), Systematic review and meta-analysis (2), Cochrane review (1),&lt;br&gt;Randomized controlled trial assessing prophylactic heparin (1), Randomized controlled trial comparing two regimens of APC (1), Clinical practice guidelines (1).&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>